

# AMERICAN PANCREATIC ASSOCIATION

## 47<sup>th</sup> Annual Meeting

October 26-29, 2016 • Boston, Massachusetts



CME PROVIDER:



UNIVERSITY OF MIAMI  
MILLER SCHOOL  
of MEDICINE



AMERICAN PANCREATIC  
ASSOCIATION



### **GOVERNING BOARD**

Carlos Fernandez-del Castillo, MD, President  
Anirban Maitra, MBBS, Past President  
Miklos Sahin-Toth, PhD, President-Elect  
Ashok Saluja, PhD, Secretary-Treasurer  
Darwin Conwell, MD – Councilor  
Margaret Tempero, MD - Councilor  
Anil Rustgi, MD - Councilor

### **COURSE DIRECTOR**

Ashok K. Saluja, PhD, Course Director  
Carlos Fernandez-del Castillo, MD, Course Co-Director

### **APA CONTACT INFORMATION**

Ashok K. Saluja, PhD  
APA Secretary-Treasurer  
Professor & Vice Chair, Surgery  
University of Miami Miller School of Medicine  
asaluja@miami.edu

PO Box 352406  
Miami, FL 33135

Telephone | 305-243-6039  
Fax | 305-243-6263  
Email | [apa@miami.edu](mailto:apa@miami.edu)

[www.american-pancreatic-association.org](http://www.american-pancreatic-association.org)

## MESSAGE FROM THE PRESIDENT



Welcome to Boston!

On behalf of the board of the American Pancreatic Association, thank you for attending our 47<sup>th</sup> Annual Meeting. We received over 300 abstracts, and as you can see from the program, the oral presentations and posters showcase cutting edge basic, translational, and clinical science, including topics that just 10 years ago would have seemed like science fiction. We also have several mini symposia on novel or controversial clinical and basic science topics, “meet the professor” breakfast sessions, and our traditional state of the art lectures, where you will hear about the stressed acinar cell and what the future looks like for treating pancreatic cancer.

Our pre-meeting conference is on Intraductal Papillary Mucinous Neoplasms, and our intent was to bring basic scientists and clinicians together to discuss what needs to be done to advance the field in this disease. Experts from many parts of the world have come to participate, and we hope you will take advantage of their presence.

We continue to benefit from the incredible support of several foundations that enhance our program. This year, for the first time, the Hirshberg symposium will focus on Pancreatic Cancer Surgery, and the Kenner foundation has brought distinguished representatives to speak about biomarkers for early detection. In addition, PanCan has brought four of their young investigators to present their work. Last year we had this forum for the first time to great acclaim, and we hope it will continue in the future.

The APA meeting is unique not just for its scientific content, but also because it brings us together in the meals and social events, all of which are included with your registration. This package deal is indeed a great value, and we hope you will take advantage of it. The organizing team, in particular our secretary/treasurer Ashok Saluja and his assistant Maria Fernandez have worked very hard to make this happen, and we thank them enthusiastically.

### **Carlos Fernández-del Castillo, MD**

Jorge and Darlene Pérez Endowed Chair in Surgery  
Director, Pancreas and Biliary Surgery Program  
Massachusetts General Hospital  
Professor of Surgery, Harvard Medical School



## ACCREDITATION

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint partnership of the University of Miami Leonard M. Miller School of Medicine and American Pancreatic Association. The University of Miami Leonard M. Miller School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

## CREDIT DESIGNATION

The University of Miami Leonard M. Miller School of Medicine designates this live activity for a maximum of **28.25 AMA PRA Category 1 Credits™**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

## LEARNING OBJECTIVES

This activity is designed for physicians and researchers. Upon completion of this course, participants will be able to:

1. To evaluate the potential for liquid biopsies in longitudinal monitoring of pancreatic cancer patients for evolution in the tumor genome and appearance of new therapeutic vulnerabilities.
2. To recognize the use of liquid biopsies as a potential earlier marker of disease relapse or recurrence.
3. To explain the implications of an incidentally-discovered solid lesion in the pancreas.
4. To describe the diagnostic tools available in the differential diagnosis of pancreatic solid lesions.
5. To contrast the management approaches for small, incidentally discovered PNETs
6. Develop methods of early diagnosis.
7. Differentiate chronic pancreatitis from alternative diagnoses
8. Construct an appropriate cohort of patients at high risk of pancreatic cancer
9. Compare mechanisms of tumor associated diabetes with other forms of diabetes
10. Select patients for various treatment options

## DOCUMENTATION OF ATTENDANCE FOR CME

Sign in at Registration desk, complete electronic evaluation and credit adjustment form.

## EVALUATIONS & CREDIT ADJUSTMENT FORM

Conference evaluations are a valuable tool in assisting to better serve you. An e-mail with a link to the electronic evaluation form and credit adjustment form will be sent to you at the end of the program. Please complete your evaluation form on-line. We welcome your comments and suggestions. Certificates of Attendance will be e-mailed to attendees approximately 6 to 8 weeks after the conference. An outcome evaluation will be conducted 2 to 3 months following the course to measure the impact this activity has had in changing performance and patient outcomes. We encourage and appreciate your participation.

## FACULTY DISCLOSURE PAGE

### Disclosure and Conflict of Interest Resolution Statement

In accordance with the 2004 Updated ACCME Standards for Commercial Support the University of Miami Leonard M. Miller School of Medicine requires everyone in a position to control the content of a Continuing Medical Education activity – the Course Director(s), Planning Committee Members and all individuals participating as speakers, moderators or authors to disclose all relevant financial relationships with any commercial interest. All potential conflicts of interest are identified and resolved prior to the education activity being provided to learners. Disclosure of relevant financial relationship(s) will be provided to learners prior to the beginning of the educational activity.

## **SUPPORTERS**

The American Pancreatic Association would like to extend a special thank you to the following organizations for their support of this meeting through educational grants:

### **Platinum Supporters**

AbbVie  
Celgene  
ChiRhoClin

### **Gold Supporters**

Hirshberg Foundation for Pancreatic Cancer Research  
Kenner Family Research Fund  
Massachusetts General Hospital

### **Silver Supporters**

Allergan Foundation  
Boston Scientific  
Cook Medical  
Digestive Care  
National Pancreas Foundation  
Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine  
Vay Liang W. Go, Pancreas Journal

## **YOUNG INVESTIGATOR AWARDS WINNERS**

Toshiya Abe	Shingo Kagawa	Marta Sandini
Maisam Abu-El-Haija	Jae Seung Kang	Heather Schofield
Andreas Andreou	Muhammad Kizilgul	Matthias Sandler
Jane Armstrong	Audrey Lane	Nikita Sharma
Jodie Barkin	Xuqi Li	Isabelle Sheers
Myrriah Chavez-Tomar	Minyang Liu	Masaki Sunagawa
Michelle Cooley	Thomas Mace	Kazuki Takakura
Melissa Fenech	Scott Messenger	Rupjyoti Talukdar
Ming Gao	Sandeep Nadella	Sandra Van Brunschot
Bharti Garg	Balazs Nemeth	Li Wen
Robert Hollemans	Alice Nomura	Min Yang
Yinshi Huang	Yongsheng Ouyang	Jordan Yaron
Wei Huang	Santanu Paul	Jun Yu
Eliana Jones	Bernhard Renz	Haseeb Zubair

## EXHIBITORS

The American Pancreatic Association would like to thank the following companies for providing marketing and exhibit support:

Abbvie  
Akcea Therapeutics  
Boston Scientific  
ChiRhoClin  
Cook Medical  
Digestive Care  
National Pancreas Foundation

Please visit our exhibitors' booths in the Grand Ballroom B Foyer

The American Pancreatic Association would like to thank Celgene for supporting Wi-Fi.

## ABSTRACT SELECTION COMMITTEE

The APA Board would like to thank the following for reviewing the over 500 abstracts received:

Sulagna Banerjee - University of Miami  
Howard Crawford - University of Michigan  
Vikas Dudeja - University of Miami  
Carlos Fernandez-del Castillo - Harvard/MGH  
Toru Furukawa- Tokyo Woman's Medical University, Japan  
Pramod Garg- AIIMS, India  
Guy Groblewski- UW, Madison  
Anna Gukovskaya- UCLA  
Aida Habtezion- Stanford University  
Peter Hegyi- University of Szeged, Hungary  
Joe Hines- UCLA  
Karen Horvath- UW Seattle  
Sohail Hussain- Children's Hospital Pittsburgh  
Myung Hwan-Kim- Asan Medical Center, Korea  
Min Li- Oklahoma University  
Ravikant Maddipatti- UPenn  
Anirban Maitra- MD Anderson  
Atsushi Masamune -Tohoku University, China  
Julia Mayerle - University of Greifswald, Germany  
Nipun Merchant -University of Miami  
Kazuichi Okazaki - Kansai University

Marina Pasca di Magliano - University of Michigan  
Nageshwar Reddy - AIG, India  
Max Reichert - UPenn  
Andrew Rhim - MD Anderson  
Anil Rutschi - UPenn  
Miklos Sahin- Toth -Boston University  
Veena Sangwan -McGill University, Canada  
Kyoko Shimizu - Tokyo Women's University, Japan  
Vijay Singh - Mayo, Arizona  
Vikesh Singh - Johns Hopkins  
Kyoichi Takaori - Kyoto University  
Masao Tanaka - Kyushu University  
Margaret Tempero - UCSF  
Christina Twyman-St. Victor - UPenn  
Aliye Uc - University of Iowa  
Huaizhi Wang - Southwest Hospital 3rd Medical University, China  
Andrea Wang- Gilliam - Washington University  
Christopher Wolfgang - Johns Hopkins  
Bechein Wu - Kaiser Permanente  
Yianjun Yu -Fudan University, China

## MEETING AT A GLANCE

### WEDNESDAY, OCTOBER 26

7:00 a.m. – 8:00 a.m.	Breakfast
8:00 a.m. – 4:30 p.m.	Pre-Meeting—IPMN: Beyond Guidelines and Treatment
12:15 p.m. – 1:30 p.m.	Lunch
5:00 p.m. – 7:00 p.m.	Hirshberg Opening Symposium: Recent Advances in Pancreatic Cancer Surgery
7:00 p.m. – 9:00 p.m.	Presidential Reception

### THURSDAY, OCTOBER 27

7:00 a.m. – 8:30 a.m.	Breakfast & Poster Viewing
8:30 a.m. – 10:00 a.m.	Abstract Session: Pancreatic Cancer
10:15 a.m. – 11:30 a.m.	Mini Symposium: Incidentally-discovered non-functioning neuroendocrine tumors
11:30 a.m. – 12:00 p.m.	Frank Brooks State of the Art Lecture
12:00 p.m. – 2:00 p.m.	Lunch & Poster Session
2:00 p.m. – 3:05 p.m.	Abstract Session: Pancreatitis
3:05 p.m. – 4:20 p.m.	Mini Symposium: Immunobiology and Immunotherapy of Pancreatic Adenocarcinoma
4:30 p.m. – 6:45 p.m.	Kenner Family Research Fund Forum: Early Detection of Pancreatic Cancer: The Role of Industry in the Development of Biomarkers
7:00 p.m. – 10:00 p.m.	Reception & Awards Dinner

### FRIDAY, OCTOBER 28

7:00 a.m. – 8:30 a.m.	Breakfast & Poster Viewing
8:30 a.m. – 10:00 a.m.	Abstract Session: Pancreatitis
10:15 a.m. – 10:45 a.m.	Paul Webster Clinical State of the Art Lecture
10:45 a.m. – 12:00 p.m.	Parallel Symposium: Prevention of post ERCP pancreatitis: Stents vs Suppositories and other controversies
	Parallel Session: What Matters in Pancreatitis
12:00 p.m. – 2:00 p.m.	Lunch & Poster Session
2:00 p.m. – 2:30 p.m.	Business Meeting
2:30 p.m. – 3:45 p.m.	Mini Symposium: Multidisciplinary Management of Pancreatic Necrosis
4:00 p.m. – 5:15 p.m.	Mini Symposium: Novel diagnostic platforms in pancreatic cancer
5:15 p.m. – 6:30 p.m.	Parallel Sessions: Clinical Science Abstracts
	Parallel Sessions: Basic Science Abstracts
7:00 p.m.	Women in Pancreas Reception & Dinner

### SATURDAY, OCTOBER 29

7:00 a.m. – 8:30 a.m.	Breakfast
8:30 a.m. – 10:00 a.m.	Abstract Session: Pancreatic Cancer
10:00 a.m. – 10:30 a.m.	Mini Symposium: Update on NIH Consortium of the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer (CPDPC)
10:45 a.m. – 12:00 p.m.	Mini Symposium: Regeneration, inflammation and cancer
12:00 p.m. – 1:15 p.m.	Mini Symposium: PanCan Young Investigators
1:15 p.m.	

## ONSITE REGISTRATION HOURS

Location | *Exeter Foyer*

Wednesday, 10/26 7am – 7pm

Thursday, 10/27 7am – 6pm

Friday, 10/28 7am – 6:30pm

Saturday, 10/29 7am – 1:15pm

## SOCIAL EVENTS

### PRESIDENTIAL RECEPTION

Wednesday, October 26 | 7:00 pm – 9:00 pm

Location | *Georgina ABC*

The Presidential Reception is held in honor of APA President Carlos Fernandez-del Castillo.

### AWARDS DINNER & RECEPTION

Thursday, October 27 | 7:00 pm – 10:00 pm

Reception 7:00 pm – 8:00 pm

Location | *Georgian ABC*

Dinner 8:00 pm – 10:00 pm

Location | *Grand Ballroom A*

The following awards will be presented: Hirshberg Foundation and National Pancreas Foundation Awards for Best abstracts in Pancreatitis and Pancreatic Cancer, the Distinguished Service and the Vay Liang & Frisca Go Award for Lifetime Achievement along with felicitations of Young Investigators awardees.

### WOMEN IN PANCREAS RECEPTION & DINNER

Friday, October 28, 7:00 pm

Reception Location | *Arlington Berkeley Clarendon*

Dinner Location | *Georgian*

All women registered are invited to attend this event. RSVPs are requested; contact the reservation desk. Keynote Speakers: Stephen Blattner, MD, MBA and Judith Simmons, MD, from exāgoMD, LLC and Jacqueline Rosenthal from ZurickDavis.

### APA FOUNDATION

The APA Foundation was officially launched three years ago with the purpose of providing education, research, and charitable support to the APA mission and initiatives. Our society continues to provide a forum for communications and support for young investigators to present their outstanding research work in pancreatic diseases. Our society is now celebrating its 47<sup>th</sup> annual meeting this year. Our foundation has an excellent start in creating an endowment fund. Thank you to the Board of Directors and the APA members whose generosity has contributed to our foundation. The future of our society and its mission is in our own hands.

Please send your contributions to the APA Foundation:

11411 Four Fillies Road

Pinecrest, FL 33156

The Board of Directors, Steve Pandol MD, Ashok Saluja MD, Edward Bradley MD, William Chey MD, Edward D. Purich PhD, Agi Hirshberg, Barbara Kenner PhD, Peter Banks MD, Howard Reber MD, Andrew Warshaw MD, Paul Webster MD, and Vay Liang Go MD, Chair, would like to express our heartfelt gratitude for your support.



## DISTINGUISHED SERVICE AWARD



### SUDHIR SRIVASTAVA, PH.D., MPH, MS

Dr. Srivastava is Senior Scientific Officer and Chief of the Cancer Biomarkers Research Group in the Division of Cancer Prevention, National Cancer Institute. He joined the National Cancer Institute in 1988. Since 1990, he has served as program director in the Division of Cancer Prevention and focused his responsibility in developing molecular signatures of cancer cells for cancer detection research programs with primary emphasis on cancer screening, early detection, risk assessment and informatics.

Dr. Srivastava is an internationally recognized leader in cancer biomarker research. He is best known for his seminal contributions to improving systems approach to biomarker discovery, development and validation. In 2000, Dr. Srivastava developed and implemented a novel approach to collaborative clinical research on cancer biomarkers through the establishment of the Early Detection Research Network (EDRN; [www.cancer.gov/edrn](http://www.cancer.gov/edrn)), a flagship program at the National Cancer Institute, National Institutes of Health. Under his leadership the network has begun translating biomarkers into clinical tests for early detection and diagnosis, risk assessment, and prognosis. He has spearheaded the role of chemical sciences in oncology by establishing the NCI's Alliance of Glycobiologists ([glycomics.cancer.gov](http://glycomics.cancer.gov)) to study the structure-function relationship of glycans and biomarkers in cancer detection and diagnosis. He has played a key role in conceptualizing and implementing informatics infrastructure for the EDRN in collaboration with NASA (Jet Propulsion Laboratory), a model collaboration being followed elsewhere in NIH. For his creativity, he received a JPL Group Achievement Award in 2011.

Dr. Srivastava is best known for his work on developing medical guidelines on the diagnosis of Hereditary Non-polyposis Colorectal Cancer (HNPCC). He played a pivotal role in the development of the Bethesda Guidelines for diagnosing HNPCC, which is in clinical practice world-wide. He has received several honors and awards and is a member of a number of scientific committees world-wide. In 1995, he was elected to the American Joint Committee on Cancer (AJCC) which is responsible for developing staging criteria for cancers for worldwide use and currently serves on the AJCC Executive Committee. He has been a visiting Professor at several medical and academic institutions, and has delivered several inaugural and keynote addresses.

He is the founding Editor-in Chief of the journal Cancer Biomarkers, and was the editor of Disease Markers (2002-2013) published by the IOS press and serves as Associate Editors and reviewers for several internally know journals. He has published more than 200 research papers, review articles and commentaries in peer reviewed journals. He has edited several monographs and edited five books.

In 2016, he received a Cancer Prevention Distinguished Alumni Award for his accomplishments and mentoring of fellows. He was featured in *Wired* magazine in August 2003 for his leadership in cancer diagnostics. He has been planning and managing comprehensive extramural scientific programs for more than 26 years. This year, he was also invited to brief the US Congress on progress made on biomarkers for cancer early detection. He has successfully managed several mission-critical goals of the National Cancer Institute at various fronts including: conceptual, infrastructure, dependency linkage, and coordination among various federal, academic and private sector constituents. For these activities, he has received numerous NIH Director Awards and NIH Merit Awards.

Dr. Srivastava received his Ph.D. Degree in biological science from Banaras Hindu University in 1977. Subsequently, he received his M.S. degree in Computer Science from the Virginia Commonwealth University in 1987 and a MPH degree from the Johns Hopkins University in 1997. He did postdoctoral work at the University of Osaka, Japan; the University of California at San Francisco; and the University of Arizona, Tucson.

## VAY LIANG & FRISCA GO AWARD FOR LIFETIME ACHIEVEMENT



### CHRIS E. FORSMARK, MD

Dr. Chris Forsmark was born and raised in Colorado, growing up in the mountains near Granby before his family moved to Denver. His mother, a schoolteacher, and his father, a bookkeeper, were both exceedingly well read and instilled an appreciation of hard work and self-improvement. He developed an interest in medicine while a high school student and graduated from the University of Colorado, Boulder, with a degree in chemical engineering, and then attended medical school at Johns Hopkins. During training at Hopkins, he developed an interest in gastrointestinal and liver diseases due to the impressive number of outstanding faculty and trainees. He received the Warfield Longcope prize (best student in internal medicine), along with election to Phi Beta Kappa and Alpha Omega Alpha at graduation. He moved to the University of California, San Francisco for internal medicine training, chief residency, and GI fellowship. It was here that he became specifically interested in pancreatic diseases, due to mentorship and inspiration from Jim Grendell, John Cello, and Roger Liddle. It was also here that he developed life-long connections with others interested in the pancreas and fibrosis including Mel Wilcox, Scott Friedman, and Brent Neuschwander-Tetri.

Dr. Forsmark joined the faculty of the University of Florida in 1990, choosing this institution due to mentorship from Phil Toskes who has been attending the APA meetings since 1991. Although much of his activity related to advanced endoscopy, Dr. Toskes proved instrumental in helping him develop an understanding of medical pancreatology, pancreatic physiology, and the ingredients necessary for a successful academic and clinical research career. Dr. Forsmark became a tenured professor at UF in 2003. He served as the Director of Endoscopy and subsequently the Chief of the Division of Gastroenterology, Hepatology, and Nutrition of the University of Florida. He also served as Chair of the AGA Pancreas Section, President of the Florida Gastroenterologic Society, and Chair of the ABIM Gastroenterology Board. He is the former Associate Editor for Pancreas for the *American Journal of Gastroenterology*, and on the editorial board of several journals including *Pancreas* and *Pancreatology*. He serves as a board member for the National Pancreas Foundation. He is perhaps most proud of the opportunity to serve as President of the APA in 2006, organizing a combined APA-IAP meeting.

Dr. Forsmark is at heart a clinician, involved in both the medical management and endoscopic management of many patients with acute and chronic pancreatitis and with pancreatic malignancies. In conjunction with Phil Toskes, a rather unique training program combining advanced endoscopy and medical pancreatology was created at UF, which now has numerous graduates. Much of his research has focused on issues that combine the endoscopic and medical approaches to these patients, and in particular methods of early diagnosis of chronic pancreatitis. He is the author of more than 90 peer-reviewed publications, numerous book chapters, and multiple reviews and editorials. Most recently, he and his colleagues at UF participate in the NIDDK/NCI UO-1 consortium to study chronic pancreatitis, diabetes, and pancreatic cancer. This 5-10 year project will attempt to delineate the intricate and tri-directional relationships between these diseases, with a goal of more accurate diagnosis, more effective therapy, and earlier detection. Dr Forsmark and Dr Steven Pandol chair this UO-1 consortium.

Dr. Forsmark wishes to express his gratitude to the APA for the tremendous honor of the Go Lifetime Achievement Award, and to Bill and Frisca Go for their generosity. He feels there are so many people who are equally deserving of recognition within the APA. He is especially thankful for the advice and guidance provided by leaders in the APA, including Bill Go, Ashok Saluja, Howard Reber, Ed Bradley, Roger Liddle, Phil Toskes, Raul Urrutia, and so many others. He would also like to acknowledge and thank his wife Rusty, who for 36 years has provided support, counsel and love, and his 2 (outstanding) daughters Kate and Britta.

## IPMN: BEYOND GUIDELINES AND TREATMENT

Pre-Meeting Directors | Carlos Fernandez-del Castillo and Anirban Maitra

APA PRE-MEETING | Boston 2016

Wednesday, October 26

Grand Ballroom A

7:00 – 8:00am

Breakfast

Location / *Georgian*

8:00 – 9:00am

### **Biology of IPMN: Insights through bench research**

Leader | Nabeel Bardeesy, PhD, Massachusetts General Hospital Cancer Center, Harvard Medical School

Maximilian Reichert, MD, Technical University of Munich

*Investigating the Molecular Origin of Pancreatic Cystic Neoplasm to Develop Targeted Therapies*

Nilotpal Roy, PhD, University of California, San Francisco

*The role of SWI/SNF chromatin remodeling complex in IPMN-derived PDAC*

9:00 – 10:00am

### **Pathology of IPMN: The value of classification and sub classification**

Leader | Mari Mino-Kenudson, MD

Toru Furukawa, MD, PhD, Tokyo Women's Medical University

*Subtype classification of IPMN and its impact on patient care*

Olca Basturk, MD, Memorial Sloan Kettering Cancer Center

*Implications of minimally-invasive IPMN*

10:00 – 10:15am

Break

Location / *Grand Ballroom B Foyer*

10:15 – 11:15am

### **Molecular pathology of IPMN: Genes and expression explain transformation**

Leader | Anirban Maitra, MBBS

Michael Goggins, MD, Johns Hopkins University

*Molecular Genetics of IPMN*

Jens Siveke, MD, University Hospital Essen

*The Role of Epigenetic Alterations in IPMN development*

11:15 – 12:15pm

**Clinical dilemmas in IPMN: Are we over treating a disease?**

Leader | Timothy Gardner, MD, MS

Suresh T. Chari, MD, Mayo Clinic College of Medicine

*Most incidentally discovered pancreatic cysts are innocuous and do not need resection*

Christopher Wolfgang, MD, MS, PhD, Johns Hopkins University

*IPMNs have malignant potential and close surveillance is needed for those patients*

12:15 – 1:30pm

Lunch

Location / *Georgian AB*

1:30 – 2:30pm

**Cyst fluid analysis in IPMN: Diagnosis and identification of high-risk lesions**

Leader | Annemarie Lennon, MD, PhD

Peter Allen, MD, FACS, Memorial Sloan Kettering Cancer Center

*A panel of inflammatory markers distinguishes low from high-grade IPMNs*

Nickolas Papadopoulos, PhD, Johns Hopkins, Sidney Kimmel CCC, Ludwig Center

*Identification of genetic mutations in the fluid of IPMNs*

Martha Bishop Pitman, MD, Massachusetts General Hospital/ Harvard Medical School

*The value of fluid cytology in triaging IPMN*

2:30 – 3:30pm

**State of the art imaging in IPMN**

Leader | Dushyant V. Sahani, MD

William R. Brugge, MD, Massachusetts General Hospital

*Innovations in Endoscopic Ultrasound*

Koenraad J. Mortele, MD, Beth Israel Deaconess Medical Center

*Recent advances in MRI and MRCP*

3:30 – 4:30pm

**Present and future challenges in IPMN**

Panel Discussion Moderator | Carlos Fernandez-del Castillo, MD

Participants

Masao Tanaka, MD, PhD, FACS, Kyushu University, Japan

Philippe Levy, PhD, Hopital Beaujon AHP, Clichy, France

Jin-Young Jang, MD, PhD, Seoul National University

Santhi S. Vege, MD, Mayo Clinic, Rochester

Thilo Hackert, MD, University of Heidelberg, Germany

Claudio Bassi, MD, Pancreas Institute Verona, Italy

Tooru Shimosegawa MD, PhD, Tohoku University Graduate School of Medicine

# THE AMERICAN PANCREATIC ASSOCIATION'S 47th Annual Meeting

**WEDNESDAY, October 26**

*Grand Ballroom A*

**5:00 – 7:00 pm**

**Hirshberg Symposium: Recent Advances in Pancreatic Cancer Surgery**

Moderator | Carlos Fernandez-del Castillo, MD and Ashok K. Saluja, PhD

Oscar Joe Hines, MD, David Geffen School of Medicine at UCLA

*Three decades of progress in pancreatic surgery: safer and more standardized operations*

Michael L. Kendrick, MD, Mayo Clinic Rochester

*Emergence and role of minimally invasive surgery for pancreatic cancer*

Cristina R. Ferrone, MD, MGH, Harvard Medical School

*Modern neoadjuvant therapy downstages pancreatic cancer and increases candidates for surgery*

Thilo Hackert, MD, University of Heidelberg, Germany

*Crossing to new frontiers: surgery for recurrent and metastatic pancreatic cancer*

**7:00 – 9:00pm**

Presidential Reception

Location | *Georgian ABC*

**THURSDAY, October 27**

*Grand Ballroom A*

**7:00 – 8:30am**

Breakfast & Poster Viewing

Breakfast

Location / *Georgian ABC*

Meet the Professor Breakfast/ *Georgian ABC*

Poster Viewing

Location / *Grand Ballroom B and Statler*

**8:30 – 10:00am**

Pancreatic Cancer Abstract Session

Location / *Grand Ballroom A*

Moderators | Min Li, PhD and Guido Eibl, MD



**A New Mouse Model Demonstrates the Necessity of Mutant P53 Expression for Pancreatic Cancer Progression**

H. Schofield<sup>1</sup>, J. Zeller<sup>1</sup>, A.E. Cali Daylan<sup>2</sup>, C. Kumar<sup>1</sup>, E. Fearon<sup>1</sup>, M. Pasca Di Magliano<sup>1</sup>

<sup>1</sup>University of Michigan/USA, <sup>2</sup>Hacettepe University Medical School/Turkey

**Pancreatic Microtumors: A Novel Platform for Screening Chemotherapeutic Agents**

M. Goodwin, S. Urs, Z. Sila, D. Simeone

Surgery, University of Michigan, Ann Arbor, MI/USA

**NFkB in Tumor Stroma Modulates Cancer Growth in Mouse Models of Pancreatic Cancer**

B. Garg, B. Giri, S. Modi, V. Sethi, S. Banerjee, A.K. Saluja, V. Dudeja

Sylvester Comprehensive Cancer Center, Department of Surgery, University of Miami Miller School of Medicine, USA

**II-6 and Pd-L1 Antibody Blockade Combination Therapy Limits Tumor Progression in Murine Models of Pancreatic Cancer**

T. Mace<sup>1</sup>, R. Shakya<sup>1</sup>, J.R. Pitarresi<sup>1</sup>, B. Swanson<sup>1</sup>, C. McQuinn<sup>1</sup>, S. Loftus<sup>1</sup>, L. Yu<sup>1</sup>, G. Young<sup>1</sup>, X. Zhong<sup>2</sup>, T. Zimmers<sup>2</sup>, M. Ostrowski<sup>1</sup>, T. Ludwig<sup>1</sup>, M. Dillhoff<sup>1</sup>, C. Schmidt<sup>1</sup>, D. Conwell<sup>1</sup>, T. Bekaii-Saab<sup>3</sup>, G. Lesinski<sup>1</sup>

<sup>1</sup>The Ohio State University/USA, <sup>2</sup>Indiana University/USA, <sup>3</sup>Mayo Clinic/USA

**Espac-4: A Multicenter, International, Randomized Controlled Phase III Trial of Adjuvant Combination Chemotherapy of Gemcitabine (Gem) and Capecitabine (Cap), Versus Monotherapy Gemcitabine in Patients With Resected Pancreatic Ductal Adenocarcinoma**

J.P. Neoptolemos<sup>1</sup>, D. Palmer<sup>1</sup>, P. Ghaneh<sup>1</sup>, J. Valle<sup>2</sup>, D. Cunningham<sup>3</sup>, J. Wadsley<sup>4</sup>, T. Meyer<sup>5</sup>, A. Anthoney<sup>6</sup>, B. Glimelius<sup>7</sup>, S. Falk<sup>8</sup>, P. Lind<sup>9</sup>, J. Izbicki<sup>10</sup>, G. Middleton<sup>11</sup>, P. Ross<sup>12</sup>, H. Wasan<sup>13</sup>, A. McDonald<sup>14</sup>, T. Crosby<sup>15</sup>, E. Psarelli<sup>1</sup>, P. Hammel<sup>16</sup>, M.W. Büchler<sup>17</sup>

<sup>1</sup>University of Liverpool, Liverpool/United Kingdom, <sup>2</sup>University of Manchester & The Christie, Manchester/United Kingdom, <sup>3</sup>Royal Marsden Hospital, London/United Kingdom, <sup>4</sup>Weston Park Hospital, Sheffield/United Kingdom, <sup>5</sup>Royal Free Hospital, London/United Kingdom, <sup>6</sup>St James's University Hospital, Leeds/United Kingdom, <sup>7</sup>University of Uppsala, Uppsala/Sweden, <sup>8</sup>Bristol Hematology and Oncology Centre, Bristol/United Kingdom, <sup>9</sup>Karolinska University Hospital, Stockholm/Sweden, <sup>10</sup>University of Hamburg Medical Institutions UKE, Hamburg/Germany, <sup>11</sup>Royal Surrey County Hospital, Guildford/United Kingdom, <sup>12</sup>Guy's Hospital, London/United Kingdom, <sup>13</sup>Hammersmith Hospital, London/United Kingdom, <sup>14</sup>The Beatson West of Scotland Cancer Centre, Glasgow/United Kingdom, <sup>15</sup>Velindre Hospital, Cardiff/United Kingdom, <sup>16</sup>Hopital Beaujon, Clichy/France, <sup>17</sup>University of Heidelberg, Heidelberg/Germany

**Alterative Lengthening Of Telomeres and Loss of Daxx/Atrx Expression Predicts Metastatic Disease and Poor Survival in Patients With Pancreatic Neuroendocrine Tumors**

A.D. Singhi<sup>1</sup>, T.-C. Liu<sup>2</sup>, J.L. Roncaioli<sup>3</sup>, H.J. Zeh<sup>4</sup>, A.H. Zureikat<sup>4</sup>, A. Tsung<sup>4</sup>, J.W. Marsh<sup>4</sup>, K.K. Lee<sup>4</sup>, M.E. Hogg<sup>4</sup>, N. Bahary<sup>5</sup>, R.E. Brand<sup>5</sup>, K. McGrath<sup>5</sup>, A. Slivka<sup>5</sup>, K.L. Cressman<sup>1</sup>, K. Fuhrer<sup>1</sup>, R.J. O'Sullivan<sup>3</sup>

<sup>1</sup>Department of Pathology, University of Pittsburgh Medical Center, PA/USA,

<sup>2</sup>Department of Pathology, Washington University, MN/USA, <sup>3</sup>Department of Pharmacology and Chemical Biology, University of Pittsburgh, PA/USA, <sup>4</sup>Department of Surgery, University of Pittsburgh Medical Center, PA/USA, <sup>5</sup>Department of Medicine, University of Pittsburgh Medical Center, PA/USA

**Digital Next-Generation Sequencing Identifies Low-Abundance Mutations in Pancreatic Juice Samples of Patients With Pancreatic Cancer and Intraductal Papillary Mucinous Neoplasms**

J. Yu<sup>1</sup>, Y. Sadakari<sup>1</sup>, K. Shindo<sup>1</sup>, M. Suenaga<sup>1</sup>, A. Brant<sup>1</sup>, J.A.N. Almario<sup>1</sup>, M. Borges<sup>1</sup>, T. Barkley<sup>1</sup>, S. Fesharakizadeh<sup>1</sup>, M. Ford<sup>1</sup>, R.H. Hruban<sup>1, 2</sup>, E.J. Shin<sup>3</sup>, A.M. Lennon<sup>2, 4</sup>, M.I. Canto<sup>2, 3</sup>, M. Goggins<sup>1, 2, 3</sup>

<sup>1</sup>Pathology department, The Johns Hopkins University, MD/United States of America,

<sup>2</sup>Medicine department, The Johns Hopkins University, MD/United States of America,

<sup>3</sup>Oncology department, The Johns Hopkins University, MD/United States of America,

<sup>4</sup>Surgery department, The Johns Hopkins University, MD/United States of America

10:00 – 10:15am

Break

Location | *Grand Ballroom B Pre-function*

10:15 – 11:30am

**MINI SYMPOSIUM: Incidentally-discovered non-functioning neuroendocrine tumors**

Location | Grand Ballroom A

Moderators | Cristina Ferrone, MD and Massimo Falconi, MD

Massimo Falconi, MD, San Raffaele Hospital, Milan

*The natural history of non-functioning PNETs*

Peter Allen, MD, FACS, Memorial Sloan Kettering Cancer Center

*Most patients with incidentally discovered PNETs can be managed non-operatively*

Tetsuhide Ito, MD, PhD, Kyushu University, Japan

*Management of non-functioning PNETs in Japan*

Christopher Wolfgang, MD, MS, PhD, Johns Hopkins University

*Size and risk of lymph node metastases in non-functioning PNETs*

11:30-12:00 pm

**Frank Brooks State of the Art Lecture (Basic Science)**

Location | *Grand Ballroom A*

Introduction | Ashok K. Saluja, PhD

Craig Logsdon, PhD, MD Anderson

*The stressed acinar cell: Adapt, die or disaster*

12:00 – 2:00 pm

Lunch & Poster Session

Lunch | *Georgian ABC*

Poster Session

Location | Grand Ballroom B and Statler

Guided viewing of the posters of distinction – 1-2pm

Lead by | Murray Korc, MD and Minoti V. Apte, MBBS, PhD

Fred S. Gorelick, MD and Johanna Laukkarinen, MD, PhD

Meet at Registration / Location | *Exeter Foyer*

2:00 – 3:05pm

Pancreatitis Abstract Session

Location | *Grand Ballroom A*

Moderators | Guy E. Groblewski, PhD and Anna Gukovskaya, PhD

**Downregulation of Atg4b Stimulates Autophagy and Ameliorates Alcohol-Induced Pancreatic Injury**

J.M. Elperin<sup>1</sup>, S. Suriany<sup>1</sup>, G.E. Lee<sup>1</sup>, S.W. French<sup>2</sup>, A.S. Gukovskaya<sup>1</sup>, I. Gukovsky<sup>1</sup>,  
O.A. Mareninova<sup>1</sup>

<sup>1</sup>Veterans Affairs Greater Los Angeles Healthcare System and University of California at Los Angeles/United States of America, <sup>2</sup>Southern California Research Center for ALPD and Cirrhosis, Los Angeles, CA/United States of America

**Genetic Deletion of Ampk Results in Greater Baseline and Secretagogue-Stimulated Enzyme Activity and Cellular Injury**

C.A. Shugrue<sup>1</sup>, A.J. Ceplenski<sup>1</sup>, E.J. Foglio<sup>2</sup>, V. Patel<sup>1</sup>, M. Foretz<sup>3</sup>, B. Viollet<sup>3</sup>, F.S. Gorelick<sup>1,4</sup>

<sup>1</sup>Department of Internal Medicine, Section of Digestive Diseases, Yale University School of Medicine, New Haven, CT/United States of America, <sup>2</sup>Department of Pediatrics, Yale University School of Medicine, New Haven, CT/United States of America, <sup>3</sup>Institut Cochin, INSERM, Paris/France, <sup>4</sup>VA Connecticut Healthcare, West Haven, CT/United States of America

**Epithelial Cell-Specific Calcineurin Signaling Mediates Inflammation in the Context of Pancreatitis**

L. Wen, A. Orabi, T.A. Javed, S. Sanker, K. Boggs, J.F. Eisses, S.Z. Husain  
Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA/United States of America

**Endoscopic or Surgical Step-Up Approach for Necrotizing Pancreatitis, a Multi-Center Randomized Controlled Trial**

S. Van Brunschot

On behalf of the Dutch Pancreatitis Study Group/Netherlands

**Tissue Immunohistochemistry Differentiates Diabetic Exocrine Pancreatopathy From Chronic Pancreatitis**

S. Majumder<sup>1</sup>, N.A. Philip<sup>1</sup>, Y. Zen<sup>2</sup>, L. Zhang<sup>3</sup>, R.P. Sah<sup>1</sup>, W.S. Harmsen<sup>1</sup>, F.T. Enders<sup>1</sup>,  
T.C. Smyrk<sup>3</sup>, S.T. Chari<sup>1</sup>

<sup>1</sup>Mayo Clinic/United States of America, <sup>2</sup>Kobe University/Japan, <sup>3</sup>Laboratory Medicine & Pathology, Mayo Clinic/United States of America

**Effect of Intrapancreatic Fat on Diabetes Risk After Total Pancreatectomy With Islet Autotransplantation**

M. Kizilgul<sup>1</sup>, M. Bellin<sup>1,2</sup>, M. Abdulla<sup>1</sup>, D. Heller<sup>1</sup>, G.J. Beilman<sup>3</sup>, S. Chinnakotla<sup>3</sup>, T.B. Dunn<sup>3</sup>, T.L. Pruett<sup>1</sup>, B.J. Hering<sup>1</sup>, J.J. Wilhelm<sup>1</sup>

<sup>1</sup>Schulze Diabetes Institute, University of Minnesota/United States of America, <sup>2</sup>Department of Pediatrics, University of Minnesota, Minneapolis, MN/United States of America, <sup>3</sup>Surgery, University of Minnesota, Minneapolis, MN/United States of America

3:05 – 4:20pm

**MINI SYMPOSIUM: Immunobiology and Immunotherapy of Pancreatic Adenocarcinoma**

Location | *Grand Ballroom A*

Moderator | Kyoichi Takaori, MD, PhD and Margaret A. Tempero, MD

George Miller, MD, New York University

*Unraveling the Immunobiology of Pancreatic Cancer*

David Linehan, MD, University of Rochester Medical Center

*CCR2: A new immune target for Pancreatic Cancer*

Margaret A. Tempero, MD, University of California San Francisco  
*Integrating Immunotherapy into Pancreatic Cancer Treatment: Lessons from a SU2C Team*

4:20 – 4:30pm

Break  
Location | *Terrace Foyer*

4:30 – 6:45pm

**Kenner Family Research Fund Forum: Early Detection of Pancreatic Cancer: The Role of Industry in the Development of Biomarkers**

Location | *Terrace*

Barbara Kenner, PhD, Kenner Family Research Fund  
*Forum Overview*

Sudhir Srivastava, PhD, MPH  
Chief, Cancer Biomarkers Research Group  
National Cancer Institute  
*Current State of Biomarkers*

Anne-Renee Hartman, MD,  
Medical Director and Director of Clinical Product Development  
*GRAIL*

Christer Wingren, PhD  
Chief Technology Officer  
Laura Chirica, PhD  
Chief Commercial Officer  
*Immunovia*

Niven R. Nirain, MD  
Co-Founder, President, and CEO of Berg  
A. James Moser, MD, FACS  
Co-Director, Pancreas and Liver Institute  
Beth Israel Deaconess Medical Center  
*Project Survival*

Suresh T. Chari, MD, Mayo Clinic College of Medicine  
Stephen J. Pandol, MD, Cedars-Sinai Medical Center  
*Discussion and Analysis*

7:00 – 10:00pm

Awards Dinner & Reception

Reception 7:00 – 8:00 pm  
Location | *Georgian ABC*  
Dinner 8:00 – 10:00 pm  
Location | *Grand Ballroom A*

## FRIDAY, October 28

### Grand Ballroom A

7:00 – 8:30am

Breakfast & Poster Viewing

Breakfast

Location | *Georgian ABC*

Meet the Professor Breakfast

Location | *Georgian ABC*

Poster Viewing

Location | *Grand Ballroom B and Statler*

8:30 – 10:00am

Pancreatitis Abstract Session

Location | *Grand Ballroom A*

Moderators | Vikas Dudeja, MD and Kazuichi Okazaki, MD, PhD

#### **Investigating the Novel Function of Hippo Signaling in Pancreatic Acinar Cells**

M. Gao<sup>1</sup>, J. Liu<sup>1</sup>, J. Leighton<sup>1</sup>, X. Yin<sup>1</sup>, R.L. Johnson<sup>2</sup>, P. Wang<sup>1</sup>

<sup>1</sup>Department of Cellular and Structural Biology, UT HEALTH SCIENCE CENTER AT SA, San Antonio/United States of America, <sup>2</sup>Department of Cancer Biology, Division of Basic Science Research, The University of Texas MD Anderson Cancer Center, Houston/United States of America

#### **Glycogen Synthase Kinase-3beta Ablation Limits Pancreatitis Induced Acinar-To-Ductal Metaplasia**

L. Ding<sup>1</sup>, G.-Y. Liou<sup>2</sup>, J.-S. Zhang<sup>1</sup>, P. Storz<sup>2</sup>, D.D. Billadeau<sup>1</sup>

<sup>1</sup>Division of Oncology Research, Schulze Center for Novel Therapeutics, Mayo Clinic, Rochester, MN/United States of America, <sup>2</sup>Department of Cancer Biology, Mayo Clinic, Jacksonville, FL/United States of America

#### **Therapeutic Adam 10 And 17 Inhibition Reduces Local and Systemic Inflammation in Acute Pancreatitis**

J. George<sup>1</sup>, A. Dixit<sup>1</sup>, A. Sareen<sup>2</sup>, H. Cheema<sup>1</sup>, B. Giri<sup>1</sup>, V. Dudeja<sup>1</sup>, R. Dawra<sup>1</sup>, A.K. Saluja<sup>1</sup>

<sup>1</sup> Sylvester Comprehensive Cancer Center, Department of Surgery, University of Miami Miller School of Medicine, United States of America, <sup>2</sup>Surgery, University of Minnesota, United States of America

#### **Small Molecule CCR2 Antagonist Therapy in Experimental Model of Chronic Pancreatitis**

J. Xue<sup>1\*#</sup>, Q. Zhao<sup>1#</sup>, V. Sharma<sup>1</sup>, J. Kalisiak<sup>2</sup>, Y. Zeng<sup>2</sup>, A. Krasinski<sup>2</sup>, P. Zhang<sup>2</sup>, J. McMahon<sup>2</sup>, J. Campbell<sup>2</sup>, I. Charo<sup>2</sup>, T. Schall<sup>2</sup>, A. Habtezion<sup>1</sup>

<sup>1</sup>Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA 94305, USA, <sup>2</sup>ChemoCentryx, Mountain View, CA 94043, USA, \*Renji-MedX Stem Cell Research Center, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, China, #Contributed equally

#### **Cholecystectomy (Ccy) During Index Admission for Acute Pancreatitis (Ap) Decreases the Risk of Recurrences and Readmissions: A National-Level Analysis**

S.G. Krishna<sup>1</sup>, A. Hinton<sup>1</sup>, D. Yadav<sup>2</sup>, D. Conwell<sup>1</sup>

<sup>1</sup>Ohio State University Medical Center, Columbus, OH/United States of America,

<sup>2</sup>University of Pittsburgh Medical Center/United States of America



### **Minimally Invasive Versus Open Necrosectomy for Necrotizing Pancreatitis**

R.A. Hollemans<sup>1</sup>, S. Van Brunschot<sup>2</sup>, O. Bakker<sup>3</sup>, M.G. Besselink<sup>1</sup>, T.H. Baron<sup>4</sup>, H.G. Beger<sup>5</sup>, M.A. Boermeester<sup>1</sup>, T.L. Bollen<sup>6</sup>, M.J. Bruno<sup>7</sup>, R. Carter<sup>8</sup>, R. Charnley<sup>9</sup>, D. Coelho<sup>10</sup>, B. Dahl<sup>11</sup>, M.G. Dijkgraaf<sup>12</sup>, N. Doctor<sup>13</sup>, G. Farkas<sup>14</sup>, P.J. Fagenholz<sup>15</sup>, C. Fernandez-Del Castillo<sup>16</sup>, P. Fockens<sup>17</sup>, M.L. Freeman<sup>18</sup>, T.B. Gardner<sup>19</sup>, H. Van Goor<sup>20</sup>, H.G. Gooszen<sup>21</sup>, G. Hannink<sup>22</sup>, R. Logan<sup>23</sup>, C.J. McKay<sup>24</sup>, M.P. Peev<sup>25</sup>, J.P. Neoptolemos<sup>26</sup>, A. Oláh<sup>27</sup>, R.W. Parks<sup>28</sup>, M. Raraty<sup>29</sup>, B. Rau<sup>30</sup>, T. Rösch<sup>31</sup>, M. Rovers<sup>22</sup>, H. Seifert<sup>32</sup>, A.K. Siriwardena<sup>33</sup>, K.D. Horvath<sup>34</sup>, H.C. Van Santvoort<sup>35</sup>  
<sup>1</sup>Surgery, Academic Medical Center Amsterdam/Netherlands, <sup>2</sup>Gastroenterology, Academic Medical Center Amsterdam/Netherlands, <sup>3</sup>Surgery, University Medical Center Utrecht/Netherlands, <sup>4</sup>Gastroenterology and Hepatology, University of North Carolina, NC/United States of America, <sup>5</sup>Surgery, University of Ulm/Germany, <sup>6</sup>Radiology, St. Antonius Hospital/Netherlands, <sup>7</sup>Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam/Netherlands, <sup>8</sup>Glasgow Royal Infirmary/United Kingdom, <sup>9</sup>Department of HPB Surgery, Newcastle upon Tyne Hospitals, Newcastle Upon Tyne/United Kingdom, <sup>10</sup>Hospital Clementino Fraga Filho, Rio De Janeiro/Brazil, <sup>11</sup>Of Internal Medicine, Oldenburg Municipal Hospital, Oldenburg/Germany, <sup>12</sup>Clinical Research Unit, Academic Medical Center, Amsterdam/Netherlands, <sup>13</sup>Surgery, Jaslok Hospital and Research Center/India, <sup>14</sup>University of Szeged, Szeged/Hungary, <sup>15</sup>Massachusetts General Hospital, Boston/United States of America, <sup>16</sup>Department of Surgery, Massachusetts General Hospital, MA/United States of America, <sup>17</sup>Academic Medical Center Amsterdam/Netherlands, <sup>18</sup>Gastroenterology, University of Minnesota, Minneapolis/United States of America, <sup>19</sup>Gastroenterology and Hepatology, Dartmouth-Hitchcock Medical Center/United States of America, <sup>20</sup>Surgery, Radboud University Medical Center/Netherlands, <sup>21</sup>Operating Rooms - Evidence Based Surgery, Radboud University Medical Center, Nijmegen/Netherlands, <sup>22</sup>Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen/Netherlands, <sup>23</sup>Surgery, Freeman Hospital, Newcastle Upon Tyne/United Kingdom, <sup>24</sup>Surgery, Glasgow Royal Infirmary, Glasgow/United Kingdom, <sup>25</sup>Surgery, Massachusetts General Hospital, Boston/United States of America, <sup>26</sup>National Institutes of Health Research Liverpool Pancreas Biomedical Research Unit, Royal Liverpool and Broadgreen University Hospitals, Liverpool/United Kingdom, <sup>27</sup>Surgery, Petz-Aladár teaching hospital, Győr/Hungary, <sup>28</sup>Surgery, University of Edinburgh, Edinburgh/United Kingdom, <sup>29</sup>Surgery, Royal Liverpool and Broadgreen University Hospitals, Liverpool/United Kingdom, <sup>30</sup>Surgery, University of Rostock, Rostock/Germany, <sup>31</sup>Interdisciplinary Endoscopy, University Hospital Hamburg-Eppendorf, Hamburg/Germany, <sup>32</sup>Internal Medicine, Oldenburg Municipal Hospital, Oldenburg/Germany, <sup>33</sup>Surgery, Manchester Royal Infirmary, Manchester/United Kingdom, <sup>34</sup>Surgery, University of Washington, Seattle/United States of America, <sup>35</sup>Surgery, St. Antonius Hospital, Nieuwegein/Netherlands

### **Role of Chymotrypsin C in Cerulein-Induced Pancreatitis in the Mouse**

Z. Jancso, A. Geisz, B.C. Nemeth, M. Sahin-Toth  
Boston University, Boston/United States of America

10:00 – 10:15am

Break

Location | *Grand Ballroom B Pre-function*

10:15 - 10:45am

**Paul Webster Clinical Start of Art Lecture**

Location | *Grand Ballroom A*

Introduction | Carlos Fernandez-del Castillo, MD

David Patrick Ryan, MD, Harvard Medical School  
*Pancreatic Cancer in 2017: Where are we and where are we heading?*

10:45 - 12:00pm

**Parallel Session: Prevention of post ERCP pancreatitis: Stents vs Suppositories and other controversies**

Location | *Grand Ballroom A*

Moderators | Martin L. Freeman, MD and Nageshwar Reddy, MD

Martin L. Freeman, MD, University of Minnesota  
*Case Presentation*

Sohail Husain, MD, Children's Hospital of Pittsburgh of UPMC  
*Probing the Mechanisms Underlying Post-ERCP Pancreatitis*

Shyam Varadarajulu, MD, Florida Hospital Center for Interventional Endoscopy  
*Pancreatic stents are paramount, NSAIDs a nuisance*

Jamie Barkin, MD, MACP, MACG, University of Miami Miller School of Medicine  
*NSAIDs are necessary, pancreatic stents peripheral*

Gregory Cote, MD, Medical University of South Carolina  
*The truth is somewhere in the middle*

Martin Freeman, MD, University of Minnesota  
*Case Presentation*

Panel Debate

10:45 - 12:00pm

**Parallel Session: What Matters in Pancreatitis**

Location | *Terrace*

Moderators | Aida Habtezion, MD, MSc and Julia Mayerle, MD

Miklos Sahin-Toth, MD, PhD, Boston University School of Medicine  
*In chronic pancreatitis it's all genetics!*

Pramod Garg, MD, All India Institute of Medical Sciences  
*In chronic pancreatitis it's all environment*

Markus M. Lerch, MD, University Medicine Greifswald, Germany  
*In acute pancreatitis it's all genetics*

Vijay P. Singh, MBBS, Mayo Clinic  
*In acute pancreatitis it's all environment*

12:00 – 2:00 pm

Lunch & Poster Session

Lunch

Location | *Georgian ABC*

Poster Session

Location | *Grand Ballroom B and Statler*

Guided viewing of the posters of distinction – 1-2pm  
Lead by | Rodger Liddle, MD and Jill Palmer Smith, MD, PhD  
Dana K. Andersen, MD and Robert Sutton, MB, BS, FRCS, DPhil  
Meet at Registration / Location | *Exeter Foyer*

2:00 - 2:30pm

**Business Meeting**

Location | *Grand Ballroom A*

**Presidential Address** Carlos Fernandez-del Castillo, MD

**Secretary-Treasurer's Report** Ashok K. Saluja, PhD

**Report from the Nominating Committee** Carlos Fernandez-del Castillo, MD

2:30 - 3:45pm

**MINI SYMPOSIUM: Multidisciplinary Management of Pancreatic Necrosis**

Location | *Grand Ballroom A*

Moderators | Peter A. Banks, MD & Julia McNabb- Baltar, MD, MPH

Julia McNabb-Baltar, MD, MPH, Brigham and Women's Hospital, Boston  
*Case Presentation*

Vikesh Singh, MD, MSc, Johns Hopkins University School of Medicine  
*The Epidemiology of and Risk Factors for Pancreatic Necrosis*

Koenraad J. Mortelet, MD, Beth Israel Deaconess Medical Center  
*Radiologic Imaging Standards*

Christopher C. Thompson, MD, Brigham and Women's Hospital, Boston  
*Update on Endoscopic Management*

Peter J. Fagenholz, MD, Massachusetts General Hospital  
*Minimally Invasive Surgery Approaches*

Bechien U. Wu, MD, Kaiser Permanente  
*State of Art: Pancreatic Necrosis - A Multidisciplinary Approach to Management*

Panel Discussion: Moderators - all speakers

3:45 – 4:00pm

Break

Location | *Grand Ballroom B Pre-function*

4:00 - 5:15pm

**MINI SYMPOSIUM: Novel diagnostic platforms in pancreatic cancer**

Location | *Grand Ballroom A*

Moderators | Andrew D. Rhim, MD and Maximilian Reichert, MD

David T. Ting, MD, Massachusetts General Hospital Cancer Center, Harvard Medical School  
*Pancreatic cancer circulating tumor cells*

Andrew D. Rhim, MD, MD Anderson Cancer Center  
*Ultrasensitive approaches to mutation detection in liquid biopsies*

Surinder K. Batra, PhD, University of Nebraska Medical Center  
*Serum microRNAs in pancreatic cancer*

5:15 - 6:30pm

### **Parallel Session: (Clinical Science Abstracts)**

Location | *Grand Ballroom A*

Moderators | Yi Miao, MD and Jens Werner, MD, MBA

#### **Elevated Circulating Histones Associate With Multiple Organ Dysfunction Syndromes in Acute Pancreatitis**

T. Liu<sup>1</sup>, W. Huang<sup>2</sup>, S. Abrams<sup>1</sup>, L. Wang<sup>3</sup>, P. Szatmary<sup>2</sup>, Y. Alhamdi<sup>1</sup>, Z.Q. Lin<sup>3</sup>, I. Welters<sup>4</sup>, G. Wang<sup>1</sup>, C.H. Toh<sup>5</sup>, R. Sutton<sup>2</sup>

<sup>1</sup>Department of Clinical Infection, Microbiology and Immunology, Institute of Infection and Global Health, University of Liverpool/United Kingdom, <sup>2</sup>NIHR Liverpool Pancreas Biomedical Research Unit, Royal Liverpool University Hospital NHS Trust, University of Liverpool/United Kingdom, <sup>3</sup>Department of Integrated Traditional Chinese and Western Medicine, Sichuan Provincial Pancreatitis Centre, West China Hospital, Sichuan University/China, <sup>4</sup>Intensive Care Unit, Royal Liverpool University Hospital, Liverpool/United Kingdom, <sup>5</sup>Roald Dahl Haemostasis & Thrombosis Centre, Royal Liverpool University Hospital/United Kingdom

#### **Autoimmune Pancreatitis in Children: Working Guidelines for Diagnosis and Management**

I. Scheers<sup>1</sup>, J.J. Palermo<sup>2</sup>, S. Freedman<sup>3</sup>, M. Wilschanski<sup>4</sup>, U. Shah<sup>5</sup>, M. Abu-El-Haija<sup>2</sup>, B. Barth<sup>6</sup>, D. Fishman<sup>7</sup>, C. Garipey<sup>8</sup>, M. Giefer<sup>9</sup>, M. Heyman<sup>10</sup>, R. Himes<sup>7</sup>, S.Z. Husain<sup>11</sup>, T.K. Lin<sup>2</sup>, Q. Liu<sup>12</sup>, M.E. Lowe<sup>11</sup>, M. Mascarenhas<sup>13</sup>, V. Morinville<sup>14</sup>, C.Y. Ooi<sup>15</sup>, E. Perito<sup>10</sup>, D.A. Piccoli<sup>13</sup>, J. Pohl<sup>16</sup>, S.J. Schwarzenberg<sup>17</sup>, D. Troendle<sup>6</sup>, S. Werlin<sup>18</sup>, B. Zimmerman<sup>19</sup>, A. Uc<sup>19</sup>, T. Gonska<sup>1</sup>

<sup>1</sup>Hospital for Sick Children, Toronto/Canada, <sup>2</sup>Cincinnati Children's Hospital Medical Center, Cincinnati/United States of America, <sup>3</sup>Harvard Medical School, Beth Israel Deaconess Medical Center, Boston/United States of America, <sup>4</sup>Hadassah Hebrew University Hospital, Jerusalem/Israel, <sup>5</sup>Harvard Medical School, Massachusetts General Hospital for Children, Boston/United States of America, <sup>6</sup>University of Texas Southwestern Medical School, Dallas/United States of America, <sup>7</sup>Baylor College of Medicine, Houston/United States of America, <sup>8</sup>Nationwide Children's hospital, Columbus/United States of America, <sup>9</sup>Seattle Children's Hospital, Seattle/United States of America, <sup>10</sup>University of California at San Francisco, San Francisco/United States of America, <sup>11</sup>Children's Hospital of Pittsburgh of UPMC, Pittsburgh/United States of America, <sup>12</sup>Keck School of Medicine, University of Southern California, Children's Hospital Los Angeles, Los Angeles/United States of America, <sup>13</sup>The Children's Hospital of Philadelphia, Philadelphia/United States of America, <sup>14</sup>Montreal Children's Hospital, McGill University, Montreal/Canada, <sup>15</sup>Discipline of Pediatrics, School of Women's and Children's Health, Medicine, University of New South Wales and Sydney Children's Hospital Randwick, Sydney/Australia, <sup>16</sup>University of Utah, Salt Lake City/United States of America, <sup>17</sup>University of Minnesota Masonic Children's Hospital, Minneapolis/United States of America, <sup>18</sup>Medical College of Wisconsin, Milwaukee/United States of America, <sup>19</sup>University of Iowa Carver College of Medicine, Iowa City/United States of America

#### **Progression of Acute Pancreatitis to Acute Recurrent Pancreatitis in the Pediatric Population: A Single Center Prospective Database Report**

K.F. Sweeny, T.K. Lin, J.D. Nathan, J.J. Palermo, L. Hornung, T. Thompson, M. Abu-El-Haija

Cincinnati Children's Hospital Medical Center, Cincinnati/United States of America

**Pancreatic Mucinous Cystic Neoplasms (McN) Of Any Size, Without Worrisome Features or Symptoms Can Be Safely Surveyed In Women but Should Be Resected In Men: A Multinational Cohort Study Including 211 Patients**

G. Keane<sup>1</sup>, A. Shamili<sup>2</sup>, L. Nilsson<sup>3</sup>, A. Antila<sup>4</sup>, J.B. Millastre<sup>5</sup>, M.V.Z. Monica<sup>6</sup>, C. Verdejo<sup>7</sup>, Y. Vaalavuo<sup>4</sup>, T. Hoskins<sup>8</sup>, S. Robinson<sup>8</sup>, G. Ceyhan<sup>9</sup>, M. Abuhilal<sup>10</sup>, S. Pereira<sup>11</sup>, J. Laukkanen<sup>4</sup>, M. Del Chiaro<sup>12</sup>

<sup>1</sup>Institute for Liver and Digestive Health, University College London, United Kingdom  
Freeman Hospital, Newcastle/United Kingdom, <sup>2</sup>Southampton University Hospital/United Kingdom, <sup>3</sup>Karolinska Institute/Sweden, <sup>4</sup>Tampere University Hospital/Finland, <sup>5</sup>Gastroenterology, Miguel Servet University Hospital/Spain, <sup>6</sup>Pathology, Nijmegen University Hospital/Netherlands, <sup>7</sup>GASTROENTEROLOGY, HOSPITAL GENERAL UNIVERSITARIO DE CIUDAD REAL/Spain, <sup>8</sup>Freeman Hospital, Newcastle/United Kingdom, <sup>9</sup>Technische Universität München/Germany, <sup>10</sup>Southampton University Hospital, United Kingdom/United Kingdom, <sup>11</sup>Institute for Liver and Digestive Health, University College London United Kingdom Freeman Hospital, Newcastle/United Kingdom, <sup>12</sup>Div. of Surgery, Dept. of Clinical Science, Intervention and Technology (CLINTEC), Karolinska Institute, Stockholm/Sweden

**DNA Analysis of Pancreatic Cystic Fluid Has Incremental Predictive Value in Assessing Future Risk of Malignant Outcomes**

J.J. Farrell<sup>1</sup>, S. Jackson<sup>2</sup>, N. Toney<sup>2</sup>, T. Gonda<sup>3</sup>

<sup>1</sup>Yale Center for Pancreatic Disease, Yale University, New Haven, CT/United States of America, <sup>2</sup>Clinical Development, Interpace Diagnostics Corporation, Pittsburgh, PA/United States of America, <sup>3</sup>Division of Digestive and Liver Disease, Columbia University, New York, NY/United States of America

**Risk for Pancreatic Cancer in Patients With Pancreatic Cysts and Family History of Pancreatic Cancer**

A. Sharma, S. Mukewar, N. Philip, S.S. Vege, S.T. Chari

Gastroenterology and Hepatology, Mayo Clinic, MN/United States of America

5:15 - 6:30pm

**Parallel Session: (Basic Science Abstracts)**

Location | *Terrace*

Moderators | Aliye Uc, MD and Aditi Bhargava, PhD

**Exosome-Mediated Communication Between Pancreatic Carcinoma Cells and Pancreatic Stellate Cells Is Ca<sup>2+</sup> Regulated and Dependent on the Snare- And Ca<sup>2+</sup>-Binding Protein, Munc13-4**

S. Messenger<sup>1</sup>, T. Martin<sup>2</sup>

<sup>1</sup>Department of Biochemistry, University of Wisconsin/United States of America,

<sup>2</sup>University of Wisconsin/United States of America

**Bile Acids (Ba) In Human Pancreatic Necrosis(Pn) Worsen Acute Pancreatitis (Ap) Via a Non-Micellar Interaction With Fatty Acids(Fa)**

K. Patel<sup>1</sup>, B. Khatua<sup>1</sup>, J.R. Yaron<sup>1</sup>, C. De Oliveira<sup>1</sup>, R.J. Singh<sup>2</sup>, G. Papachristou<sup>3</sup>, D. Yadav<sup>3</sup>, K. Lee<sup>4</sup>, F. Murad<sup>5</sup>, V.P. Singh<sup>1</sup>

<sup>1</sup>Department of Medicine, Mayo Clinic, Scottsdale, AZ/United States of America, <sup>2</sup>Lab Medicine and Pathology, Mayo Clinic, MN/United States of America, <sup>3</sup>Medicine, University of Pittsburgh, PA/United States of America, <sup>4</sup>Surgery, University of Pittsburgh, PA/United States of America, <sup>5</sup>NorthShore University Health System, IL/United States of America



### **Sp1 Downregulation Leads to Disruption of Endoplasmic Reticulum Homeostasis and Cell Death**

P. Dauer, A. Nomura, V.K. Gupta, V. Dudeja, S. Banerjee, A.K. Saluja

Sylvester Comprehensive Cancer Center, Department of Surgery, University of Miami Miller School of Medicine, USA

### **Carboxyl Ester Lipase Hybrid Gene and the Unfolded Protein Response: A Novel Trypsin Independent Model of Injury in Pancreatic Acinar Cells**

W.M. Sunseri<sup>1</sup>, G. Jones<sup>2</sup>, X. Xiao<sup>3</sup>, M.E. Lowe<sup>4</sup>

<sup>1</sup>Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA/USA, <sup>2</sup>Children's Hospital of Pittsburgh of UPMC/US, <sup>3</sup>UPMC, Children's Hospital of Pittsburgh, Pittsburgh, PA/USA, <sup>4</sup>Department of Pediatrics, Children's Hospital of Pittsburgh of University of Pittsburgh Medical Center, Pittsburgh/USA

### **Mtp-Independent Modulation of Bioenergetics by Oxidants Determines Pancreatic Acinar Cell Death Pathway Activation**

J. Armstrong<sup>1</sup>, N. Cash<sup>2</sup>, J. Morton<sup>2</sup>, Y. Ouyang<sup>1</sup>, A. Tepikin<sup>2</sup>, R. Sutton<sup>1</sup>, D. Criddle<sup>2</sup>

<sup>1</sup>NIHR Pancreas Biomedical Research Unit, University of Liverpool, Liverpool/United Kingdom, <sup>2</sup>Cellular and Molecular Physiology, University of Liverpool/UK

### **Yap Is Critical Mediator of Tgf-B1 Induced Emt and Cell Invasion in Pancreatic Cancer**

X. Li<sup>1</sup>, Z. Jiang<sup>2</sup>, Q. Ma<sup>2</sup>

<sup>1</sup>Department of General Surgery, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an/China, <sup>2</sup>Department of Hepatobiliary Surgery, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an/China

### **Selective Regulation of Intraductal Papillary Mucinous Neoplasms by the Bet Family of Chromatin Adaptors**

Y. Huang<sup>1</sup>, C.E. Adams<sup>1</sup>, K.N. Von Alt<sup>1</sup>, Y. Kato<sup>2</sup>, Y. Mizukami<sup>2,3</sup>, K.C. Patra<sup>2</sup>, N. Bardeesy<sup>2</sup>, K.D. Lillemoe<sup>1</sup>, C. Fernandez-Del Castillo<sup>1</sup>, A.L. Warshaw<sup>1</sup>, A.S. Liss<sup>1</sup>

<sup>1</sup>Department of Surgery and the Andrew L Warshaw, MD, Institute for Pancreatic Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA/USA, <sup>2</sup>Cancer Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA/USA, <sup>3</sup>Center for Clinical and Biomedical Research, Sapporo Higashi Tokushukai Hospital, Sapporo/Japan

7:00pm

### **Women in Pancreas Reception & Dinner**

Reception Location | *Arlington Berkeley Clarendon*

Dinner Location | *Georgian*

Co-chairs | Aida Habtezion, MD, MSc, Kimberly Kelly, PhD, Diane Simeone, MD

### **Dimensions of Influence and Negotiation**

Keynote Speakers | Stephen Blattner, MD MBA

Judith Simmons, MD

exagoMD

*Leadership Strategy, Leadership Structure, Leadership Effectiveness*

[www.exagomd.com](http://www.exagomd.com)

Jacqueline Rosenthal

Senior Vice President

ZurickDavis

*Strategic Solutions in Healthcare Search*

[www.zurickdavis.com](http://www.zurickdavis.com)

## SATURDAY, October 29

### Grand Ballroom A

7:00 – 8:30am

Breakfast

Location | Georgian ABC

8:30 – 10:00am

Pancreatic Cancer Abstract Session

Location | *Grand Ballroom A*

Moderators | Sulagna Banerjee, PhD and Marina Pasca Di Magliano, PhD

#### **Haploinsufficiency of Beclin1 Inhibits Panin Development in a Krasg12d Mouse Model of Pancreatic Tumorigenesis**

K. Takakura<sup>1</sup>, E. Mascarinas<sup>2</sup>, B. Decant<sup>2</sup>, D. Dawson<sup>3</sup>, G. Eibl<sup>4</sup>, A. Gukovskaya<sup>5</sup>, P. Grippo<sup>2</sup>

<sup>1</sup>Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA/United States of America, <sup>2</sup>Medicine, University of Illinois-Chicago, IL/United States of America, <sup>3</sup>Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, CA/United States of America, <sup>4</sup>Surgery, David Geffen School of Medicine at UCLA, CA/United States of America, <sup>5</sup>Medicine, David Geffen School of Medicine at UCLA, CA/United States of America

#### **A Novel B2 Adrenergic-Nerve Growth Factor Feed Forward Loop Promotes Pancreatic Cancer**

B.W. Renz<sup>1</sup>, R. Takahashi<sup>2</sup>, M. Macchini<sup>2</sup>, T. Tanaka<sup>2</sup>, Y. Hayakawa<sup>3</sup>, C.B. Westphalen<sup>4</sup>, M. Ilmer<sup>1</sup>, X. Chen<sup>2</sup>, A. Kleespies<sup>1</sup>, D.L. Worthley<sup>5</sup>, A.C. Iuga<sup>6</sup>, J. Werner<sup>1</sup>, K.P. Olive<sup>6</sup>, T.C. Wang<sup>2</sup>

<sup>1</sup>Department of General, Visceral, Vascular and Transplantation Surgery, University of Munich, Munich/Germany, <sup>2</sup>Division of Digestive and Liver Diseases, Columbia University Medical Center, Irving Cancer Research Center, New York, NY/United States of America, <sup>3</sup>University of Tokyo/Japan, <sup>4</sup>University of Munich/Germany, <sup>5</sup>University of Adelaide/Australia, <sup>6</sup>Columbia University Medical Center, Irving Cancer Research Center, New York, NY/United States of America

#### **Serum Exosomal MicroRNA-191, -21, -451a Are Considered To Be Efficient Diagnostic Marker of Pancreatic Neoplasm**

T. Goto, H. Konishi, J. Sasajima, S. Fujibayashi, T. Utsumi, H. Sato, Y. Sugiyama, T. Iwama, M. Ijiri, K. Takahashi, K. Tanaka, A. Sakatani, Y. Nomura, N. Ueno, S. Kashima, S. Takauji, K. Moriichi, M. Fujiya, T. Okumura  
Asahikawa medical university/Japan

#### **Egfr1 Targeted Delivery of 5 Fluorouracil Using Tumor Specific Theranostic Aptamers in Pancreatic Ductal Adenocarcinoma**

U.M. Mahajan<sup>1</sup>, J.P. Kühn<sup>2</sup>, T. Marschall<sup>1</sup>, B. Appel<sup>3</sup>, F. Lämmerhirt<sup>1</sup>, M. Sendler<sup>1</sup>, P.R. Wagh<sup>1</sup>, S. Müller<sup>3</sup>, F.-U. Weiss<sup>1</sup>, M.M. Lerch<sup>1</sup>, J. Mayerle<sup>1</sup>

<sup>1</sup>Department of Medicine A, University Medicine, Ernst-Moritz-Arndt-University Greifswald, Greifswald/Germany, <sup>2</sup>Department of Diagnostic Radiology and Neuroradiology, University Medicine, Ernst-Moritz-Arndt University, Greifswald, Germany/Germany, <sup>3</sup>Institute of Biochemistry, Ernst-Moritz-Arndt University, Greifswald, Germany/Germany

#### **Regulation of Yes-Associated Protein 1 in Activated Pancreatic Stellate Cells**

J. Yang, H.-Y. Su, R.T. Waldron, Q. Chen, Q. Wang, A. Lugea, S.J. Pandol  
Cedars-Sinai Medical Center/United States of America

**Risk of Malignant Transformation in Suspected Branch Duct Intraductal Papillary Mucinous Neoplasms Extends Beyond 5 Years**

I. Pergolini<sup>1</sup>, K. Sahora<sup>1</sup>, C.R. Ferrone<sup>1</sup>, W.R. Brugge<sup>2</sup>, M. Patino<sup>3</sup>, K.D. Lillemoe<sup>1</sup>, A.L. Warshaw<sup>1</sup>, C. Fernandez-Del Castillo<sup>1</sup>

<sup>1</sup>Department of Surgery, Massachusetts General Hospital, Boston, MA/United States of America, <sup>2</sup>Department of Gastroenterology, Massachusetts General Hospital, MA/United States of America, <sup>3</sup>Department of Radiology, Massachusetts General Hospital, MA/United States of America

**Surgical Resection Following Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Cancer: Re-Defining the Standards**

M. Sandini<sup>1</sup>, G. Marchegiani<sup>1</sup>, L. Maggino<sup>1</sup>, E. Viviani<sup>1</sup>, A. Montresor<sup>1</sup>, A. Binco<sup>1</sup>, G. Malleo<sup>2</sup>, R. Salvia<sup>1</sup>, C. Bassi<sup>1</sup>

<sup>1</sup>Department of Surgery, Pancreas Institute, University of Verona Hospital/Italy, <sup>2</sup>Surgery B, AOUI Verona Hospital Trust/Italy

10:00 – 10:30am

**MINI SYMPOSIUM: Update on NIH Consortium of the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer (CPDPC)**

Location | *Grand Ballroom A*

Moderators | Jose Serrano, MD, PhD and Jo Ann S. Rinaudo, PhD

Chris E. Forsmark, MD, University of Florida  
Stephen J. Pandol, MD, Cedars-Sinai Medical Center  
*The Goals and Structure of the CPDPC Consortium*

Ziding Feng, PhD, MD Anderson  
*CPDPC Coordinating Center*

Suresh T. Chari, MD, Mayo Clinic College of Medicine and Anirban Maitra, MBBS, MD Anderson  
*Early Detection of Pancreatic Cancer*

Mark Goodarzi/ Aida Habtezion, MD, MSc, Stanford Medicine  
*Type 3 C diabetes and interactions between exocrine and endocrine disorders of the pancreas*

*Recurrent and Chronic Pancreatitis: Natural history, prevention and treatment*  
ADULTS:

Darwin Conwell, MD, Ohio State University, Wexner Medical Center  
Dhiraj Yadav, MD, MPH, University of Pittsburgh

PEDIATRIC:

Aliye Uc, MD, University of Iowa Carver College of Medicine  
Mark E. Lowe, MD, PhD, Children's Hospital of Pittsburgh of UPMC

10:30 – 10:45am

Break

Location | *Grand Ballroom B Pre-function*

10:45 – 12:00pm

**MINI SYMPOSIUM: Regeneration, inflammation and cancer**

Location | *Grand Ballroom A*

Moderators | Miklos Sahin-Toth, MD, PhD and Kimberly Kelly, PhD

Peter Storz, PhD, Mayo Clinic, Jacksonville  
*Acinar-to-ductal metaplasia (ADM) in pancreatic disease*

Ravikanth Maddipati, MD, University of Pennsylvania, Perelman School of Medicine  
*Clonality in ADM and PanIN: Lessons to pancreatic cancer*

Fernando D. Camargo, PhD, Stem Cell Program, Boston Children's Hospital  
*Liver regeneration. Lessons that might apply to the pancreas*

Qiao Zhou, PhD, Harvard Stem Cell Institute  
*Derivation of insulin-secreting beta cells from stomach tissues*

12:00 – 1:15pm

**MINI SYMPOSIUM: PanCan Young Investigators**

Location | *Grand Ballroom A*

Moderators | Nipun Merchant, MD and Diane Simeone, MD

Nada Kalaany, PhD, Harvard Medical School / Boston Children's Hospital  
*Role of Arginine Metabolism in Obesity-associated Pancreatic Cancer*

Ethan Abel, PhD, University of Michigan  
*HNF1A Regulates Pancreatic Cancer Stem Cell Function*

Gregory L. Beatty, MD, PhD, University of Pennsylvania  
*Immunotherapy for pancreatic cancer – the challenges and opportunities*

Kirsten L. Bryant, PhD, University of North Carolina at Chapel Hill  
*Dual Inhibition of KRAS-Effector Signaling and Autophagy Synergistically Impairs Pancreatic Cancer Cell Proliferation*

1:15pm

Lunch

Location | *Georgian*

## POSTERS OF DISTINCTION | THURSDAY, OCTOBER 27

### P1-1

TRAINING FOR ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY (ERCP) IN CHILDREN: INSIGHTS FROM THE KIDS. S. El-Dika<sup>1</sup>, K. Williams<sup>2</sup>, A. Hinton<sup>1</sup>, S. McCarthy<sup>1</sup>, J.R. Groce<sup>1</sup>, P. Hart<sup>1</sup>, S.G. Krishna<sup>1</sup>, D. Conwell<sup>1</sup>; <sup>1</sup>Ohio State University-Wexner Medical Center, Columbus, OH/United States of America, <sup>2</sup>Natiowide Childrens Hospital, Columbus, OH/United States of America

### P1-2

TFF1 (TREFOIL FACTOR FAMILY 1) ACT AS TUMOR SUPPRESSOR TO INHIBIT INVASIVE TRANSFORMATION OF PANIN INTO PDAC IN VIVO. J. Yamaguchi, Y. Yokoyama, T. Kokuryo, M. Nagino; Surgical Oncology, Nagoya University Graduate School of Medicine, Nagoya/Japan

### P1-3

LIPOCALIN-2 PROMOTES OBESITY-INDUCED PANCREATIC DUCTAL ADENOCARCINOMA BY REGULATING INFLAMMATION IN THE TUMOR MICROENVIRONMENT. S.B. Gomez<sup>1</sup>, A.K. Swidnicka-Siergiejko<sup>1</sup>, N. Badi<sup>2</sup>, M. Chavez-Tomar<sup>2</sup>, G. Lesinski<sup>2</sup>, T. Bekaii-Saab<sup>3</sup>, M.R. Farren<sup>2</sup>, T. Mace<sup>2</sup>, C. Schmidt<sup>4</sup>, Y. Liu<sup>1</sup>, D. Deng<sup>1</sup>, R. Hwang<sup>5</sup>, L. Zhou<sup>5</sup>, T. Moore<sup>5</sup>, D. Chatterjee<sup>6</sup>, H. Wang<sup>6</sup>, X. Leng<sup>7</sup>, R. Arlinghaus<sup>7</sup>, C.D. Logsdon<sup>1</sup>, Z. Cruz-Monserrate<sup>2</sup>; <sup>1</sup>Cancer Biology, University of Texas, M. D. Anderson Cancer Center/United States of America, <sup>2</sup>Department of Internal Medicine, The Ohio State University Wexner Medical Center, Columbus/United States of America, <sup>3</sup>Hematology and Medical Oncology, Mayo Clinic, AZ/United States of America, <sup>4</sup>Surgery, The Ohio State University Wexner Medical Center, OH/United States of America, <sup>5</sup>Surgery, University of Texas, M. D. Anderson Cancer Center, TX/United States of America, <sup>6</sup>Pathology, University of Texas, M. D. Anderson Cancer Center/United States of America, <sup>7</sup>Translational Molecular Pathology, University of Texas, M. D. Anderson Cancer Center/United States of America

### P1-4

GENETIC ABLATION OF MITOCHONDRIAL DEACETYLASE SIRTUIN 3 EXACERBATES CERULEIN PANCREATITIS. Y. Qin<sup>1, 2</sup>, J. Yuan<sup>1</sup>, S.R. Malla<sup>1</sup>, M. Geng<sup>1, 3</sup>, R.T. Waldron<sup>1, 4</sup>, O.A. Mareninova<sup>1</sup>, A. Lugea<sup>1, 4</sup>, S.J. Pandolfi<sup>1, 4</sup>, A.S. Gukovskaya<sup>1</sup>; <sup>1</sup>VA Greater Los Angeles Healthcare System, University of California at Los Angeles, and Southern California Research Center for ALPD and Cirrhosis, Los Angeles, California, CA/United States of America, <sup>2</sup>The Division of Gastroenterology and Hepatology, Youjiang Medical University for Nationalities, Baise 533000, Guangxi Zhuang Autonomous Region/China, <sup>3</sup>Frank Netter H. MD School of Medicine at Quinnipiac University, CT/United States of America, <sup>4</sup>Cedars-Sinai Medical Center, Los Angeles/United States of America

### P1-5

ENDO180 REGULATE PHOSPHORYLATION OF MYOSIN LIGHT CHAIN 2 ACTIVITY AND INCREASE THE ABILITY OF EXTRACELLULAR MATRIX REMODELING IN LEADING PANCREATIC STELLATE CELLS. K. Koikawa, K. Ohuchida, S. Kibe, Y. Ando, S. Takesue, H. Nakayama, T. Abe, S. Endo, T. Okumura, T. Moriyama, K. Nakata, Y. Miyasaka, T. Manabe, T. Ohtsuka, E. Nagai, K. Mizumoto, M. Nakamura; Department of Surgery and Oncology, Kyushu University/Japan

### P1-6

DIABETES BURDEN FOLLOWING TOTAL PANCREATECTOMY WITH ISLET AUTOTRANSPLANTATION (TPIAT). A. Lane<sup>1</sup>, P. Ptacek<sup>1</sup>, K.L. Berry<sup>2</sup>, T.B. Dunn<sup>2</sup>, T.L. Preutt<sup>2</sup>, M. Cook<sup>2</sup>, S. Chinnakotla<sup>2</sup>, M. Freeman<sup>3</sup>, S.J. Schwarzenberg<sup>1</sup>, G.J. Beilman<sup>2</sup>, M. Bellin<sup>1, 2, 3</sup>; <sup>1</sup>Pediatrics, University of Minnesota, Minneapolis, MN/United States of America, <sup>2</sup>Surgery, University of Minnesota, Minneapolis, MN/United States of America, <sup>3</sup>Medicine, University of Minnesota, Minneapolis, MN/United States of America

### P1-7

LOSS OF NECROPTOTIC RIP3 CAN NOT ATTENUATE IMPAIRED AUTOPHAGY-INDUCED PANCREATITIS. X. Zhou<sup>1</sup>, L. Xie<sup>2</sup>, F. Bergmann<sup>3</sup>, O. Strobel<sup>4</sup>, M.W. Büchler<sup>4</sup>, T. Hackert<sup>4</sup>, F. Fortunato<sup>2</sup>; <sup>1</sup>Section surgical research, University Clinic Heidelberg, Heidelberg/Germany, <sup>2</sup>Section of surgical research, University Clinic Heidelberg, Heidelberg/Germany, <sup>3</sup>Institute of Pathology, University Clinic Heidelberg/Germany, <sup>4</sup>Department of General Surgery, University Hospital Heidelberg/Germany



**P1-8**

CLINICAL IMPACT OF NONSELECTIVE BETA-BLOCKERS ON SURVIVAL IN PATIENTS WITH PANCREATIC CANCER- REVIVAL OF WELL KNOWN DRUGS? B.W. Renz<sup>1</sup>, S. Graf<sup>1</sup>, B. Mayer<sup>1</sup>, M. Macchini<sup>2</sup>, S. Vecchiarelli<sup>3</sup>, C. Ricci<sup>3</sup>, T.C. Wang<sup>2</sup>, R. Casadei<sup>3</sup>, M. Di Marco<sup>3</sup>, A. Kleespies<sup>1</sup>, J. Werner<sup>1</sup>; <sup>1</sup>Department of General, Visceral, Vascular and Transplantation Surgery, University of Munich, Munich/Germany, <sup>2</sup>Division of Digestive and Liver Diseases, Columbia University Medical Center, Irving Cancer Research Center, New York, NY/United States of America, <sup>3</sup>University of Bologna/Italy

**P1-9**

GENETIC DELETION OF THE ADAPTOR PROTEIN, AP3, RESULTS IN SECRETORY AND PROCESSING DEFECTS IN ACINAR CELLS. A.J. Ceplenski<sup>1</sup>, C.A. Shugrue<sup>1</sup>, T. Kolodecik<sup>1</sup>, G. Groblewski<sup>2</sup>, S. Messenger<sup>2</sup>, D.D. Thomas<sup>2</sup>, F. Gorelick<sup>1, 3</sup>; <sup>1</sup>Internal Medicine digestive diseases, Yale University/United States of America, <sup>2</sup>University of Wisconsin/United States of America, <sup>3</sup>Veterans Administration CT Healthcare/United States of America

**P1-10**

RENALASE FORMS HIGH MOLECULAR WEIGHT COMPLEX IN PLASMA FOR TISSUE TRANSLOCATION IN ACUTE PANCREATITIS. K. Date<sup>1, 2</sup>, T. Kolodecik<sup>1</sup>, F. Gorelick<sup>1, 3</sup>; <sup>1</sup>Internal Medicine digestive diseases, Yale University/United States of America, <sup>2</sup>Graduate School of Humanities and Science, Ochanomizu University/Japan, <sup>3</sup>Veterans Administration CT Healthcare/United States of America

**P1-11**

ORAL ADMINISTRATION IS AS EFFECTIVE AS INTRAPERITONEAL ADMINISTRATION OF MINNELIDE AGAINST PANCREATIC CANCER. N. Sharma, S. Modi, B. Giri, J. George, B. Garg, V. Sethi, S. Banerjee, V. Dudeja, A. Saluja; Department of Surgery, Sylvester Comprehensive Cancer Center, University of Miami, FL

**P1-12**

HSP70 DEFICIENT IMMUNE CELLS LEAD TO GREATER IMMUNE MEDIATED KILLING IN PANCREATIC CANCER. B. Giri<sup>1</sup>, B. Garg<sup>2</sup>, S. Modi<sup>2</sup>, V. Sethi<sup>1</sup>, J. George<sup>3</sup>, S. Ramakrishnan<sup>2</sup>, S. Banerjee<sup>1</sup>, A.K. Saluja<sup>4</sup>, V. Dudeja<sup>2</sup>; <sup>1</sup>University of Miami, University of Miami, Miami/United States of America, <sup>2</sup>University of Miami/United States of America, <sup>3</sup>Surgery, University of Miami/United States of America, <sup>4</sup>Surgery, University of Miami, FL/United States of America

**P1-13**

PARANEOPLASTIC WEIGHT LOSS IN PANCREATIC CANCER (PC) WITH SELECTIVE REDUCTION IN SUBCUTANEOUS RELATIVE TO VISCERAL FAT MEDIATED BY PC EXOSOMES. R.P. Sah<sup>1</sup>, S. Nagpal<sup>1</sup>, A. Sharma<sup>1</sup>, N. Ahmed<sup>1</sup>, S. Mohapatra<sup>1</sup>, N. Takahashi<sup>1</sup>, D. Mukhopadhyay<sup>2</sup>, S.T. Chari<sup>1</sup>; <sup>1</sup>Mayo Clinic, MN/United States of America, <sup>2</sup>Mayo Clinic, FL/United States of America

**P1-14**

RISK OF SUBSEQUENT PANCREATIC CANCER AFTER RESECTION OF MAIN-DUCT INTRA DUCTAL PAPILLARY NEOPLASMS (MD-IPMN). S. Majumder, N.A. Philip, N. Takahashi, R.P. Sah, K.C. Mara, S.T. Chari; Mayo Clinic/United States of America

**P1-15**

EXTRACELLULAR CA<sup>2+</sup> CONTRIBUTES TO THE BENEFICIAL EFFECTS OF LACTATED RINGER'S DURING ACUTE PANCREATITIS. J.R. Yaron, K. Patel, B. Khatua, C. De Oliveira, V.P. Singh; Department of Medicine, Mayo Clinic, Scottsdale, AZ/United States of America

**P1-16**

INTRADUCTAL PAPILLARY MUCINOUS NEOPLASMS IN YOUNG PATIENTS EXHIBIT DISTINCT BIOLOGY, CLINICOPATHOLOGICAL CHARACTERISTICS, AND FAVORABLE PROGNOSIS. V. Morales-Oyarvide<sup>1</sup>, M. Mino-Kenudson<sup>2</sup>, C.R. Ferrone<sup>1</sup>, A.L. Warshaw<sup>1</sup>, K.D. Lillemoe<sup>1</sup>, I. Pergolini<sup>1</sup>, M. Attiyeh<sup>3</sup>, N. Rezaee<sup>4</sup>, P.J. Allen<sup>3</sup>, C.L. Wolfgang<sup>4</sup>, C. Fernandez-Del Castillo<sup>1</sup>; <sup>1</sup>Department of Surgery, Massachusetts General Hospital, Boston/United States of America, <sup>2</sup>Department of Pathology, Massachusetts

General Hospital, Boston/United States of America, <sup>3</sup>Department of Surgery, Memorial Sloan Kettering Cancer Center, New York City/United States of America, <sup>4</sup>Department of Surgery, Johns Hopkins University School of Medicine, Baltimore/United States of America

**P1-17**

DOES FAMILY HISTORY PREDICT GENETIC TEST RESULTS FOR CHRONIC PANCREATITIS? R.E. Brand<sup>1</sup>, N. Shah<sup>2</sup>, D. Yadav<sup>1</sup>, A. Slivka<sup>1</sup>, J. Larusch<sup>1</sup>, D. Whitcomb<sup>1</sup>; <sup>1</sup>Department of Medicine, University of Pittsburgh Medical Center, PA/United States of America, <sup>2</sup>Dental Public Health, University of Pittsburgh Medical Center/United States of America

**P1-18**

NALTREXONE REDUCES AND MORPHINE WORSENS CHRONIC PANCREATITIS PROGRESSION IN MOUSE MODELS OF THE DISEASE. J. George<sup>1</sup>, H. Cheema<sup>1</sup>, A. Dixit<sup>2</sup>, U. Barlass<sup>1</sup>, B. Giri<sup>3</sup>, Y. Ryu<sup>2</sup>, S. Banerjee<sup>1</sup>, S. Roy<sup>4</sup>, R. Dawra<sup>2</sup>, A.K. Saluja<sup>2</sup>, V. Dudeja<sup>5</sup>; <sup>1</sup>Surgery, University of Miami/United States of America, <sup>2</sup>Surgery, University of Miami, FL/United States of America, <sup>3</sup>University of Miami, University of Miami, Miami/United States of America, <sup>4</sup>Surgery, University of Minnesota/United States of America, <sup>5</sup>University of Miami/United States of

**P1-19**

LAPAROSCOPIC-ASSISTED VERSUS OPEN TOTAL PANCREATECTOMY AND ISLET AUTOTRANSPLANTATION: A CASE-MATCHED STUDY OF PEDIATRIC PATIENTS. M. Berger<sup>1</sup>, T.B. Dunn<sup>1</sup>, G.J. Beilman<sup>1</sup>, M. Freeman<sup>2</sup>, M. Bellin<sup>3</sup>, S.J. Schwarzenberg<sup>3</sup>, S. Chinnakotla<sup>1</sup>; <sup>1</sup>Surgery, University of Minnesota, Minneapolis, MN/United States of America, <sup>2</sup>Medicine, University of Minnesota, Minneapolis, MN/United States of America, <sup>3</sup>Pediatrics, University of Minnesota, Minneapolis, MN/United States of America

**P1-20**

PANCREATIC DUCTAL ADENOCARCINOMA CAN BE GENERATED FROM HUMAN ACINAR CELLS. N. Akanuma<sup>1</sup>, J. Liu<sup>1</sup>, F.E. Sharkey<sup>2</sup>, A.D. Singhi<sup>3</sup>, H. Crawford<sup>4</sup>, P. Wang<sup>1</sup>; <sup>1</sup>Department of Cellular and Structural Biology, UT HEALTH SCIENCE CENTER AT SA, San Antonio/United States of America, <sup>2</sup>Department of Pathology, UT HEALTH SCIENCE CENTER AT SA, San Antonio/United States of America, <sup>3</sup>Department of Pathology, University of Pittsburgh Medical Center/United States of America, <sup>4</sup>Department of Molecular and Integrative Physiology & Internal Medicine, University of Michigan/United States of America

**P1-21**

ADIPORON SUPPRESSES CYTOKINE MEDIATED STAT3 ACTIVATION THROUGH SOCS3 TO INHIBIT PANCREATIC CANCER GROWTH. F. Messaggio, N. Nagathihalli, N. Merchant, M. Vansaun; Department of Surgery, University of Miami, Miller School of Medicine, Sylvester Comprehensive Cancer Center, Miami, FL/United States of America

## POSTERS

**P1-22**

PANCREAS DIVISUM IS ASSOCIATED WITH A HIGHER RISK OF RECURRENT ACUTE PANCREATITIS ONLY IN THE PRESENCE OF PRSS1 AND CATHEPSIN B POLYMORPHISMS. M. Aslam<sup>1</sup>, S. Avanthi<sup>2</sup>, V.V. Ravikanth<sup>2</sup>, B. Govardhan<sup>2</sup>, N. Zaheer<sup>2</sup>, D.N. Reddy<sup>2</sup>, R. Talukdar<sup>2</sup>; <sup>1</sup>Medical Gastroenterology, Asian Institute of Gastroenterology/India, <sup>2</sup>Asian Institute of Gastroenterology/India

**P1-23**

FUNCTIONAL STUDIES IMPLICATE AN IMBALANCED ACTIVATION OF DENDRITIC CELLS IN THE PATHOGENESIS OF MURINE AUTOIMMUNE PANCREATITIS. L. Borufka<sup>1</sup>, E. Volmer<sup>1</sup>, S. Müller<sup>1</sup>, R. Engelmann<sup>2</sup>, H. Nizze<sup>3</sup>, S. Ibrahim<sup>4</sup>, R. Jaster<sup>1</sup>; <sup>1</sup>Department of Medicine, Division of Gastroenterology, Rostock University Medical Center, Rostock/Germany, <sup>2</sup>Institute of Immunology and Core Facility for Cell Sorting & Cell Analysis, Rostock University Medical Center/Germany, <sup>3</sup>Institute of Pathology, Rostock University Medical Center/Germany, <sup>4</sup>Institute of Experimental Dermatology, University of Luebeck/Germany

**P1-24**

INCIDENCE AND TIMING OF THE DEVELOPMENT OF CONCOMITANT PANCREATIC DUCTAL ADENOCARCINOMA DURING SURVEILLANCE FOR RESECTED AND UNRESECTED INTRADUCTAL PAPILLARY MUCINOUS NEOPLASMS. K. Date<sup>1</sup>, T. Ohtsuka<sup>1</sup>, S. Nakamura<sup>1</sup>, Y. Gotoh<sup>1</sup>, Y. Nakashima<sup>1</sup>, T. Fujimoto<sup>1</sup>, K. Saeki<sup>2</sup>, N. Mochidome<sup>2</sup>, Y. Mori<sup>1</sup>, Y. Sadakari<sup>1</sup>, K. Nakata<sup>1</sup>, Y. Miyasaka<sup>1</sup>, K. Ohuchida<sup>1</sup>, T. Manabe<sup>1</sup>, E. Nagai<sup>1</sup>, Y. Oda<sup>2</sup>, M. Nakamura<sup>1</sup>; <sup>1</sup>Department of Surgery and Oncology, Kyushu University, Fukuoka/Japan, <sup>2</sup>Department of Anatomic Pathology, Kyushu University, Fukuoka/Japan

**P1-25**

DOWNSIZING CHEMOTHERAPY FOR LOCALLY ADVANCED PANCREATIC CANCER TREATED WITH NAB-PACLITAXEL PLUS GEMCITABINE FOLLOWED BY RADICAL SURGERY: TOXICITY AND CLINICAL OUTCOME. S. Kagawa, H. Yoshitomi, H. Shimizu, M. Ohtsuka, K. Furukawa, T. Takayashiki, S. Takano, S. Kuboki, D. Suzuki, N. Sakai, H. Nojima, M. Miyazaki; Department of General Surgery, Chiba University, Chiba/Japan

**P1-26**

THE RELATIONSHIP OF NUTRITIONAL STATUS WITH PAIN MEDICATION USE IN CHRONIC PANCREATITIS PATIENTS. L. Bocelli<sup>1</sup>, M. Min<sup>2</sup>, B. Patel<sup>3</sup>, S. Han<sup>4</sup>, J. Kheder<sup>1</sup>, W. Wassef<sup>1</sup>; <sup>1</sup>Gastroenterology, University of Massachusetts Medical Center/United States of America, <sup>2</sup>Internal Medicine, University of Massachusetts Medical Center, MA/United States of America, <sup>3</sup>Internal Medicine Residency, UMass Medical School/United States of America, <sup>4</sup>Gastroenterology, University of Colorado School of Medicine, CO/United States of America

**P1-27**

RISK FACTORS FOR ASPARAGINASE ASSOCIATED PANCREATITIS: A SYSTEMATIC REVIEW. F.T. Rose<sup>1</sup>, J.-A. Oparaji<sup>2</sup>, A. Orabi<sup>1</sup>, A.S. Howard<sup>3</sup>, D.C. Okafor<sup>3</sup>, R. Turner<sup>4</sup>, M.E. Lowe<sup>1</sup>, K.A. Ritchey<sup>1</sup>, S.Z. Husain<sup>1</sup>; <sup>1</sup>Department of Pediatrics, Children's Hospital of Pittsburgh of University of Pittsburgh Medical Center, Pittsburgh/United States of America, <sup>2</sup>Pediatrics, Walter Reed National Military Medical Center, MD/United States of America, <sup>3</sup>School of Medicine, University of Pittsburgh, PA/United States of America, <sup>4</sup>University of Pittsburgh, PA/United States of America

**P1-28**

MALNUTRITION AND PANCREATIC ENZYME SUPPLEMENTATION IN CHRONIC PANCREATITIS PATIENTS. M. Min<sup>1</sup>, B. Patel<sup>2</sup>, S. Han<sup>3</sup>, J. Kheder<sup>4</sup>, L. Bocelli<sup>4</sup>, W. Wassef<sup>4</sup>; <sup>1</sup>Internal Medicine, University of Massachusetts Medical Center, MA/United States of America, <sup>2</sup>Internal Medicine Residency, UMass Medical School/United States of America, <sup>3</sup>Gastroenterology, University of Colorado School of Medicine, CO/United States of America, <sup>4</sup>Gastroenterology, University of Massachusetts Medical Center/United States of America

**P1-29**

CONTRIBUTION OF ACTIVATING TRANSCRIPTION FACTOR  $\beta$  TO DEVELOPMENT OF ACINAR-TO-DUCTAL CELL METAPLASIA. J. Toma<sup>1</sup>, C. Young<sup>1</sup>, K. Berger<sup>1</sup>, C. Pin<sup>1, 2</sup>; <sup>1</sup>Physiology and Pharmacology, University of Western Ontario, Children's Health Research Institute, University of Western Ontario/Canada, <sup>2</sup>Paediatrics, University of Western Ontario, London/Canada

**P1-30**

A CASE PRESENTATION OF DISTAL BILE DUCT ADENOCARCINOMA; DISTINGUISHING BETWEEN CHOLANGIOCARCINOMA AND PANCREATIC DUCTAL ADENOCARCINOMA. H. Karasaki, Y. Mizukami, Y. Ono, M. Ogata, D. Yoshikawa, T. Maejima, K. Nagashima, T. Kono; Center for Clinical and Biomedical Research, Sapporo Higashi Tokushukai Hospital/Japan

**P1-31**

IKK-EPSILON ENHANCES NUCLEAR-RETENTION AND STABILIZATION OF C-MYC TO PROMOTE GLYCOLYTIC-METABOLISM AND PANCREATIC TUMOR GROWTH. H. Zubair<sup>1</sup>, S. Azim<sup>1</sup>, S.K. Srivastava<sup>1</sup>, A. Ahmad<sup>1</sup>, A. Bhardwaj<sup>1</sup>, M.A. Khan<sup>1</sup>, G.K. Patel<sup>1</sup>, S. Arora<sup>1</sup>, J.E. Carter<sup>2</sup>, S. Singh<sup>1</sup>, A.P. Singh<sup>1, 3</sup>; <sup>1</sup>USA Mitchell Cancer Institute, Mobile, AL/United States of America, <sup>2</sup>Department of Pathology, College of Medicine University of South Alabama, Mobile, AL/United States of America, <sup>3</sup>Department of Biochemistry and Molecular Biology, College of Medicine University of South Alabama, Mobile, AL/United States of America

**P1-32**

DELETION OF ATRX IN ADULT PANCREATIC ACINAR CELLS LEADS TO INCREASED CELL STRESS, DNA DAMAGE, AND SENSITIVITY TO PANCREATITIS. R. Baker<sup>1</sup>, C. Young<sup>2</sup>, C. Howlett<sup>3</sup>, C. Pin<sup>4</sup>; <sup>1</sup>Biology, Children's Health Research Institute, University of Western Ontario, London/Canada, <sup>2</sup>Physiology & Pharmacology, University of Western Ontario, Children's Health Research Institute, London/Canada, <sup>3</sup>Pathology and Laboratory Medicine, Schulich School of Medicine & Dentistry, University of Western Ontario, London, ON/Canada, <sup>4</sup>Paediatrics, University of Western Ontario, London/Canada

**P1-33**

NEXT GENERATION SEQUENCING TO DETECT DELETERIOUS GERMLINE MUTATIONS IN PATIENTS WITH APPARENTLY SPORADIC PANCREATIC DUCTAL ADENOCARCINOMA. K. Shindo<sup>1</sup>, J. Yu<sup>1</sup>, M. Suenaga<sup>1</sup>, S. Fesharakizadeh<sup>1</sup>, J.A.N. Almario<sup>1</sup>, A. Siddiqui<sup>1</sup>, M. Borges<sup>1</sup>, C. Cho<sup>1</sup>, N. Roberts<sup>1</sup>, R. Hruban<sup>1</sup>, A. Klein<sup>2</sup>, M. Hashizume<sup>3</sup>, M. Nakamura<sup>4</sup>, M. Goggins<sup>1</sup>; <sup>1</sup>Pathology department, The Johns Hopkins University, MD/United States of America, <sup>2</sup>Oncology, The Johns Hopkins University School of Medicine/United States of America, <sup>3</sup>Center for Advanced Medical Innovation, Kyushu University/Japan, <sup>4</sup>Department of Surgery and Oncology, Kyushu University/Japan

**P1-34**

FUNCTIONAL ROLE OF 4F2HC IN PANCREATIC DUCTAL ADENOCARCINOMA. D. Bianconi<sup>1</sup>, M. Herac<sup>2</sup>, A. Gleiss<sup>3</sup>, M. Unseld<sup>4</sup>, R. Weigl<sup>4</sup>, M. Schindl<sup>5</sup>, W. Scheithauer<sup>4</sup>, C. Zielinski<sup>4</sup>, G. Prager<sup>4</sup>; <sup>1</sup>Internal Medicine I, Oncology, Medical University of Vienna, Vienna/Austria, <sup>2</sup>Clinical Institute of Pathology, Medical University of Vienna/Austria, <sup>3</sup>Section for Clinical Biometrics, Center for Medical Statistics, Informatics, and Intelligent Systems, Medical University of Vienna/Austria, <sup>4</sup>Internal Medicine I, Oncology, Medical University of Vienna/Austria, <sup>5</sup>Department of Surgery, Medical University of Vienna/Austria

**P1-35**

INVERTED U DOSE-RESPONSE OF NONSPECIFIC CYCLOPHILIN INHIBITOR CYCLOSPORIN A ON MURINE PANCREATIC ACINAR CELL INJURY AND EXPERIMENTAL ACUTE PANCREATITIS. X.Y. Zhang<sup>1</sup>, M. Chvanov<sup>2</sup>, D. Latawiec<sup>1</sup>, L. Wen<sup>1</sup>, Y. Ouyang<sup>2</sup>, R. Mukherjee<sup>1</sup>, W. Huang<sup>1</sup>, <sup>3</sup>A. Tepikin<sup>2</sup>, D. Criddle<sup>2</sup>, R. Sutton<sup>1</sup>; <sup>1</sup>NIHR Liverpool Pancreas Biomedical Research Unit, Royal Liverpool University Hospital, University of Liverpool/United Kingdom, <sup>2</sup>Department of Cellular and Molecular Physiology, University of Liverpool/United Kingdom, <sup>3</sup>Sichuan Provincial Pancreatitis Centre, Department of Integrated Traditional Chinese and Western Medicine, West China Hospital, Sichuan University/China

**P1-36**

CLINICAL EVALUATION AND MANAGEMENT OF EXOCRINE PANCREATIC INSUFFICIENCY (EPI) AFTER PANCREATIC RESECTION: A RETROSPECTIVE ANALYSIS. S. Masood, V.T. Kommineni, A.K. Mathur, N.N. Katariya, A.A. Moss, C.C. Nguyen, L.J. Miller, D.O. Faigel, R. Pannala; Mayo Clinic, Scottsdale, AZ/United States of America

**P1-37**

PATHOPHYSIOLOGICAL MODULATION OF PANCREATIC ACINAR CELL BIOENERGETICS BY CHOLECYSTOKININ. J. Morton<sup>1</sup>, <sup>2</sup>J. Armstrong<sup>2</sup>, N. Cash<sup>1</sup>, Y. Ouyang<sup>1</sup>, A. Tepikin<sup>1</sup>, R. Sutton<sup>2</sup>, D. Criddle<sup>1</sup>, <sup>2</sup>D. Criddle<sup>2</sup>; <sup>1</sup>Dept. of Cellular and Molecular Physiology, Institute of Translational Medicine, University of Liverpool/United Kingdom, <sup>2</sup>NIHR Liverpool Pancreas Biomedical Research Unit, Royal Liverpool University Hospital University of Liverpool/United Kingdom

**P1-38**

COLLABORATION BETWEEN AUTOPHAGY, THE UNFOLDED PROTEIN RESPONSE, AND ENDOSOMAL TRAFFICKING MAINTAINS ACINAR CELL DIFFERENTIATION. E. Jones<sup>1</sup>, S. Messenger<sup>1</sup>, M. Cooley<sup>1</sup>, D.D. Thomas<sup>1</sup>, R.T. Waldron<sup>2</sup>, <sup>3</sup>A. Lugea<sup>2</sup>, <sup>3</sup>S.J. Pandol<sup>2</sup>, <sup>3</sup>G. Groblewski<sup>1</sup>; <sup>1</sup>University of Wisconsin/United States of America, <sup>2</sup>Cedars-Sinai Medical Center, Los Angeles/United States of America, <sup>3</sup>VA Greater Los Angeles Healthcare System, University of California at Los Angeles, CA/United States of America

**P1-39**

POLYMORPHISM OF THE HEME OXYGENASE-1 (HO-1) PROMOTER AND CYTOKINES EXPRESSION IN ACUTE PANCREATITIS. A.K. Gulla<sup>1</sup>, A. Gulbinas<sup>2</sup>, G. Barauskas<sup>2</sup>, Z. Dambrauskas<sup>2</sup>; <sup>1</sup>Department of Surgery, Georgetown University Hospital, Washington Dc/United States of America, <sup>2</sup>Department of Surgery, Lithuanian University of Health Sciences, Kaunas/Lithuania

**P1-40**

NF-KB ACTIVATION WITH RADIOCONTRAST EXPOSURE DURING POST-ERCP PANCREATITIS IS DEPENDENT ON BCL10 IN THE SCAFFOLDING CBM COMPLEX. S. Sanker, A.I. Orabi, D. Hu, L.M. McAllister-Lucas, P.C. Lucas, S.Z. Husain; Department of Pediatrics, Children's Hospital of Pittsburgh of UPMC. University of Pittsburgh, Pittsburgh, PA/United States of America

**P1-41**

PR55? SUBUNIT OF PP2A SUPPORTS THE TUMORIGENIC AND METASTATIC POTENTIAL OF PANCREATIC CANCER CELLS. Y. Yan, A.L. Hein, P. Seshacharyulu, S. Rachagani, M. Ouellette, Y.M. Sheinin, M.P. Ponnusamy, S. Batra; University of Nebraska Medical Center/United States of America

**P1-42**

KNOCKING DOWN ZIP4 INHIBITS EPITHELIAL-MESENCHYMAL TRANSITION-INDUCED METASTASIS OF PANCREATIC CANCER. M. Liu<sup>1</sup>, J. Yang<sup>1</sup>, C. Houchen<sup>1</sup>, R. Postier<sup>2</sup>, M. Li<sup>1, 2</sup>; <sup>1</sup>Medicine, University of Oklahoma Health Science Center, Oklahoma City, OK/United States of America, <sup>2</sup>Surgery, University of Oklahoma Health Science Center/United States of America

**P1-43**

COMPARISON OF THE INTERNATIONAL CONSENSUS GUIDELINES FOR PREDICTING MALIGNANCY IN INTRADUCTAL PAPILLARY MUCINOUS NEOPLASMS. S. Yamada, T. Fujii, H. Takami, M. Hayashi, H. Sugimoto, Y. Kodera; Gastroenterological Surgery, Nagoya University, Graduate School of Medicine, Nagoya/Japan

**P1-44**

FUNCTIONAL AND NON-FUNCTIONAL PANCREATIC NEUROENDOCRINE TUMOURS. M. Yang; Department of Pancreatic Surgery, West China Hospital, Sichuan University/China

**P1-45**

RISK FACTOR OF POSTOPERATIVE PANCREATIC FISTULA AFTER DISTAL PANCREATECTOMY USING TRIPLE-ROW STAPLER. H. Kawaida, M. Watanabe, N. Hosomura, H. Amemiya, H. Kono, M. Matsuda, H. Fujii; First Department of Surgery, University of Yamanashi, Chyuo-shi, Yamanashi/Japan

**P1-46**

RISK FACTORS FOR PANCREATIC STONE FORMATION IN TYPE 1 AUTOIMMUNE PANCREATITIS: A NATIONWIDE SURVEY BY THE JAPAN PANCREAS SOCIETY. T. Ito<sup>1</sup>, S. Kawa<sup>2</sup>, K. Kubota<sup>3</sup>, T. Kamisawa<sup>4</sup>, K. Okazaki<sup>5</sup>, T. Shimosegawa<sup>6</sup>; <sup>1</sup>Gastroenterology, Shinshu university school of medicine, Matsumoto/Japan, <sup>2</sup>Center for health, safety, and environmental management, Shinshu university, Matsumoto/Japan, <sup>3</sup>Gastroenterology, Yokohama City University Graduate School of Medicine/Japan, <sup>4</sup>Gastroenterology, Tokyo Metropolitan Komagome Hospital/Japan, <sup>5</sup>Gastroenterology, Kansai Medical University/Japan, <sup>6</sup>Gastroenterology, Tohoku University Graduate School of Medicine/Japan

**P1-47**

A QUALITY OF LIFE COMPARISON IN CHRONIC PANCREATITIS PATIENTS BETWEEN SMOKERS AND NON-SMOKERS. B. Patel<sup>1</sup>, M. Min<sup>1</sup>, S. Han<sup>2</sup>, J. Kheder<sup>3</sup>, L. Bocelli<sup>3</sup>, A. Wachholtz<sup>4</sup>, W. Wassef<sup>3</sup>; <sup>1</sup>Internal Medicine, University of Massachusetts Medical School/United States of America, <sup>2</sup>Division of Gastroenterology and Hepatology, University of Colorado, CO/United States of America, <sup>3</sup>Department of Gastroenterology, University of Massachusetts Medical Center/United States of America, <sup>4</sup>Psychiatry, University of Massachusetts, MA/United States of America



**P1-48**

HUMAN PANCREATITIS ORGANELLAR DISORDERS: EX-VIVO MODELS. A. Lugea<sup>1</sup>, G. Groblewski<sup>2</sup>, R.T. Waldron<sup>1</sup>, S. Messenger<sup>2</sup>, D.D. Thomas<sup>2</sup>, E. Jones<sup>2</sup>, H.-Y. Su<sup>1</sup>, O.A. Mareninova<sup>3</sup>, S. Gretler<sup>3</sup>, J. Yang<sup>1</sup>, I. Gukovsky<sup>2</sup>, A.S. Gukovskaya<sup>3</sup>, F. Gorelick<sup>4</sup>, S.J. Pandol<sup>1</sup>; <sup>1</sup>Cedars-Sinai Medical Center/United States of America, <sup>2</sup>University of Wisconsin/United States of America, <sup>3</sup>UCLA/VAGLAHS/United States of America, <sup>4</sup>Yale University/United States of America

**P1-49**

OPTIMIZATION OF ONCOLYTIC CHEMOVIRAL PROTOCOLS FOR THERAPY OF PANCREATIC CANCER. S.P. Grekova<sup>1</sup>, A. Heller<sup>1</sup>, A.L. Angelova<sup>2</sup>, M. Aprahamian<sup>3</sup>, T. Giese<sup>4</sup>, E. Soyka<sup>1</sup>, S. Bauer<sup>1</sup>, S. Rüffer<sup>4</sup>, J. Rommelaere<sup>2</sup>, T. Hackert<sup>1</sup>, O. Strobel<sup>1</sup>, Z. Raykov<sup>2</sup>, N. Giese<sup>1</sup>; <sup>1</sup>Department of General Surgery, University Hospital Heidelberg/Germany, <sup>2</sup>Programme Infection and Cancer, Tumor Virology Division F010, DKFZ/Germany, <sup>3</sup>Institut de Recherche Contre les Cancers de l'Appareil Digestif (IRCAD)/France, <sup>4</sup>Institute of Immunology, University Hospital Heidelberg/Germany

**P1-50**

CORRELATION OF A LONG NON-CODING RNA, H19, WITH METASTASIS OF PANCREATIC CANCER. T. Ishiwata<sup>1</sup>, H. Yoshimura<sup>2</sup>, Y. Matsuda<sup>3</sup>, N. Ishikawa<sup>1</sup>, K. Takubo<sup>1</sup>, T. Arai<sup>3</sup>, J. Aida<sup>1</sup>; <sup>1</sup>Department of Aging and Carcinogenesis, Research Team for Geriatric Pathology, Tokyo Metropolitan Institute of Gerontology, Tokyo/Japan, <sup>2</sup>Division of Physiological Pathology, Department of Applied Science, School of Veterinary Nursing and Technology, Nippon Veterinary and Life Science University, Tokyo/Japan, <sup>3</sup>Department of Pathology, Tokyo Metropolitan Geriatric Hospital, Tokyo/Japan

**P1-51**

INTERLEUKIN (IL) 10 AND PYRIDONE 6 (P6) MODIFY THE MIGRATION OF PANCREATIC CANCER CELLS IN CO-CULTURES WITH MACROPHAGES. A. Salmiheimo<sup>1, 2</sup>, H. Mustonen<sup>1, 2</sup>, S. Vainionpää<sup>1, 2</sup>, E. Kempainen<sup>1, 2</sup>, P. Puolakkainen<sup>1, 2</sup>, H. Seppänen<sup>1, 2</sup>; <sup>1</sup>Helsinki University Hospital/Finland, <sup>2</sup>University of Helsinki/Finland

**P1-52**

TFF1 MIGHT INHIBIT INVASION BUT ACCELERATE LYMPH NODE METASTASIS OF PANCREATIC DUCTAL ADENOCARCINOMA. M. Sunagawa, J. Yamaguchi, Y. Yokoyama, T. Kokuryo, M. Nagino; Surgical Oncology, Nagoya University Graduate School of Medicine, Nagoya/Japan

**P1-53**

CIRCUMPORTAL PANCREAS, A RARE CONGENITAL ANOMALY, INCREASES A RISK OF PANCREATIC FISTULA AFTER PANCREATECTOMY. T. Ohtsuka<sup>1</sup>, Y. Mori<sup>1</sup>, K. Ishigami<sup>2</sup>, T. Fujimoto<sup>1</sup>, Y. Miyasaka<sup>1</sup>, K. Nakata<sup>1</sup>, K. Ohuchida<sup>1</sup>, T. Manabe<sup>1</sup>, E. Nagai<sup>1</sup>, Y. Oda<sup>3</sup>, M. Nakamura<sup>1</sup>; <sup>1</sup>Department of Surgery and Oncology, Kyushu University/Japan, <sup>2</sup>Department of Clinical Radiology, Kyushu University/Japan, <sup>3</sup>Department of Anatomical Pathology, Kyushu University/Japan

**P1-54**

PARTICIPATION OF CRK-ASSOCIATED SUBSTRATE (CAS) IN HUMAN PANCREATIC CANCER CELL MIGRATION, INVASION AND METASTATIC PROCESSES. H. Okamoto<sup>1</sup>, T. Kusama<sup>1</sup>, J. Itakura<sup>1</sup>, H. Fujii<sup>2</sup>; <sup>1</sup>Gastrointestinal, Breast&Endocrine Surgery, University of Yamanashi, Chuo-city, Yamanashi/Japan, <sup>2</sup>First Department of Surgery, University of Yamanashi, Chyo-shi, Yamanashi/Japan

**P1-55**

PANCREATIC INTRAEPITHELIAL NEOPLASIA ALTER MACROPHAGE POPULATIONS TO MEDIATE PANCREATIC TUMORIGENESIS. G.-Y. Liou<sup>1</sup>, B. Edenfield<sup>1</sup>, L. Zhang<sup>2</sup>, D. Dawson<sup>3</sup>, N. Bardeesy<sup>4</sup>, P. Storz<sup>1</sup>; <sup>1</sup>Cancer Biology, Mayo Clinic, FL/United States of America, <sup>2</sup>Laboratory Medicine & Pathology, Mayo Clinic/United States of America, <sup>3</sup>Pathology & Laboratory Medicine, UCLA/United States of America, <sup>4</sup>Department of Medicine, Harvard Medical School/United States of America



**P1-56**

INVASIVE SIZE PREDICTS RECURRENCE AND SURVIVAL OF SMALL INVASIVE CARCINOMA ARISING IN INTRADUCTAL PAPILLARY MUCINOUS NEOPLASM OF THE PANCREAS. M. Mino-Kenudson<sup>1</sup>, V. Morales-Oyarvide<sup>2</sup>, K. Date<sup>3</sup>, T. Ohtsuka<sup>3</sup>, Y. Omori<sup>4</sup>, M. Tanino<sup>5</sup>, Y. Mizukami<sup>6</sup>, S.-M. Hong<sup>7</sup>, D.W. Hwang<sup>8</sup>, S.C. Kim<sup>8</sup>, G. Zamboni<sup>9</sup>, P. Castelli<sup>10</sup>, R. Higuchi<sup>11</sup>, M. Yamamoto<sup>11</sup>, K. Shimizu<sup>12</sup>, M. Nakamura<sup>3</sup>, H. Maguchi<sup>13</sup>, C. Fernandez-Del Castillo<sup>14</sup>, T. Furukawa<sup>15</sup>; <sup>1</sup>Department of Pathology, Massachusetts General Hospital, MA/United States of America, <sup>2</sup>Dana Faber Cancer Center, MA/United States of America, <sup>3</sup>Department of Surgery and Oncology, Kyushu University/Japan, <sup>4</sup>Department of Pathology, Teine Keijinkai Hospital, Sapporo/Japan, <sup>5</sup>Department of Cancer Pathology, Hokkaido University Graduate School of Medicine/Japan, <sup>6</sup>Center for Clinical and Biomedical Research, Sapporo Higashi Tokushukai Hospital/Japan, <sup>7</sup>Pathology, Asan Medical Center, University of Ulsan College of Medicine/Korea, Republic of, <sup>8</sup>Division of Hepatobiliary and Pancreas Surgery, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine/Korea, Republic of, <sup>9</sup>Pathology, University of Verona and Don Calabria Hospital/Italy, <sup>10</sup>Pathology, Don Calabria Hospital/Italy, <sup>11</sup>Surgery, Institute of Gastroenterology, Tokyo Women's Medical University/Japan, <sup>12</sup>Gastroenterology, Institute of Gastroenterology, Tokyo Women's Medical University/Japan, <sup>13</sup>Center for Gastroenterology, Teine Keijinkai Hospital/Japan, <sup>14</sup>Department of Surgery, Massachusetts General Hospital, MA/United States of America, <sup>15</sup>Institute for Integrated Medical Sciences, Tokyo Women's Medical University/Japan

**P1-57**

CHANGES IN THE EXPRESSION OF RRM SUBUNITS INDUCE GEMCITABINE RESISTANCE IN A GROWTH DEPENDENT MANNER. K.S. Mann, S. Brumskill, P. Ghaneh, W. Greenhalf; Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Bx/United Kingdom

**P1-58**

INHIBITION OF JAK/STAT SIGNALING LIMITS THE ACTIVATION OF PANCREATIC STELLATE CELLS IN VITRO AND CAERULEIN-INDUCED PANCREATITIS IN VIVO. H. Komar<sup>1</sup>, T. Mace<sup>1</sup>, G. Serpa<sup>1</sup>, O. Elnaggar<sup>1</sup>, D. Conwell<sup>2</sup>, P. Hart<sup>2</sup>, C. Schmidt<sup>3</sup>, M. Dillhoff<sup>1</sup>, J. Ming<sup>1</sup>, G. Lesinski<sup>4</sup>; <sup>1</sup>The Ohio State University/United States of America, <sup>2</sup>Ohio State University-Wexner Medical Center, Columbus, OH/United States of America, <sup>3</sup>Surgery, The Ohio State University Wexner Medical Center, OH/United States of America, <sup>4</sup>Department of Internal Medicine, The Ohio State University Wexner Medical Center, Columbus/United States of America

**P1-59**

SURVIVAL AND PROGNOSTIC FACTORS OF NEOADJUVANT TREATMENT AND OPERATION FOR BORDERLINE RESECTABLE PANCREATIC CANCER. H.S. Kim<sup>1</sup>, J.-Y. Jang<sup>1</sup>, Y. Han<sup>1</sup>, K.B. Lee<sup>2</sup>, J.R. Kim<sup>1</sup>, H. Kim<sup>1</sup>, W. Kwon<sup>1</sup>, S.-W. Kim<sup>1</sup>; <sup>1</sup>Department of Surgery and Cancer Research Institute, Seoul National University College of Medicine/Korea, Republic of, <sup>2</sup>Department of Pathology, Seoul National University Hospital/Korea, Republic of

**P1-60**

TREATMENT STRATEGY FOR NEUROENDOCRINE TUMOR OF THE PANCREAS. J. Itakura, M. Watanabe, N. Hosomura, H. Amemiya, H. Kawaida, H. Okamoto, H. Kohno; Surgery, University of Yamanashi, Yamanashi/Japan

**P1-61**

ROLE OF THE HIPPO-YAP AND MSP-RON SIGNALING PATHWAYS IN PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) METASTASIS TO THE LIVER. Q. Wang, C. Chheda, S. Pandol; Medicine, Cedars-Sinai Medical Center, Los Angeles, CA/United States of America

**P1-62**

NEOADJUVANT CHEMOTHERAPY FOR PANCREATIC CANCER. E. Hashimoto, H. Shimamura, K. Takeda; Department of Surgery, Sendai Medical Center, Sendai/Japan

**P1-63**

SERUM LEVEL OF WISTERIA FLORIBUNDA AGGLUTININ-POSITIVE MAC-2-BINDING PROTEIN REFLECTS THE SEVERITY OF CHRONIC PANCREATITIS. T. Fujiyama, K. Ueda, Y. Tachibana, M. Miki, K. Yasunaga, T. Takaoka, K. Kawabe, T. Ito; Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University/Japan

**P1-64**

VISCERAL ARTERIAL CALCIUM BURDEN AND LIKELIHOOD OF PANCREATIC FISTULA AFTER PANCREATIC RESECTION. A. Gomes<sup>1</sup>, I. Santiago<sup>2</sup>, R. Rocha<sup>3</sup>, R. Marinho<sup>3</sup>, M. Sousa<sup>3</sup>, M. Fragoso<sup>3</sup>, D. Aparício<sup>3</sup>, A. João<sup>3</sup>, A. Soares<sup>3</sup>, V. Nunes<sup>3</sup>; <sup>1</sup>Surgery, Hospital Prof.Dr. Fernando Fonseca/Portugal, <sup>2</sup>Champalimaud Foundation/Portugal, <sup>3</sup>Surgery, Hospital Prof.Dr. Fernando Fonseca, Amadora/Portugal

**P1-65**

HISTONE DEMETHYLASE KDM3A REGULATES CANCER STEM CELLS FOR PANCREATIC CANCER PROGRESSION. S. Paul<sup>1</sup>, C. Ghosh<sup>2</sup>, D. Subramaniam<sup>3</sup>, K. Palaniyandi<sup>2</sup>, T. Iwakuma<sup>2</sup>, S. Anant<sup>3</sup>, A. Dhar<sup>2</sup>; <sup>1</sup>Cancer Biology, The University of Kansas Medical Center, Kansas City/United States of America, <sup>2</sup>Cancer Biology, The University of Kansas Medical Center, Kansas City, KS/United States of America, <sup>3</sup>Surgery, The University of Kansas Medical Center, Kansas City, KS/United States of America

**P1-66**

ASSOCIATION OF HIGH HLA CLASS I ANTIGEN EXPRESSION WITH POOR PROGNOSIS IN INTRADUCTAL PAPILLARY MUCINOUS NEOPLASMS (IPMN). L. Cai<sup>1</sup>, T. Michelakos<sup>1</sup>, C. Fernandez-Del Castillo<sup>1</sup>, M. Mino-Kenudson<sup>2</sup>, A.L. Warshaw<sup>1</sup>, K.D. Lillemoe<sup>1</sup>, S. Ferrone<sup>1</sup>, C.R. Ferrone<sup>1</sup>; <sup>1</sup>Department of Surgery, Massachusetts General Hospital, MA/United States of America, <sup>2</sup>Pathology, Massachusetts General Hospital, Boston, MA/United States of America

**P1-67**

IMMUNOLOGICAL EVENTS AND CLINICAL COURSE OF PANCREATIC NEUROENDOCRINE TUMORS (PNETS). T. Michelakos<sup>1</sup>, L. Cai<sup>1</sup>, C. Fernandez-Del Castillo<sup>1</sup>, A.L. Warshaw<sup>1</sup>, K.D. Lillemoe<sup>1</sup>, S. Ferrone<sup>1</sup>, V. Deshpande<sup>2</sup>, C.R. Ferrone<sup>1</sup>; <sup>1</sup>Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA/United States of America, <sup>2</sup>Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA/United States of America

**P1-68**

TARGETING PANCREATIC CANCER BY EGCG IN GEMCITABINE RESISTANCE. C. Ghosh<sup>1</sup>, S. Paul<sup>2</sup>, S. Anant<sup>3</sup>, A. Dhar<sup>1</sup>; <sup>1</sup>Cancer Biology, The University of Kansas Medical Center, Kansas City, KS/United States of America, <sup>2</sup>Cancer Biology, The University of Kansas Medical Center, Kansas City/United States of America, <sup>3</sup>Surgery, The University of Kansas Medical Center, Kansas City, KS/United States of America

**P1-69**

BIOGLUE® SEALED FISH-MOUTH CLOSURE OF THE PANCREATIC REMNANT AS A FEASIBLE ALTERNATIVE TO STAPLER CLOSURE DURING LAPAROSCOPICAL DISTAL PANCREATECTOMY. F. Klein, R. Zorron, J. Pratschke, M. Bahra; Department of General, Visceral and Transplantation Surgery, Charite Universitätsmedizin Berlin/Germany

**P1-70**

A SYSTEMATIC REVIEW AND QUANTITATIVE ANALYSIS OF DIFFERENT THERAPIES FOR PANCREAS DIVISUM. T. Hackert, M. Hafezi, B. Mayschak, P. Probst, M.W. Büchler, A. Mehrabi; Department of General, Visceral, and Transplantation Surgery, University of Heidelberg, Heidelberg/Germany

**P1-71**

NOTCH4 ACTS AS AN ONCOGENIC SIGNAL IN PANCREATIC TUMORIGENESIS. W. Qiu<sup>1</sup>, S. Chadi<sup>1</sup>, N. Tsay<sup>1</sup>, A.R. Chambers<sup>1</sup>, D.D. Suh<sup>1</sup>, P.A. Sims<sup>2</sup>, C.J. Shawber<sup>3</sup>, J. Kitajewski<sup>4</sup>, H.E. Remotti<sup>5</sup>, G.H. Su<sup>5</sup>; <sup>1</sup>Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY/USA, <sup>2</sup>Department of Systems Biology, Columbia University, New York, NY/USAA, <sup>3</sup>Department of Obstetrics and Gynecology, Columbia University, New York, NY/USA, <sup>4</sup>Department of Physiology & Biophysics, University of Illinois at Chicago, Chicago, IL/USA, <sup>5</sup>Pathology, Columbia University, New York, NY/USA

**P1-72**

POTENTIAL TARGETS AND ROLE OF EZH2 IN PANCREATIC CANCER. A. Habib, W. Pan, N. Alzofon, S. Wang, S. Urayama; Internal Medicine, University of California, Davis, CA/United States of America

**P1-73**

EARLY SURGERY IS BENEFICIAL FOR PAIN CONTROL AND PANCREATIC FUNCTION PRESERVATION IN CHRONIC PANCREATITIS: A RETROSPECTIVE STUDY OF 297 CONSECUTIVE PATIENTS. N. Ke1, W. Huang2, Q.M. Nunes2, X. Liu1, R. Sutton2; 1West China Hospital/China, 2Royal Liverpool University Hospital/United Kingdom

**P1-74**

EVALUATION OF SECRETIN-ENHANCED MRCP IN CHRONIC PANCREATITIS. S. Siminkovitch1, P. Gecov2, B. Vladimirov1, G. Nedelkov2, M. Kovacheva-Slavova1, B. Golemanov1; 1Gastroenterology, University Hospital Tsaritsa Ioanna-ISUL/Bulgaria, 2Medical Imaging, University Hospital Tsaritsa Ioanna-ISUL/Bulgaria

**P1-75**

HIGH-GRADE PANIN/CARCINOMA IN SITU OF THE PANCREAS ASSOCIATED WITH CYSTIC CHANGES AND FIBROSIS. Y. Matsuda1, T. Furukawa2, S. Yachida3, M. Nishimura4, A. Seki1, K. Nonaka1, J. Aida5, K. Takubo5, T. Ishiwata5, W. Kimura6, T. Arai1, M. Mino-Kenudson7; 1Department of Pathology, Tokyo Metropolitan Geriatric Hospital, Tokyo/Japan, 2Institute for Integrated Medical Sciences, Tokyo Women's Medical University/Japan, 3Division of Cancer Genomics, National Cancer Center Research Institute/Japan, 4Department of Endoscopy, Tokyo Metropolitan Geriatric Hospital, Tokyo/Japan, 5Department of Aging and Carcinogenesis, Research Team for Geriatric Pathology, Tokyo Metropolitan Institute of Gerontology/Japan, 6Department of Gastroenterological, General, Breast & Thyroid Surgery, Yamagata University/Japan, 7Department of Pathology, Massachusetts General Hospital, MA/United States of America

**P1-76**

DOES UNAVAILABILITY OF BILIARY INTERVENTION AT RURAL AND SMALL HOSPITALS IMPACT IMMEDIATE PATIENT OUTCOMES IN BILIARY ACUTE PANCREATITIS? A NATIONAL ANALYSIS. A. Malli1, S. El-Dika2, S. McCarthy1, J.R. Groce2, A. Hinton2, D. Conwell2, S.G. Krishna2; 1Ohio State University-Wexner Medical Center, OH/United States of America, 2Ohio State University-Wexner Medical Center, Columbus, OH/United States of America

**P1-77**

STATIN USE IS NOT ASSOCIATED WITH SIRS OR OUTCOMES IN ACUTE PANCREATITIS. J. McNabb-Baltar1, V. Antoine-Gustave2, V. Kadiyala3, D.X. Jin3, S.L. Suleiman3, D. Conwell4, P.A. Banks3; 1Center for Pancreatic Disease, Division of Gastroenterology, Hepatology, and Endoscopy, Brigham and Women's Hospital, Boston, MA/United States of America, 2Gotham Medical Associates/United States of America, 3Center for Pancreatic Disease, Division of Gastroenterology, Hepatology, and Endoscopy, Brigham and Women's Hospital, Boston, MA/United States of America, 4Ohio State University-Wexner Medical Center, Columbus, OH/United States of America

**P1-78**

ADJUVANT CHEMOTHERAPY AFTER RESECTION OF PANCREATIC DUCTAL ADENOCARCINOMA - A RETROSPECTIVE SINGLE CENTER ANALYSIS OF 251 CONSECUTIVE PATIENTS IN A NON-SELECTED COHORT. U.A. Wittel, M. Reinmuth, F. Makowiec, O. Sick, R.M. Fritsch, U.T. Hopt; University of Freiburg Medical Center/Germany

**P1-79**

RADIOCONTRAST INDUCES MITOCHONDRIAL DYSFUNCTION AND IMPAIRED MITOPHAGY IN POST-ERCP PANCREATITIS THROUGH THE DEPHOSPHORYLATION OF DRP1 BY CALCINEURIN. L. Wen1, N. Shalbueva2, O.A. Mareninova2, A.I. Orabi1, T.A. Javed1, A.S. Gukovkaya2, S.Z. Husain1; 1Department of Pediatric, University of Pittsburgh and the Children's Hospital of Pittsburgh of UPMC, United States of America, Pittsburgh, PA/United States of America, 2Veterans Affairs Greater Los Angeles Healthcare System, University of California Los Angeles and Southern California Research Center for Alcoholic Liver and Pancreatic Diseases and Cirrhosis, CA/United States of America

**P1-80**

RADICAL CARBON-ION RADIOTHERAPY FOR LOCALLY ADVANCED UNRESECTABLE PANCREATIC CANCER. K. Nakata<sup>1</sup>, T. Ohtsuka<sup>1</sup>, Y. Mori<sup>2</sup>, Y. Miyasaka<sup>1</sup>, S. Makoto<sup>3</sup>, E. Nagai<sup>1</sup>, M. Nakamura<sup>1</sup>; <sup>1</sup>Department of Surgery and Oncology, Kyushu University/Japan, <sup>2</sup>Department of Surgery and Oncology, Kyushu University, Fukuoka/Japan, <sup>3</sup>On Beam Therapy Center, SAGA HIMAT Foundation/Japan

**P1-81**

AN INTERNATIONAL EXTERNAL INTER-AND INTRAOBSERVER VARIABILITY STUDY EVALUATING NEEDLE BASED CONFOCAL LASER ENDOMICROSCOPY (NCLE) FOR DIAGNOSIS OF PANCREATIC CYSTIC LESIONS (PCLS). S.G. Krishna<sup>1</sup>, W.R. Brugge<sup>2</sup>, J.M. Dewitt<sup>3</sup>, P. Kongkam<sup>4</sup>, B. Napoleon<sup>5</sup>, C. Robles-Medrand<sup>6</sup>, D. Tan<sup>7</sup>, S. El-Dika<sup>1</sup>, P. Hart<sup>1</sup>, D. Conwell<sup>1</sup>; <sup>1</sup>Ohio State University Medical Center, Columbus, OH/United States of America, <sup>2</sup>Department of Gastroenterology, Massachusetts General Hospital, MA/United States of America, <sup>3</sup>Indiana University/United States of America, <sup>4</sup>Chulalongkorn University/Thailand, <sup>5</sup>Hôpital Privé Jean Mermoz/France, <sup>6</sup>Ecuadorian Institute of Digestive Disease/Ecuador, <sup>7</sup>Singapore General Hospital/Singapore

**P1-82**

TWO GASEOUS TRANSMITTERS IN L-ORNITHINE-INDUCED ACUTE PANCREATITIS IN RATS. S. Chooklin, S. Chuklin, B. Pidhirnyy; Regional Clinical Hospital, Lviv/Ukraine

**P1-83**

NECROTIZING PANCREATITIS FOLLOWING PARTIAL PANCREATODUODENECTOMY: AN ANALYSIS OF 1235 CONSECUTIVE CASES. M. Loos, M. Dietrich, O. Strobel, U. Hinz, M.W. Büchler, T. Hackert; Department of General, Visceral, and Transplantation Surgery, University of Heidelberg, Heidelberg/Germany

**P1-84**

ELEVATED PLASMA SOLUBLE UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR (P-SUPAR) ON RECOVERY AFTER FIRST ACUTE ALCOHOL-INDUCED PANCREATITIS (AAP) PREDICTS 10-YEAR MORTALITY. A. Aronen<sup>1</sup>, J. Aittoniemi<sup>2</sup>, R. Huttunen<sup>3</sup>, A. Nikkola<sup>1</sup>, J. Nikkola<sup>1</sup>, O. Linnell<sup>4</sup>, I. Nordback<sup>1</sup>, J. Sand<sup>1</sup>, J. Laukkanen<sup>1</sup>; <sup>1</sup>Department of Gastroenterology and Alimentary Tract Surgery, Tampere University Hospital, Tampere/Finland, <sup>2</sup>Fimlab Laboratories, Tampere/Finland, <sup>3</sup>Department of Internal Medicine, Tampere University Hospital, Tampere/Finland, <sup>4</sup>School of Medicine, University of Tampere, Tampere/Finland

**P1-85**

THE RATE OF POST-ERCP PANCREATITIS ASSOCIATED WITH SINGLE OPERATOR PERORAL SPYGLASS CHOLANGIOSCOPY (SOC) IS WELL TOLERATED WITH AN ESTABLISHED PRACTICE. A. Siiki<sup>1</sup>, M. Ukkonen<sup>1</sup>, J. Laukkanen<sup>2</sup>; <sup>1</sup>Dept. of Gastroenterology and Alimentary Tract Surgery, Tampere University Hospital/Finland, <sup>2</sup>Department of Gastroenterology and Alimentary Tract Surgery, Tampere University Hospital, Tampere/Finland

**P1-86**

INCREASED SEMAPHORIN 3C PROMOTES TUMOR GROWTH AND METASTASIS IN PANCREATIC DUCTAL ADENOCARCINOMA BY INACTIVATING PI3K/AKT SIGNALING PATHWAY. X. Xu, H. Wang; Institute of Hepatopancreatobiliary Surgery, Southwest Hospital, Third Military Medical University, Chongqing/China

**P1-87**

OBESITY AS A RISK FACTOR IN PEDIATRIC ACUTE RECURRENT AND CHRONIC PANCREATITIS. A. Uc<sup>1</sup>, M. Abu-El-Haija<sup>2</sup>, B. Barth<sup>3</sup>, M. Bellin<sup>4</sup>, D. Fishman<sup>5</sup>, S. Freedman<sup>6</sup>, C. Gariepy<sup>7</sup>, M. Giefer<sup>8</sup>, T. Gonska<sup>9</sup>, M. Heyman<sup>10</sup>, R. Himes<sup>5</sup>, S. Husain<sup>11</sup>, T.K. Lin<sup>2</sup>, Q. Liu<sup>12</sup>, V. Morinville<sup>13</sup>, J.D. Nathan<sup>14</sup>, C.Y. Ooi<sup>15</sup>, J.J. Palermo<sup>14</sup>, E. Perito<sup>10</sup>, J. Pohl<sup>16</sup>, S. Rhee<sup>10</sup>, S.J. Schwarzenberg<sup>4</sup>, D. Troendle<sup>3</sup>, S. Werlin<sup>17</sup>, M. Wilschanski<sup>18</sup>, B. Zimmerman<sup>19</sup>, M.E. Lowe<sup>20</sup>; <sup>1</sup>Pediatrics, University of Iowa/United States of America, <sup>2</sup>Cincinnati Children's Hospital Medical Center/United States of America, <sup>3</sup>UTSW/United States of America, <sup>4</sup>Pediatrics, University of Minnesota, Minneapolis, MN/United States of America, <sup>5</sup>Baylor College of Medicine/United States of America, <sup>6</sup>Harvard Medical School/United States of America, <sup>7</sup>Nationwide Children's hospital/United States of America,

8Seattle Children's Hospital/United States of America, 9Hospital for Sick Children/Canada, 10UCSF/United States of America, 11Children's Hospital of Pittsburgh of University of Pittsburgh Medical Center/United States of America, 12Children's Hospital Los Angeles/United States of America, 13Montreal Children's Hospital/Canada, 14Cincinnati Children's Hospital Medical Center, Cincinnati/United States of America, 15UNSW/Australia, 16University of Utah/United States of America, 17MCW/United States of America, 18Hadassah Hebrew University Hospital/Israel, 19University of Iowa/United States of America, 20Department of Pediatrics, Children's Hospital of Pittsburgh of University of Pittsburgh Medical Center, Pittsburgh/United States of America

**P1-88**

SENNOSIDE A AFFECT INTESTINAL MOTILITY BY REDUCING IL-1 $\beta$  AND TNF- $\alpha$  TO INCREASE CPI-17 IN SMALL INTESTINAL SMOOTH MUSCLE CELLS IN RATS WITH ACUTE NECROTISING PANCREATITIS. C. Zhang<sup>1</sup>, Z.Q. Lin<sup>1</sup>, W. Zhang<sup>2</sup>, X. Zhang<sup>1</sup>, C. Du<sup>1</sup>, P. Xue<sup>1</sup>, Q. Xia<sup>1</sup>; <sup>1</sup>Department of Integrated Traditional Chinese and Western Medicine, Sichuan Provincial Pancreatitis Centre, West China Hospital, Sichuan University, Chengdu, 610041, People's Republic of China/China, <sup>2</sup>Department of Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan Province, 610041, People's Republic of China/China

**P1-89**

THE MICRO-FORCEPS FOR PANCREATIC CYSTS: A GAME CHANGER? O. Yuksel<sup>1</sup>, O. Basar<sup>1</sup>, D. Yang<sup>2</sup>, J. Samarasena<sup>3</sup>, C.J. Dimaio<sup>4</sup>, M.S. Wagh<sup>5</sup>, D.G. Forcione<sup>1</sup>, A.N. Ronald<sup>6</sup>, M.B. Pitman<sup>6</sup>, W.R. Brugge<sup>1</sup>; <sup>1</sup>Department of Gastroenterology, Massachusetts General Hospital, MA/United States of America, <sup>2</sup>Gastroenterology, University of Florida Health/United States of America, <sup>3</sup>Gastroenterology, University of California/United States of America, <sup>4</sup>Gastroenterology, Mount Sinai Hospital/United States of America, <sup>5</sup>Gastroenterology, University of Colorado/United States of America, <sup>6</sup>Pathology, Massachusetts General Hospital/United States of America

**P1-90**

EXTINCTION OF ABCB5 EXPRESSION IN PANCREATIC CANCER CELLS. T. Hank<sup>1</sup>, M.W. Herbst<sup>1</sup>, K. Hu<sup>1</sup>, D. Maennle<sup>1</sup>, A.S. Bauer<sup>2</sup>, K. Felix<sup>1</sup>, T. Hackert<sup>1</sup>, N. Giese<sup>1</sup>, O. Strobel<sup>1</sup>; <sup>1</sup>Department of General, Visceral and Transplantation Surgery, University Hospital Heidelberg/Germany, <sup>2</sup>Department of Functional Genomics, German Cancer Research Centre (DKFZ)/Germany

**P1-91**

DCLK1 REGULATES BMI-1 AND IS ASSOCIATED WITH CLINICAL OUTCOME OF PANCREATIC CANCER. O. Yongsheng, H. Wang; Institute of Hepatopancreatobiliary Surgery, Southwest Hospital, Third Military Medical University, Chongqing/China

**P1-92**

PANCREAS DIVISUM IN PEDIATRIC ACUTE RECURRENT AND CHRONIC PANCREATITIS. T.K. Lin<sup>1</sup>, M. Abu-El-Haija<sup>1</sup>, J.J. Palermo<sup>1</sup>, J.D. Nathan<sup>1</sup>, M.E. Lowe<sup>2</sup>, B. Zimmerman<sup>3</sup>, I. Inskip<sup>3</sup>, A. Uc<sup>4</sup>; <sup>1</sup>Gastroenterology, Cincinnati Children's Hospital Medical Center, Cincinnati/United States of America, <sup>2</sup>Department of Pediatrics, Children's Hospital of Pittsburgh of University of Pittsburgh Medical Center, Pittsburgh/United States of America, <sup>3</sup>University of Iowa/United States of America, <sup>4</sup>Pediatrics, University of Iowa/United States of America

**P1-93**

EFFECT OF HEPARINS ON HISTONE CATABOLISM AND CELLULAR INJURY IN ACUTE PANCREATITIS. P. Szatmary<sup>1</sup>, T. Liu<sup>1</sup>, D. Criddle<sup>1</sup>, A. Tepikin<sup>1</sup>, R. Sutton<sup>2</sup>; <sup>1</sup>Cellular and Molecular Physiology, University of Liverpool/United Kingdom, <sup>2</sup>NIHR Liverpool Pancreas Biomedical Research Unit, Royal Liverpool University Hospital, University of Liverpool/United Kingdom

**P1-94**

MISDIAGNOSIS OF CHRONIC PANCREATITIS (CP) IN A U.K REGIONAL PANCREAS CENTRE. A.R.G. Sheel<sup>1, 2</sup>, C. Halloran<sup>1, 2</sup>, P. Ghaneh<sup>1, 2</sup>, R.D. Baron<sup>1</sup>, M. Raraty<sup>1</sup>, J. Kleeff<sup>1, 2</sup>, V. Yip<sup>1</sup>, J. Evans<sup>3</sup>, F. Campbell<sup>4</sup>, R. Sutton<sup>1, 2</sup>, J. Ramesh<sup>5</sup>, J.P. Neoptolemos<sup>1, 2</sup>; <sup>1</sup>Pancreatobiliary Surgery, Royal Liverpool and Broadgreen University Hospitals Trust, Liverpool/United Kingdom, <sup>2</sup>NIHR Pancreas Biomedical Research Unit, University of Liverpool, Liverpool/United Kingdom, <sup>3</sup>Radiology, Royal Liverpool and Broadgreen University Hospitals Trust,



Liverpool/United Kingdom, 4Histopathology, Royal Liverpool and Broadgreen University Hospitals Trust, Liverpool/United Kingdom, 5Gastroenterology and Endoscopy, Royal Liverpool and Broadgreen University Hospitals Trust, Liverpool/United Kingdom

**P1-95**

**EXPLORING THE PROTEIN PROFILE OF PANCREATIC CANCER-ASSOCIATED DIABETES. L.**

Oldfield<sup>1</sup>, C. Jenkinson<sup>1</sup>, T. Purewal<sup>2</sup>, R. Sutton<sup>3</sup>, J.P. Neoptolemos<sup>4</sup>, W. Greenhalf<sup>1</sup>, E. Costello<sup>1</sup>; <sup>1</sup>Department of Molecular and Clinical Cancer Medicine, The University of Liverpool, Liverpool/United Kingdom, <sup>2</sup>Department of Diabetes and Endocrinology, Royal Liverpool University Hospital, Liverpool/United Kingdom, <sup>3</sup>NIHR Pancreas Biomedical Research Unit, University of Liverpool, Liverpool/United Kingdom, <sup>4</sup>NIHR Pancreas Biomedical Research Unit, University of Liverpool, Liverpool/United Kingdom

**P1-96**

**THE HEPARIN-BINDING PROTEOME IN MURINE EXPERIMENTAL ACUTE PANCREATITIS. Q.M.**

Nunes<sup>1</sup>, D. Su<sup>1</sup>, P.J. Brownridge<sup>2</sup>, C. Sun<sup>2</sup>, Y. Li<sup>2</sup>, W. Huang<sup>1</sup>, D.J. Rigden<sup>2</sup>, R.J. Beynon<sup>2</sup>, R. Sutton<sup>1</sup>, D.G. Fernig<sup>2</sup>; <sup>1</sup>NIHR Liverpool Pancreas Biomedical Research Unit/United Kingdom, <sup>2</sup>Department of Biochemistry, University of Liverpool/United Kingdom

**P1-97**

**PREVALENCE AND OUTCOMES OF ACUTE PANCREATITIS (AP) IN OLDER ADULTS: RESULTS FROM A PROPENSITY MATCHED ANALYSIS OF NATIONWIDE INPATIENT SAMPLE (2008-2012). S.**

Munigala<sup>1</sup>, A. Duvvuri<sup>2</sup>, K.C. Kottapalli<sup>3</sup>, D. Subramaniam<sup>4</sup>, D. Subramaniam<sup>5</sup>, G. Trikudanathan<sup>6</sup>, D. Conwell<sup>7</sup>; <sup>1</sup>Saint Louis University Center for Outcomes Research (SLUCOR)/United States of America, <sup>2</sup>Internal Medicine, Kansas City Veterans Affairs Medical Center, KS/United States of America, <sup>3</sup>Internal Medicine, Wheaton Franciscan Healthcare St. Francis Hospital, WI/United States of America, <sup>4</sup>Internal Medicine, Saint Louis University Center for Outcomes Research/United States of America, <sup>5</sup>Health Service Research, Internal Medicine, University of Kansas Medical Center, KS/United States of America, <sup>6</sup>Medicine, GI, University of Minnesota, Minneapolis/United States of America, <sup>7</sup>Ohio State University-Wexner Medical Center, Columbus, OH/United States of America

**P1-98**

**A NOVEL STRATEGY OF TARGETING INTERFERON GAMMA-INDUCED PROTEIN 10 TO INHIBIT INSTANT BLOOD MEDIATED INFLAMMATORY REACTION IN ISLET TRANSPLANTATION. G.**

Yoshimatsu<sup>1</sup>, M. Takita<sup>1</sup>, C. Darden<sup>1</sup>, C. Chang<sup>1</sup>, P.S. Saravanan<sup>1</sup>, M.C. Lawrence<sup>1</sup>, B. Naziruddin<sup>2</sup>; <sup>1</sup>Islet Cell Laboratory, Baylor Research Institute, Dallas, TX/United States of America, <sup>2</sup>Baylor University Medical Center, Dallas, TX/United States of America

**P1-99**

**THE IMPACT OF DIABETES ON OUTCOMES IN ACUTE PANCREATITIS: A REPORT FROM THE NATIONWIDE INPATIENT SAMPLE. J. McNabb-Baltar<sup>1</sup>, A. Hinton<sup>2</sup>, D. Conwell<sup>3</sup>; <sup>1</sup>Center for Pancreatic**

Disease, Division of Gastroenterology, Hepatology, and Endoscopy, Brigham and Women's Hospital, Boston, MA/United States of America, <sup>2</sup>Ohio State University-Wexner Medical Center, Columbus, OH/United States of America, <sup>3</sup>Ohio State University Medical Center, Columbus, OH/United States of America

**P1-100**

**INHIBITION OF HISTONE ACETYLATION RESULTS IN PANCREATIC CANCER CELL DEATH AND APOPTOSIS. B. Giri<sup>1</sup>, S. Modi<sup>2</sup>, V. Sethi<sup>2</sup>, J. George<sup>2</sup>, B. Garg<sup>2</sup>, S. Banerjee<sup>2</sup>, A.K. Saluja<sup>3</sup>, V. Dudeja<sup>2</sup>;**

<sup>1</sup>University of Miami, University of Miami, Miami/United States of America, <sup>2</sup>University of Miami/United States of America, <sup>3</sup>Surgery, University of Miami, FL/United States of America

**P1-101**

**PIGMENT EPITHELIUM-DERIVED FACTOR (PEDF) INHIBITS NOTCH SIGNALING IN PANIN CELLS.**

J. Gong<sup>1</sup>, G. Belinsky<sup>2</sup>, C. Chung<sup>2</sup>; <sup>1</sup>Yale University School of Medicine, CT/United States of America, <sup>2</sup>VA CT Healthcare/ Yale University School of Medicine, CT/United States of America



**P1-102**

MEK RESISTANCE VIA AMPHIREGULIN MEDIATED EGFR-STAT3 ACTIVATION IN PANCREATIC CANCER. P. Lamichhane<sup>1</sup>, N.S. Nagathihalli<sup>1</sup>, J. Castellanos<sup>2</sup>, C. Shi<sup>2</sup>, C. Roberts<sup>1</sup>, M. Vansaun<sup>1</sup>, N. Merchant<sup>1</sup>; <sup>1</sup>Surgery, University of Miami, Miami, FL/United States of America, <sup>2</sup>Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, TN/United States of America

**P1-103**

INITIAL PAIN MANAGEMENT FOR CHILDREN PRESENTING TO A PEDIATRIC EMERGENCY DEPARTMENT WITH ACUTE PANCREATITIS. A.S. Grover<sup>1</sup>, V. Kadiyala<sup>2</sup>, S.F. Manzi<sup>3, 4</sup>, V.L. Fox<sup>1</sup>; <sup>1</sup>Division of Gastroenterology, Hepatology and Nutrition, Boston Children's Hospital, Boston, MA/United States of America, <sup>2</sup>Center for Pancreatic Disease, Division of Gastroenterology, Hepatology, and Endoscopy, Brigham and Women's Hospital, Boston, MA/United States of America, <sup>3</sup>Division of Genetics and Genomics, Boston Children's Hospital, Boston, MA/United States of America, <sup>4</sup>Department of Pharmacy, Boston Children's Hospital, Boston, MA/United States of America

**P1-104**

BLOCKING DNA DAMAGE REPAIR IMPROVES EFFICACY OF THERAPEUTICS IN PANCREATIC CANCER. S. Srinivasan<sup>1</sup>, C. Shi<sup>2</sup>, C. Roberts<sup>3</sup>, M. Vansaun<sup>1</sup>, N. Merchant<sup>1</sup>, N.S. Nagathihalli<sup>1</sup>; <sup>1</sup>Surgery, University of Miami, Miami, FL/United States of America, <sup>2</sup>Vanderbilt University Medical Center, Nashville, TN/United States of America, <sup>3</sup>Surgery, University of Miami/United States of America

**P1-105**

ACUTE PANCREATITIS (AP) EARLY READMISSION RATES IN UNITED STATES: RESULTS FROM A NATIONWIDE HOSPITAL READMISSIONS DATA. S. Munigala; Saint Louis University Center for Outcomes Research (SLUCOR)/United States of America

**P1-106**

AC3/AC-ASSOCIATED PROTEIN 1 COMPLEX REGULATES ACTIN FILAMENT DYNAMICS IN PANCREATIC CANCER CELLS. H. Hassan, A. Newsom, S. Mehratra, M.E. Sabbatini; Biological Sciences, Augusta University, Augusta, GA/United States of America

**P1-107**

BLOCKING P<sub>2</sub> RECEPTOR BY SURAMIN REDUCES THE SEVERITY OF ACUTE PANCREATITIS. A. Dixit<sup>1</sup>, J. George<sup>2</sup>, Y. Ryu<sup>1</sup>, H. Cheema<sup>1</sup>, V. Dudeja<sup>3</sup>, R. Dawra<sup>1</sup>, A.K. Saluja<sup>1</sup>; <sup>1</sup>Surgery, University of Miami, FL/United States of America, <sup>2</sup>Surgery, University of Miami/United States of America, <sup>3</sup>University of Miami/United States of America

**P1-108**

HEME OXYGENASE-1 INHIBITION SENSITIZE PANCREATIC CANCER TO GEMCITABINE THERAPY. M.Y. Abdalla<sup>1</sup>, S. Rachagani<sup>2</sup>, N. Wasim<sup>2</sup>, S. Batra<sup>2</sup>, S. Kumar<sup>2</sup>; <sup>1</sup>Department of Pathology/Microbiology, University of Nebraska Medical Center, Omaha/United States of America, <sup>2</sup>Biochem and Molecular Biology, UNMC/United States of America

**P1-109**

OPTIMIZATION OF TARGETED RADIONUCLIDE THERAPY (TRT) FOR PANCREATIC CANCER. S.K. Gautam<sup>1</sup>, M.W. Nasser<sup>1</sup>, S. Gupta<sup>1</sup>, S.K. Batra<sup>1, 2</sup>, M. Jain<sup>1, 2</sup>; <sup>1</sup>Biochemistry and molecular biology, University of nebraska medical center, Omaha, NE/United States of America, <sup>2</sup>Fred and Pamela Buffett Cancer Center/United States of America

**P1-110**

ZOLEDRONIC ACID AS A NOVEL RADIOSENSITIZER FOR PANCREATIC CANCER. P. Seshacharyulu<sup>1</sup>, R.K. Nimmakayala<sup>1</sup>, S. Rachagani<sup>1</sup>, S. Kaur<sup>1</sup>, M.P. Ponnusamy<sup>1, 2</sup>, M. Jain<sup>1, 2</sup>, C. Lin<sup>1, 3</sup>, S.K. Batra<sup>1, 4</sup>; <sup>1</sup>Department of Biochemistry & Molecular Biology, University of Nebraska Medical Center, Omaha, NE/United States of America, <sup>2</sup>Fred & Pamela Buffet Cancer Center, Eppley Institute for Research in Cancer and Allied Diseases, -, NE/United States of America, <sup>3</sup>Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, -, NE/United States of America, <sup>4</sup>Fred & Pamela Buffet Cancer Center, NE/United States of America

**P1-111**

COMPARISON OF CLINICAL COURSE AND OUTCOME OF ALCOHOL INDUCED AND GALLSTONE INDUCED ACUTE PANCREATITIS. R. Kochhar<sup>1</sup>, J. Samanta<sup>1</sup>, N. Dhaka<sup>1</sup>, V. Gupta<sup>2</sup>, T.D. Yadav<sup>2</sup>, S.K. Sinha<sup>1</sup>; <sup>1</sup>Gastroenterology, Postgraduate Institute of Medical Education and Research, Chandigarh/India, <sup>2</sup>Surgery, Postgraduate Institute of Medical Education and Research, Chandigarh/India

**P1-112**

GASTROINTESTINAL FISTULAE IN ACUTE PANCREATITIS. J. Samanta<sup>1</sup>, N. Dhaka<sup>1</sup>, S. Kochhar<sup>2</sup>, R. Prasad<sup>1</sup>, S.K. Sinha<sup>1</sup>, V. Gupta<sup>3</sup>, T.D. Yadav<sup>3</sup>, R. Kochhar<sup>1</sup>; <sup>1</sup>Gastroenterology, Postgraduate Institute of Medical Education and Research, Chandigarh/India, <sup>2</sup>Radiodiagnosis, Govt Medical College and Hospital, Chandigarh/India, <sup>3</sup>Surgery, Postgraduate Institute of Medical Education and Research, Chandigarh/India

**P1-113**

CHARACTERISTICS AND LONG-TERM SURVIVAL OF RESECTED PANCREATIC CYSTIC NEOPLASMS (PCN) IN FINLAND 2000-2008. THE FIRST NATIONWIDE STUDY. Y. Vaalavuo<sup>1</sup>, A. Anttila<sup>1</sup>, R. Ahola<sup>1</sup>, A. Siiki<sup>2</sup>, M. Vornanen<sup>1</sup>, J. Sand<sup>1</sup>, J. Laukkanen<sup>1</sup>; <sup>1</sup>Department of Gastroenterology and Alimentary Tract Surgery, Tampere University Hospital, Tampere/Finland, <sup>2</sup>Dept. of Gastroenterology and Alimentary Tract Surgery, Tampere University Hospital/Finland

**P1-114**

PANCREATECTOMIES FOR METASTATIC TUMORS. Junli Wu<sup>1</sup>, Zipeng Lu<sup>1</sup>, Cuncai Dai<sup>1</sup>, Kuirong Jiang<sup>1</sup>, Wentao Gao<sup>1</sup>, Jianmin Chen<sup>1</sup>, Feng Guo<sup>1</sup>, Jishu Wei<sup>1</sup>, Chunhua Xi<sup>1</sup>, Yi Miao<sup>1</sup>; <sup>1</sup>Pancreas Center, The First Affiliated Hospital of Nanjing Medical University, China

**P1-115**

PANCREATODUODENECTOMY WITH RESECTION AND RECONSTRUCTION OF REPLACED RIGHT HEPATIC ARTERY (RRHA). Kuirong Jiang<sup>1</sup>, Zipeng Lu<sup>1</sup>, Jishu Wei<sup>1</sup>, Jianmin Chen<sup>1</sup>, Feng Guo<sup>1</sup>, Junli Wu<sup>1</sup>, Wentao Gao<sup>1</sup>, Jie Yin<sup>1</sup>, Dong Xu<sup>1</sup>, Pengfei Wu<sup>1</sup>, Chunhua Xi<sup>1</sup>, Miao Yi<sup>1</sup>; <sup>1</sup>Pancreas Center, The First Affiliated Hospital of Nanjing Medical University, China

**P1-116**

MICROENVIRONMENTAL CUES ENRICH FOR GLYCOLYTIC CD133+ "STEM-LIKE" TUMOR INITIATING CELLS IN PANCREATIC CANCER. A. Chandra, P.Dauer, N. Sharma, A. Nomura, V.Gupta, A. Saluja and S. Banerjee Sylvester Comprehensive Cancer Center, Department of Surgery, University of Miami Miller School of Medicine, United States of America

## POSTERS OF DISTINCTION | FRIDAY, OCTOBER 28

### P2-1

COMPARISON OF REMNANT INVAGINATION AND DUCT-TO-MUCOSA PANCREATICOJEJUNOSTOMY FOLLOWING WHIPPLES RESECTION: RANDOMIZED CLINICAL TRIAL IN PATIENTS AT HIGH RISK OF POSTOPERATIVE PANCREATIC FISTULA. S. Sanjeevi<sup>1</sup>, M. Del Chiaro<sup>1</sup>, B. Björnsson<sup>2</sup>, J. Sand<sup>3</sup>, R. Segersvärd<sup>1</sup>, L. Lundell<sup>1</sup>, Å. Andrén-Sandberg<sup>1</sup>, C. Ansorge<sup>1</sup>; <sup>1</sup>Div. of Surgery, Dept. of Clinical Science, Intervention and Technology (CLINTEC), Karolinska Institute, Stockholm/Sweden, <sup>2</sup>Dept. of Surgery, Linköping University/Sweden, <sup>3</sup>Dept. of Gastroenterology and Alimentary Tract Surgery, Tampere University Hospital/Finland

### P2-2

DIET-INDEPENDENT VISCERAL ADIPOSE TISSUE INFLAMMATION ACCELERATES PANCREATIC CANCER DEVELOPMENT IN THE CONDITIONAL KRASG12D MOUSE MODEL. M. Xu, X. Jung, A. Moro, C. Chou, A. Schmidt, H.-H. Chang, O.J. Hines, G. Eibl; Surgery, David Geffen School of Medicine at UCLA/United States of America

### P2-3

ENDOSOMAL REGULATORY PROTEIN D52 INTERACTS WITH ATG16L1 TO COORDINATE SECRETION AND AUTOPHAGY IN ACINAR CELLS. M. Cooley, D.D. Thomas, S. Messenger, G. Groblewski; University of Wisconsin/United States of America

### P2-4

STATIN USE SHOWS INCREASED OVERALL SURVIVAL IN PATIENTS DIAGNOSED WITH PANCREATIC CANCER: A META-ANALYSIS. D. Wang<sup>1</sup>, E. Rodriguez<sup>1</sup>, E. Donath<sup>1</sup>, J. Barkin<sup>2</sup>, A. Pakravan<sup>1</sup>; <sup>1</sup>Department of Medicine, University of Miami Miller School of Medicine, Atlantis, FL/United States of America, <sup>2</sup>Department of Gastroenterology, University of Miami Miller School of Medicine, University of Miami Pancreas Center, Miami, FL/United States of America

### P2-5

ACUTE PANCREATITIS ADMISSION TRENDS IN PEDIATRICS, A NATIONAL ESTIMATE THROUGH THE KIDS. M. Abu-El-Haija<sup>1</sup>, S. El-Dika<sup>2</sup>, A. Hinton<sup>2</sup>, D. Conwell<sup>2</sup>; <sup>1</sup>Cincinnati Children's Hospital Medical Center, Cincinnati/United States of America, <sup>2</sup>Ohio State University-Wexner Medical Center, Columbus, OH/United States of America

### P2-6

NOVEL ROLE OF PERITONEAL MESOTHELIAL CELLS THAT LEAD TO PANCREATIC CANCER PERITONEAL DISSEMINATION FORMATION. T. Abe<sup>1</sup>, K. Ohuchida<sup>1</sup>, S. Kibe<sup>1</sup>, Y. Ando<sup>1</sup>, H. Nakayama<sup>1</sup>, S. Takesue<sup>1</sup>, S. Endo<sup>1</sup>, K. Koikawa<sup>1</sup>, T. Okumura<sup>2</sup>, T. Moriyama<sup>1</sup>, K. Nakata<sup>1</sup>, Y. Miyasaka<sup>1</sup>, T. Manabe<sup>1</sup>, T. Ohtsuka<sup>1</sup>, E. Nagai<sup>1</sup>, K. Mizumoto<sup>1</sup>, M. Nakamura<sup>1</sup>; <sup>1</sup>Department of Surgery and Oncology, Kyushu University/Japan, <sup>2</sup>Department of Surgery and Oncology, Kyushu University, Fukuoka/Japan

### P2-7

INTRACELLULAR TRYPSINOGEN ACTIVATION IN PHAGOCYTING MACROPHAGES ACTS AS DAMP FUELING SEVERE ACUTE PANCREATITIS. M. Sandler<sup>1</sup>, F.-U. Weiss<sup>1</sup>, T. Wartmann<sup>2</sup>, W. Halangk<sup>3</sup>, M.M. Lerch<sup>1</sup>, J. Mayerle<sup>1</sup>; <sup>1</sup>Department of Medicine A, University Medicine, Ernst-Moritz-Arndt-University Greifswald, Greifswald/Germany, <sup>2</sup>Division of Experimental Surgery, Otto-von-Guericke University Magdeburg, Germany/Germany, <sup>3</sup>Division of Experimental Surgery, Otto-von-Guericke University Magdeburg, Germany/Germany

### P2-8

THE ROUTINE CLINICAL YIELD OF MOLECULAR ANALYSIS FOR PRECISION MEDICINE IN PANCREATIC CANCER USING PANCREATIC FNA BIOPSY MATERIAL. J. Farrell<sup>1</sup>, J. Wong<sup>2</sup>, K. Burnett<sup>3</sup>, M. Baker<sup>3</sup>, T. Maney<sup>3</sup>; <sup>1</sup>Yale University, CT/United States of America, <sup>2</sup>University of Hawaii, HI/United States of America, <sup>3</sup>Caris Life Science/United States of America

**P2-9**

KRAS MUTATION IMPARTS NEOPLASTIC POTENTIAL ON DUCT CELLS BUT NOT ACINAR CELLS IN A MOUSE MODEL OF OBSTRUCTIVE CHRONIC PANCREATITIS. F.C. Pan<sup>1</sup>, J. Kim<sup>2</sup>, C. Shi<sup>3</sup>, M.K. Washington<sup>3</sup>, J. Kopp<sup>4</sup>, M. Sander<sup>5</sup>, M. Gannon<sup>6</sup>, R.D. Beauchamp<sup>7</sup>, C.V. Wright<sup>1</sup>, A.L. Means<sup>8</sup>; <sup>1</sup>Cell and Developmental Biology, Vanderbilt University Medical Center, TN/United States of America, <sup>2</sup>Surgery, Vanderbilt University Medical Center/United States of America, <sup>3</sup>Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, TN/United States of America, <sup>4</sup>Pediatrics and Cellular and Molecular Medicine, University of California, San Diego/United States of America, <sup>5</sup>Pediatrics and Cellular and Molecular Medicine, University of California, San Diego, CA/United States of America, <sup>6</sup>Medicine, Vanderbilt University Medical Center, TN/United States of America, <sup>7</sup>Surgical Sciences, Vanderbilt University Medical Center, TN/United States of America, <sup>8</sup>Surgery, Vanderbilt University Medical Center, TN/United States of America

**P2-10**

THE IMPACT OF INTEGRATED MOLECULAR PATHOLOGY ANALYSIS ON EUS GASTROENTEROLOGIST MANAGEMENT DECISIONS FOR PANCREATIC CYSTIC LESIONS. J. Nieto<sup>1</sup>, S. Jackson<sup>2</sup>, N. Toney<sup>2</sup>, A. Lankarani<sup>1</sup>; <sup>1</sup>Borland-Groover Clinic, Jacksonville, FL/USA, <sup>2</sup>Clinical Development, Interpace Diagnostics Corporation, Pittsburgh, PA/USA

**P2-11**

PREVALENCE OF DEEP VEIN THROMBOSIS (DVT) AND PULMONARY EMBOLISM (PE) IN HOSPITALIZED ACUTE PANCREATITIS (AP) PATIENTS - A POPULATION BASED COHORT STUDY. G. Trikudanathan<sup>1</sup>, C. Umapathy<sup>2</sup>, S. Munigala<sup>3</sup>, D. Conwell<sup>4</sup>, S.G. Krishna<sup>4</sup>, <sup>5</sup>; <sup>1</sup>Medicine, GI, University of Minnesota, Minneapolis/USA, <sup>2</sup>Internal Medicine, University of Pittsburgh, PA/USA, <sup>3</sup>Saint Louis University Center for Outcomes Research (SLUCOR)/USA, <sup>4</sup>Ohio State University Medical Center, Columbus, OH/USA, <sup>5</sup>Ohio State University-Wexner Medical Center, Columbus, OH/USA

**P2-12**

LOSS OF EZH2 DOES NOT ENHANCE ONCOGENIC KRAS-PROMOTED PDAC IN ADULT TISSUE UNLESS COMBINED WITH EVENTS THAT AFFECT ACINAR CELL MATURATION. K. Berger<sup>1</sup>, C. Johnson<sup>2</sup>, G. Lomber<sup>3</sup>, C. Howlett<sup>4</sup>, R. Urrutia<sup>5</sup>, C. Pin<sup>6</sup>; <sup>1</sup>Paediatrics, University of Western Ontario/Canada, <sup>2</sup>Paediatrics, University of Western Ontario, London, ON/Canada, <sup>3</sup>Medicine, Mayo Clinic College of Medicine, MN/USA, <sup>4</sup>Pathology and Laboratory Medicine, Schulich School of Medicine & Dentistry, University of Western Ontario, London, ON/Canada, <sup>5</sup>Biochemistry and Molecular Biology, Mayo Clinic College of Medicine, MN/USA, <sup>6</sup>Paediatrics, University of Western Ontario, London/Canada

**P2-13**

THE PANCREAS-SPECIFIC ISOFORM OF SPCA2 AFFECTS STORE OPERATED CA<sup>2+</sup> ENTRY. M. Fenech<sup>1</sup>, S. Brar<sup>1</sup>, P. Stathopoulos<sup>2</sup>, C. Pin<sup>3</sup>; <sup>1</sup>Physiology and Pharmacology, University of Western Ontario, London/Canada, <sup>2</sup>Physiology and Pharmacology, University of Western Ontario, London, ON/Canada, <sup>3</sup>Paediatrics, University of Western Ontario, London/Canada

**P2-14**

RENALASE PROTECTS AGAINST PANCREATITIS BY ACTIVATING A PLASMA MEMBRANE CALCIUM ATPASE (PMCA). T. Kolodecik<sup>1</sup>, A. Reed<sup>1</sup>, K. Date<sup>1</sup>, <sup>2</sup>, F.S. Gorelick<sup>3</sup>; <sup>1</sup>Internal Medicine digestive diseases, Yale University/United States of America, <sup>2</sup>Graduate School of Humanities and Science, Ochanomizu University/Japan, <sup>3</sup>VA Connecticut Healthcare, CT/United States of America

**P2-15**

ACCURATE ADMISSION TRANSCRIPTOMIC SIGNATURE OF THE SEVERITY OF ACUTE PANCREATITIS. B. Lane<sup>1</sup>, W. Huang<sup>1</sup>, Q.M. Nunes<sup>1</sup>, K. Altaf<sup>1</sup>, L. Rainbow<sup>2</sup>, J. Armstrong<sup>1</sup>, W. Greenhalf<sup>1</sup>, D. Fernig<sup>3</sup>, C. Hertz-Fowler<sup>2</sup>, A. Cossins<sup>2</sup>, F. Falciani<sup>2</sup>, S. Maskell<sup>4</sup>, A. Morris<sup>5</sup>, R. Sutton<sup>1</sup>; <sup>1</sup>NIHR Liverpool Pancreas Biomedical Research Unit, Royal Liverpool and Broadgreen University Hospitals NHS Trust/United Kingdom, <sup>2</sup>Functional and Comparative Genomics, Institute of Integrative Biology, University of Liverpool/United Kingdom, <sup>3</sup>Department of Biochemistry, Institute of Integrative Biology, University of Liverpool/United Kingdom, <sup>4</sup>Department of Electrical Engineering and Electronics, Faculty of Science and Engineering, University of Liverpool/United Kingdom, <sup>5</sup>Department of Biostatistics, Institute of Translational Medicine, University of Liverpool/United Kingdom

**P2-16**

ACTIVATION OF IL-1 SIGNALING IN CD133+ PANCREATIC CANCER CELLS. A. Nomura, V.K. Gupta, P. Dauer, V. Dudeja, A.K. Saluja, S. Banerjee; Sylvester Comprehensive Cancer Center, Department of Surgery, University of Miami Miller School of Medicine, United States of America

**P2-17**

OPPOSING EFFECTS OF TGF- $\beta$  AND BMP2 ON MICRORNA-200B IN THE PANCREAS. P. Yu, K. Liu, Y. Cao, T. Ko; UTHealth/United States of America

**P2-18**

C-SRC IS INVOLVED IN PHYSIOLOGIC ZYMOGEN SYNTHESIS AND PACKAGING THROUGH THE GOLGI IN PANCREATIC ACINAR CELLS. G. Singh, J.R. Yaron, K. Patel, R.N. Trivedi, C. De Oliveira, V.P. Singh; Department of Medicine, Mayo Clinic, Scottsdale, AZ/United States of America

## POSTERS

**P2-19**

CLINICAL ALLOGRAFT ISLETS POST-TRANSPLANT 3 YEAR FOR TYPE 1 DIABETES MELLITUS:10 CASES REPORTED. Y. Yao, L. Wei, M. Yang, L. Luo, H. Xue, L. Luo, G. Xiang, H. Zou, G. Wang, C. Lai, S. Deng, X. Huang; Center of Cell Transplantation<sup>2</sup>Center of Hepatobiliary and Pancreatic Surgery, Affiliated Hospital of University of Electronic Science and technology<sup>2</sup>Sichuan Provincial People's Hospital, Chengdu/China

**P2-20**

SUSCEPTIBILITY GENES OF MURINE AUTOIMMUNE PANCREATITIS. S. Müller<sup>1</sup>, L. Borufka<sup>1</sup>, J. Bischof<sup>2</sup>, Y. Gupta<sup>2</sup>, F. Asghari<sup>1, 2</sup>, S. Möller<sup>2</sup>, H. Nizze<sup>3</sup>, S. Ibrahim<sup>2</sup>, R. Jaster<sup>1</sup>; <sup>1</sup>Department of Medicine, Division of Gastroenterology, Rostock University Medical Center, Rostock/Germany, <sup>2</sup>Institute of Experimental Dermatology, University of Luebeck/Germany, <sup>3</sup>Institute of Pathology, Rostock University Medical Center/Germany

**P2-21**

MOLECULAR TRACING OF INVASIVE IPMN LESIONS AND RELATED ADENOCARCINOMA TO DEFINE DISTINCT ROUTES TO INVASIVE CARCINOMAS OF THE PANCREAS. Y. Ono<sup>1</sup>, Y. Omori<sup>2</sup>, M. Tanino<sup>3</sup>, K. Takahashi<sup>4</sup>, Y. Ambo<sup>5</sup>, T. Shinohara<sup>2</sup>, H. Nishihara<sup>3</sup>, S. Tanaka<sup>3</sup>, H. Maguchi<sup>4</sup>, H. Karasaki<sup>1</sup>, Y. Mizukami<sup>1</sup>; <sup>1</sup>Center for Clinical and Biomedical Research, Sapporo Higashi Tokushukai Hospital/Japan, <sup>2</sup>Department of Pathology, Teine Keijinkai Hospital/Japan, <sup>3</sup>Department of Tumor Pathology, Hokkaido University School of Medicine/Japan, <sup>4</sup>Center for Gastroenterology, Teine Keijinkai Hospital/Japan, <sup>5</sup>Department of Surgery, Teine Keijinkai Hospital/Japan

**P2-22**

MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY IN ASSESSING PANCREATIC FUNCTION TESTING IN PEDIATRICS. A.T. Trout<sup>1</sup>, D.B. Wallihan<sup>2</sup>, M. Abu-El-Haija<sup>1</sup>; <sup>1</sup>Cincinnati Children's Hospital Medical Center/United States of America, <sup>2</sup>Charlotte Radiology, Charlotte/United States of America

**P2-23**

PREDICTING PANCREATITIS PHENOTYPE IN THREE SIBLINGS BASED ON A SHARED GENOTYPE. D. Vitale<sup>1</sup>, M. Abu-El-Haija<sup>2</sup>, T.K. Lin<sup>2</sup>; <sup>1</sup>Cincinnati Children's Hospital Medical Center/United States of America, <sup>2</sup>Gastroenterology, Cincinnati Children's Hospital Medical Center, Cincinnati/United States of America

**P2-24**

GENOME-WIDE RNAI SCREENING IDENTIFIED METASTASIS SUPPRESSOR GENES IN AN ORTHOTOPIC PANCREATIC CANCER MOUSE MODEL. T. Xia, Y. Chen; School of Biomedical Sciences, Faculty of Medicine, The Chinese University of Hong Kong/Hong Kong PRC



**P2-25**

LIQUID BIOPSY FOR EARLY DETECTION OF PANCREATIC CANCER. Y. Mizukami<sup>1</sup>, Y. Ono<sup>1</sup>, H. Karasaki<sup>1</sup>, M. Ogata<sup>1</sup>, A. Sugitani<sup>1</sup>, K. Koizumi<sup>2</sup>, S. Asahara<sup>3</sup>, K. Kawakubo<sup>4</sup>, K. Takahashi<sup>5</sup>, H. Maguchi<sup>5</sup>, K. Nagashima<sup>1</sup>; <sup>1</sup>Center for Clinical and Biomedical Research, Sapporo Higashi Tokushukai Hospital/Japan, <sup>2</sup>Center for Gastroenterology, Shonan Kamakura General Hospital/Japan, <sup>3</sup>Department of Gastroenterology, Chiba Tokushukai Hospital/Japan, <sup>4</sup>Department of Gastroenterology and Hepatology, Hokkaido University Graduate School of Medicine/Japan, <sup>5</sup>Center for Gastroenterology, Teine Keijinkai Hospital/Japan

**P2-26**

QUALITY OF LIFE PREDICTORS IN CHRONIC PANCREATITIS: A EUROPEAN COHORT STUDY. S.M. Robinson<sup>1, 2</sup>, S. Rasch<sup>3</sup>, S. Beer<sup>4</sup>, A. Mickevicius<sup>5</sup>, I. Valantiene<sup>6</sup>, R. Charnley<sup>1</sup>, J. Rosendahl<sup>7</sup>; <sup>1</sup>Department of HPB Surgery, Newcastle upon Tyne Hospitals, Newcastle Upon Tyne/United Kingdom, <sup>2</sup>Institute of Cellular Medicine Fibrosis Research Group, Newcastle University, Newcastle Upon Tyne/United Kingdom, <sup>3</sup>II. Medizinische Klinik und Poliklinik, Klinikum rechts der Isar, Technische Universität München/Germany, <sup>4</sup>Department für Innere Medizin, Neurologie und Dermatologie, Universitätsklinikum Leipzig/Germany, <sup>5</sup>Center of Hepatology, Gastroenterology and Dietetics, Vilnius University Hospital Santariskiu Klinikos/Lithuania, <sup>6</sup>Lithuanian University of Health Sciences/Lithuania, <sup>7</sup>Universitätsklinik und Poliklinik für Innere Medizin I, Universitätsklinikum Halle (Saale),/Germany

**P2-27**

RISK FACTORS FOR PANCREATIC ATROPHY IN TYPE 1 AUTOIMMUNE PANCREATITIS: A NATIONWIDE SURVEY BY THE JAPAN PANCREAS SOCIETY. M. Kitano<sup>1</sup>, T. Ito<sup>1</sup>, S. Kawa<sup>2</sup>, K. Kubota<sup>3</sup>, T. Kamisawa<sup>4</sup>, K. Okazaki<sup>5</sup>, T. Shimosegawa<sup>6</sup>; <sup>1</sup>Gastroenterology, Shinshu university school of medicine/Japan, <sup>2</sup>Shinshu University/Japan, <sup>3</sup>Gastroenterology, Yokohama City University Graduate School of Medicine/Japan, <sup>4</sup>Tokyo Metropolitan Komagome Hospital/Japan, <sup>5</sup>Kansai Medical University/Japan, <sup>6</sup>Tohoku University Graduate School of Medicine/Japan

**P2-28**

CBL-C, AN EPITHELIAL-SPECIFIC DESTRUCTOR OF ACTIVATED RTKS, DETERMINES SUBTYPE, MOTILITY AND TUMORIGENICITY OF PANCREATIC CANCER CELLS. K. Hu<sup>1</sup>, M. Schenk<sup>1</sup>, A.S. Bauer<sup>2</sup>, T. Giese<sup>3</sup>, S. Keleg<sup>1</sup>, K. Felix<sup>1</sup>, S. Le Blanc<sup>1</sup>, D. Baumann<sup>4</sup>, S. Wendler<sup>1</sup>, T. Hackert<sup>1</sup>, R. Offringa<sup>4</sup>, N. Giese<sup>1</sup>, O. Strobel<sup>1</sup>; <sup>1</sup>European Pancreas Centre, Department of General, Visceral and Transplantation Surgery, University Hospital Heidelberg, Heidelberg/Germany, <sup>2</sup>Department of Functional Genomics, German Cancer Research Centre (DKFZ)/Germany, <sup>3</sup>Institute of Immunology, University Hospital Heidelberg/Germany, <sup>4</sup>Department of Molecular Oncology of Gastrointestinal Tumors, German Cancer Research Center (DKFZ)/Germany

**P2-29**

ANACARDIC ACID INHIBITS CELL GROWTH AND SYNERGIZES WITH CHEMOTHERAPEUTICS BY THE ACTIVATION OF CHMP1A. M. Park<sup>1</sup>, D. Upton<sup>2</sup>, V. Eversole<sup>2</sup>, M. Blackmon<sup>1</sup>, S. Craver<sup>1</sup>, D. Perkins<sup>2</sup>; <sup>1</sup>KYCOM, University of Pikeville, Pikeville, KY/United States of America, <sup>2</sup>Biology and Chemistry, University of Pikeville, Pikeville, KY/United States of America

**P2-30**

ALTERNATIVE DIAGNOSES FOR MILD ELEVATIONS IN PANCREATIC ENZYMES: A CASE SERIES DESCRIPTIVE STUDY. D. Lew, S.J. Pandol, E. Afghani; Cedars-Sinai Medical Center/United States of America

**P2-31**

WRAPPING OF PANCREATICOJEJUNOSTOMY WITH PGA MESH COULD PREVENT THE PANCREATIC FISTULA AFTER PANCREATODUODENECTOMY. J.S. Kang, Y. Han, J.-Y. Jang, H. Kim, J.R. Kim, W. Kwon, S.-W. Kim; Department of Surgery and Cancer Research Institute, Seoul National University College of Medicine/Korea, Republic of

**P2-32**

CLINICOPATHOLOGICAL ANALYSIS AND PROBABILITY PREDICTION OF INVASIVE CARCINOMA IN PATIENTS WITH INTRADUCTAL PAPILLARY MUCINOUS NEOPLASM. A. Wei<sup>1</sup>, D. He<sup>2</sup>, W. Hu<sup>1</sup>; <sup>1</sup>Pancreatic Surgery Department, West China Hospital, Chengdu/China, <sup>2</sup>Pathology Department, West China Hospital, Chengdu/China



**P2-33**

ENDOSCOPIC MINOR PAPILLA SPHINCTEROTOMY IS EFFECTIVE FOR THE TREATMENT OF SYMPTOMATIC SANTORINICELE: LONG-TERM RESULTS IN A LARGE SERIES. S.F. Crinò<sup>1</sup>, L. Bernardoni<sup>2</sup>, M.C. Conti Bellocchi<sup>2</sup>, G. Malleo<sup>3</sup>, R. Manfredi<sup>4</sup>, L. Frulloni<sup>1</sup>, A. Amodio<sup>1</sup>, A. Gabbriellini<sup>1</sup>; <sup>1</sup>Gastroenterology, AOUI Verona Hospital Trust, Verona/Italy, <sup>2</sup>Gastroenterology, AOUI Verona Hospital Trust/Italy, <sup>3</sup>Surgery B, AOUI Verona Hospital Trust/Italy, <sup>4</sup>Radiology, AOUI Verona Hospital Trust/Italy

**P2-34**

PREDICTIVE FACTORS FOR LONG-TERM SURVIVAL FOLLOWING HEPATECTOMY FOR LIVER METASTASES FROM PANCREATIC CANCER. A. Andreou, F. Klein, R.B. Schmuck, A.R. Noltsch, J. Pratschke, M. Bahra; Charité Universitätsmedizin Berlin, Campus Virchow Klinikum, Berlin/Germany

**P2-35**

CORTICOTROPIN-RELEASING FACTOR RECEPTOR 2 (CRF<sub>2</sub>R) DEFICIENCY ALTERS METABOLIC AND PANCREATIC FUNCTION IN A SEX-SPECIFIC MANNER IN MICE. S. Paruthiyil<sup>1</sup>, E. Kaushal<sup>1</sup>, B. Hasdemir<sup>1</sup>, A. Bhargava<sup>2</sup>; <sup>1</sup>Osher Center, UCSF, San Francisco/United States of America, <sup>2</sup>ObGyn & Osher Center, UCSF, San Francisco/United States of America

**P2-36**

EARLY DRAIN FLUID LIPASE AS PREDICTOR OF POSTOPERATIVE PANCREATIC FISTULA AFTER PANCREATIC RESECTION: A PROSPECTIVE PILOT STUDY. T. Ingkakul, C. Pumpuang, A. Thienhiran, S. Hongjinda; Surgery, Phramongkutklao Hospital, Bangkok/Thailand

**P2-37**

DIFFERENTIATING BRANCH DUCT IPMN FROM MIXED DUCT IPMN: TEST CHARACTERISTICS OF PREOPERATIVE IMAGING MODALITIES. E.E. Ugbarugba, C. Grieco, B. Swanson, P. Hart, S. El-Dika, J. Walker, S. McCarthy, A. Manilchuk, M. Dillhoff, C. Schmidt, D. Conwell, S.G. Krishna; Ohio State University-Wexner Medical Center, Columbus, OH/United States of America

**P2-38**

A HUNGARIAN FAMILY WITH HEREDITARY PANCREATITIS AND THE P.L104P MUTATION IN THE HUMAN CATIONIC TRYPSINOGEN. B.C. Nemeth<sup>1</sup>, A.V. Patai<sup>2</sup>, M. Sahin-Toth<sup>3</sup>, P. Hegyi<sup>4</sup>; <sup>1</sup>First Department of Medicine, University of Szeged, Szeged/Hungary, <sup>2</sup>2nd Department of Internal Medicine, Semmelweis University, Budapest/Hungary, <sup>3</sup>Department of Molecular and Cell Biology, Boston University Medical Campus, Boston, MA/United States of America, <sup>4</sup>Department of Translational Medicine, University of Pecs, Pecs/Hungary

**P2-39**

TRANSGASTRIC THERAPEUTIC PANCREATIC HYPOTHERMIA AS A NOVEL THERAPY FOR ACUTE PANCREATITIS (AP). C. De Oliveira, K. Patel, V. Mishra, R.N. Trivedi, J. Bradley, J.R. Yaron, V.P. Singh; Department of Medicine, Mayo Clinic, Scottsdale, AZ/United States of America

**P2-40**

CANNABIS INDUCED ACUTE PANCREATITIS: A SYSTEMATIC REVIEW. J.A. Barkin<sup>1</sup>, Z. Nemeth<sup>2</sup>, A.K. Saluja<sup>3</sup>, J.S. Barkin<sup>1</sup>; <sup>1</sup>Dept of Medicine, Division of Gastroenterology, University of Miami, Leonard M. Miller School of Medicine, Miami, FL/United States of America, <sup>2</sup>Dept of Health Informatics, University of Miami, Leonard M. Miller School of Medicine, Miami, FL/United States of America, <sup>3</sup>Dept of Surgery, University of Miami, Leonard M. Miller School of Medicine, Miami, FL/United States of America

**P2-41**

NODE-NEGATIVE DISEASE IN PANCREATIC CANCER MIGHT NOT PRESENT DIFFERENT TUMOR BIOLOGY. K.C. Honselmann, I. Pergolini, C. Fernandez-Del Castillo, A.L. Warshaw, K.D. Lillemoe, C.R. Ferrone; Department of Surgery, Massachusetts General Hospital, Boston/United States of America

**P2-42**

COMBINATION OF L1156F AND M470V IN CFTR GENE ASSOCIATED WITH ALCOHOLIC CHRONIC PANCREATITIS IN JAPANESE. S. Kondo<sup>1</sup>, K. Fujiki<sup>2</sup>, S.B.H. Ko<sup>3</sup>, A. Yamamoto<sup>1</sup>, M. Nakakuki<sup>1</sup>, Y. Ito<sup>1</sup>, M. Kitagawa<sup>2</sup>, S. Naruse<sup>4</sup>, H. Ishiguro<sup>1</sup>; <sup>1</sup>Nagoya University Graduate School of Medicine/Japan, <sup>2</sup>Department of Nutrition, Nagoya University of Arts and Sciences, Nisshin, Aichi/Japan, <sup>3</sup>Keio University School of Medicine/Japan, <sup>4</sup>Miyoshi Municipal Hospital/Japan

**P2-43**

GNAS AND KRAS: FREQUENT MUTATIONS IN IPMN. A.-K. Stadler<sup>1</sup>, S. Fritz<sup>2</sup>, M. Volkmar<sup>3</sup>, J.H. Youm<sup>4</sup>, A. Tampakis<sup>4</sup>, M. Gaida<sup>5</sup>, R. Offringa<sup>6</sup>, J. Werner<sup>7</sup>, T. Hackert<sup>1</sup>, M.W. Büchler<sup>1</sup>, O. Strobel<sup>1</sup>; <sup>1</sup>Department of General Surgery, University Hospital Heidelberg/Germany, <sup>2</sup>University of Heidelberg/Germany, <sup>3</sup>DKFZ/Germany, <sup>4</sup>University hospital Heidelberg/Germany, <sup>5</sup>Institute of Pathology, Heidelberg University Hospital/Germany, <sup>6</sup>Department of Molecular Oncology of Gastrointestinal Tumors, German Cancer Research Center (DKFZ)/Germany, <sup>7</sup>University of Munich/Germany

**P2-44**

ZINC MEDIATES PANCREATITIS RESPONSES IN IN VITRO AND IN VIVO MOUSE MODELS OF ACUTE PANCREATITIS. M.Y. Phadke<sup>1</sup>, F. Gorelick<sup>2, 3</sup>; <sup>1</sup>Pediatric Gastroenterology, Yale University School of Medicine, New Haven, CT/United States of America, <sup>2</sup>Digestive Diseases, Yale University/United States of America, <sup>3</sup>Veterans Administration CT Healthcare/United States of America

**P2-45**

CCK RECEPTOR KNOCK-OUT PREVENTS PANCREATIC CANCER GROWTH FROM DIETARY FAT. S. Nadella<sup>1</sup>, J. Burks<sup>2</sup>, G. Inyang<sup>1</sup>, J. Wang<sup>1</sup>, R. Tucker<sup>1</sup>, J. Smith<sup>2</sup>; <sup>1</sup>Medicine, Gastroenterology, Georgetown University, Washington, DC/United States of America, <sup>2</sup>Medicine/ Gastroenterology, Georgetown University, Washington Dc, DC/United States of America

**P2-46**

CHEMOTHERAPY-INDUCED SENESCENCE PHENOTYPE CONVERSE DRUG RESISTANCE IN PANCREATIC CANCER. Y. Zhang<sup>1</sup>, Y. Wang<sup>2</sup>, B. Ji<sup>1</sup>; <sup>1</sup>CANCER BIOLOGY, MAYO CLINIC/United States of America, <sup>2</sup>Biochemistry and Molecular Biology, MAYO CLINIC/United States of America

**P2-47**

NUTRITIONAL ASSESSMENT OF DIETARY INTAKE IN CHRONIC PANCREATITIS USING A WEB-BASED FOOD FREQUENCY QUESTIONNAIRE. P. Hart, P. Madril, K. Roberts, D. Conwell, K. Crockett, M. Ramsey, M. Nahikian-Nelms; Gastroenterology, Hepatology and Nutrition, The Ohio State University Wexner Medical Center, Columbus, OH/United States of America

**P2-48**

PRO-FIBROGENIC GREMLIN IS A NOVEL MARKER OF PANCREATIC STELLATE CELLS. K. Liu<sup>1</sup>, Y. Cao<sup>1</sup>, C. Rastellini<sup>2</sup>, J. Bailey<sup>1</sup>, C. Chao<sup>2</sup>, T. Ko<sup>1</sup>; <sup>1</sup>UTHealth/United States of America, <sup>2</sup>UTMB Health/United States of America

**P2-49**

SUCCESSFUL ABLATION OF LYMPH NODES USING IRREVERSIBLE ELECTROPORATION (IRE) IN A PORCINE SURVIVAL MODEL. S. Fritz<sup>1, 2</sup>, C.M. Sommer<sup>3</sup>, T. Longerich<sup>4</sup>, C. Kuhn-Neureuther<sup>5</sup>, B. Radeff<sup>2</sup>, J. Werner<sup>6</sup>, J. Köninger<sup>3</sup>, M.W. Büchler<sup>2</sup>, T. Hackert<sup>2</sup>; <sup>1</sup>General, Visceral and Transplantation Surgery, Katharinenhospital, Stuttgart/Germany, <sup>2</sup>University of Heidelberg/Germany, <sup>3</sup>Katharinenhospital Stuttgart/Germany, <sup>4</sup>University Hospital RWTH Aachen/Germany, <sup>5</sup>AngioDynamics Heidelberg/Germany, <sup>6</sup>University of Munich/Germany

**P2-50**

AUTOPHAGY DRIVES PANCREATIC STELLATE CELLS ACTIVATION AND PROMOTES PANCREATIC CANCER. S. Endo<sup>1</sup>, K. Nakata<sup>1</sup>, K. Ohuchida<sup>1</sup>, Y. Ando<sup>1</sup>, S. Kibe<sup>1</sup>, S. Takesue<sup>1</sup>, H. Nakayama<sup>1</sup>, T. Abe<sup>1</sup>, K. Koikawa<sup>1</sup>, T. Okumura<sup>1</sup>, Y. Mizuuchi<sup>2</sup>, T. Moriyama<sup>1</sup>, Y. Miyasaka<sup>1</sup>, T. Manabe<sup>1</sup>, T. Ohtsuka<sup>1</sup>, E. Nagai<sup>1</sup>, K. Mizumoto<sup>1</sup>, Y. Oda<sup>2</sup>, M. Nakamura<sup>1</sup>; <sup>1</sup>Department of Surgery and Oncology, Kyushu University/Japan, <sup>2</sup>Department of Anatomical Pathology, Kyushu University/Japan

**P2-51**

RNA SEQUENCING REVEALS THERAPEUTIC EFFECTS OF MULTIPLE STATINS ON PANCREATIC CANCER CELLS. J. Yu<sup>1</sup>, S.-H. Liu<sup>1</sup>, R. Sanchez<sup>1</sup>, W. Fisher<sup>2</sup>, F.C. Brunica<sup>1</sup>; <sup>1</sup>Surgery, UCLA, Los Angeles/United States of America, <sup>2</sup>Baylor College of Medicine, TX/United States of America

**P2-52**

EFFECT OF THE MEDICARE SEVERITY-DIAGNOSIS RELATED GROUP CLASSIFICATION SYSTEM ON PREDICTING HOSPITAL READMISSION AFTER DISTAL PANCREATECTOMY. D. Xourafas, C. Fernandez-Del Castillo, A.L. Warshaw, K.D. Lillemoe, C.R. Ferrone; Department of Surgery, Massachusetts General Hospital, Harvard Medical School, MA/United States of America

**P2-53**

LOW SERUM PANCREATIC AMYLASE AND LIPASE LEVEL VALUES ARE SIMPLE AND USEFUL PREDICTORS TO DIAGNOSIS OF CHRONIC PANCREATITIS. H.-C. Oh<sup>1</sup>, C.-I. Kwon<sup>1</sup>, J. Easler<sup>1</sup>, I. El Hajj<sup>1</sup>, J. Watkins<sup>1</sup>, E. Fogel<sup>1</sup>, L. McHenry<sup>1</sup>, S. Sherman<sup>1</sup>, M. Zimmerman<sup>2</sup>, G. Lehman<sup>1</sup>; <sup>1</sup>Gastroenterology and Hepatology, Indiana University, IN/United States of America, <sup>2</sup>Pathology and Laboratory Medicine, Indiana University, IN/United States of America

**P2-54**

XBP1 GENETIC DELETION ACCELERATES TUMOR PROGRESSION IN KRAS-INDUCED PANCREATIC TUMORIGENESIS. H.-Y. Su, R.T. Waldron, J. Yang, C. Hu, H. Hurley, S.J. Pandol, A. Lugea; Cedars-Sinai Medical Center/United States of America

**P2-55**

FATTY ACID UPTAKE VIA CD36 ENHANCES INVASIVENESS OF PANCREATIC CANCER CELLS. T. Okumura<sup>1</sup>, K. Ohuchida<sup>2</sup>, T. Moriyama<sup>1</sup>, K. Nakata<sup>1</sup>, Y. Miyasaka<sup>1</sup>, T. Manabe<sup>1</sup>, T. Ohtsuka<sup>2</sup>, E. Nagai<sup>1</sup>, K. Mizumoto<sup>1</sup>, M. Nakamura<sup>1</sup>; <sup>1</sup>Department of Surgery and Oncology, Kyushu University, Fukuoka/Japan, <sup>2</sup>Department of Surgery and Oncology, Kyushu University/Japan

**P2-56**

HUMAN PRIMARY ACINODUCTAL CELL CULTURE AS A MODEL OF ADM AND EPITHELIAL-MESENCHYMAL INTERACTIONS. O. Shaul, H.-Y. Su, H. Hurley, A. Lugea, S.J. Pandol, R.T. Waldron; Cedars-Sinai Medical Center, Los Angeles/United States of America

**P2-57**

BENEFICIAL EFFECTS OF BERBERINE ON ACUTE NECROTIZING PANCREATITIS AND ASSOCIATED LUNG INJURY. S.-J. Park, G.-S. Bae, D.-G. Kim, M.J. Kim, S. Choi, J.H. Jeong; Herbology, WonKwang University/Korea, Republic of

**P2-58**

PANCREATICOGASTROSTOMY. H. Bari, T. Chawla, S. Effendi; General Surgery, Aga Khan University Hospital/Pakistan

**P2-59**

PATIENT-REPORTED LONG-TERM OUTCOME AFTER DUODENUM-PRESERVING PANCREATIC HEAD RESECTION (BERNE MODIFICATION) FOR CHRONIC PANCREATITIS. W. Niesen, T. Hank, U. Hinz, C. Scheele, J. Kaiser, T. Hackert, M.W. Büchler, O. Strobel; Department of General Surgery, University Hospital Heidelberg/Germany

**P2-60**

SPHINCTER OF ODDI BOTULINUM TOXIN INJECTION TO PREVENT PANCREATIC FISTULA AFTER DISTAL PANCREATECTOMY. U. Klaiber<sup>1</sup>, P. Sauer<sup>2</sup>, T. Kehayova<sup>1</sup>, P. Probst<sup>1</sup>, P. Knebel<sup>1</sup>, M.K.-M. Diener<sup>1</sup>, L. Schneider<sup>1</sup>, O. Strobel<sup>1</sup>, C.W. Michalski<sup>1</sup>, A. Ulrich<sup>1</sup>, M.W. Büchler<sup>1</sup>, T. Hackert<sup>1</sup>; <sup>1</sup>Department of General, Visceral, and Transplantation Surgery, University of Heidelberg, Heidelberg/Germany, <sup>2</sup>Interdisciplinary Center of Endoscopy, University of Heidelberg, Heidelberg/Germany

**P2-61**

OUTCOMES OF SURGICAL MANAGEMENT FOR PANCREATIC NEUROENDOCRINE TUMORS (PNETS): A SINGLE-CENTER EXPERIENCE. X. Lu, B. Hou, Y. Zhou, D. Li; General Surgery, Guangdong General Hospital/China

**P2-62**

HSF1-AMPK NEGATIVE FEEDBACK LOOP PROMOTES INVASION AND METASTASIS OF PANCREATIC CANCER. Z. Wang<sup>1</sup>, K. Chen<sup>2</sup>, Q. Xu<sup>3</sup>, Z. Wu<sup>1</sup>, Q. Ma<sup>1</sup>; <sup>1</sup>Department of Hepatobiliary Surgery, First Affiliated Hospital of Xi'an Jiaotong University/China, <sup>2</sup>First Affiliated Hospital of Xi'an Jiaotong University/China, <sup>3</sup>Department of Gan4 Surgery, First Affiliated Hospital of Xi'an Jiaotong University/China

**P2-63**

INDUCTION OF THE ARTERY FIRST APPROACH IN PANCREATODUODENECTOMY FOR PANCREATIC HEAD CANCER. H. Shimamura, H. Kodama, A. Endo, K. Takeda; Department of Surgery, Sendai Medical Center, Sendai/Japan

**P2-64**

METACHRONOUS SECONDARY LESIONS AND RECURRENCE IN THE REMNANT PANCREAS AFTER PANCREATECTOMY FOR PANCREATIC DUCTAL ADENOCARCINOMA. Y. Gotoh<sup>1</sup>, T. Ohtsuka<sup>1</sup>, S. Nakamura<sup>1</sup>, Y. Nakashima<sup>1</sup>, K. Date<sup>1</sup>, T. Fujimoto<sup>1</sup>, N. Mochidome<sup>2</sup>, Y. Mori<sup>1</sup>, Y. Sadakari<sup>1</sup>, K. Nakata<sup>1</sup>, Y. Miyasaka<sup>1</sup>, K. Ohuchida<sup>1</sup>, T. Manabe<sup>1</sup>, E. Nagai<sup>1</sup>, Y. Oda<sup>2</sup>, M. Nakamura<sup>1</sup>; <sup>1</sup>Department of Surgery and Oncology, Kyushu University, Fukuoka/Japan, <sup>2</sup>Department of Anatomic Pathology, Kyushu University, Fukuoka/Japan

**P2-65**

SPLEEN-PRESERVING DISTAL PANCREATECTOMY. T. Kawana, H. Shimamura, K. Takeda; Department of Surgery, Sendai Medical Center, Sendai/Japan

**P2-66**

A CASE SERIES OF SECONDARY PANCREATIC CANCERS. Y. Alazzawi, M. Mahmoud, S. Han, W. Wassef; Gastroenterology, UMass Memorial Medical Center, Worcester, MA/United States of America

**P2-67**

IMPACT OF POSTOPERATIVE SHORT-TERM OUTCOMES ON THE SURVIVAL OF PANCREATIC HEAD CANCER. T. Sugiura, Y. Okamura, T. Ito, Y. Ito, R. Ashida, K. Uesaka; Shizuoka Cancer Center/Japan

**P2-68**

NEW POTENTIAL ROLE FOR TRANSCRIPTION FACTOR EB IN DNA REPAIR. M. Groleau, B. Marchand, M.-J. Boucher; Medicine, University of Sherbrooke, QC/Canada

**P2-69**

CLINICAL CHARACTERISTICS OF HOSPITALIZED ACUTE PANCREATITIS PATIENTS IN OUR HOSPITAL. Y. Kawasaki, A. Asakura, M. Mori, T. Tokuda, M. Matsushita, Y. Sato, H. Saiki, Y. Onishi, Y. Tokuda, A. Ishimi, T. Kawai, M. Hamano, M. Chiba, K. Maeda, K. Yamamoto, N. Tatsumi, T. Ito; JCHO Osaka Hospital/Japan

**P2-70**

METFORMIN INHIBITS HYPOXIA INDUCED PSC ACTIVATION AND PANCREATIC CANCER CELL VIABILITY AND INVASION. Q. Xu; Department of Hepatobiliary Surgery, Xi'an Jiaotong University, Xi'an/China

**P2-71**

THE MET RECEPTOR TYROSINE KINASE IS INDISPENSABLE FOR ACINAR REGENERATION FOLLOWING RECURRENT INJURY. I. Gaziova<sup>1</sup>, C. Elferink<sup>2</sup>, L. Elferink<sup>1</sup>; <sup>1</sup>Neuroscience and Cell Biology, University of Texas Medical Branch, TX/United States of America, <sup>2</sup>Pharmacology, University of Texas Medical Branch, TX/United States of America

**P2-72**

PARTICIPATION OF BILE ACID RECEPTOR FXR IN SUPPRESSION OF ACINAR CELL AUTOPHAGY IN HUMAN CHRONIC PANCREATITIS. X. Zhou<sup>1</sup>, L. Xie<sup>2</sup>, F. Bergmann<sup>3</sup>, V. Endris<sup>3</sup>, O. Strobel<sup>4</sup>, M.W. Büchler<sup>5</sup>, T. Hackert<sup>4</sup>, F. Fortunato<sup>2</sup>; <sup>1</sup>Section surgical research, University Clinic Heidelberg, Heidelberg/Germany, <sup>2</sup>Section of surgical research, University Clinic Heidelberg, Heidelberg/Germany, <sup>3</sup>Institute of Pathology, University Clinic Heidelberg/Germany, <sup>4</sup>Department of General Surgery, University Hospital Heidelberg/Germany, <sup>5</sup>University Hospital Heidelberg/Germany

**P2-73**

ENCOURAGING OBSERVED 5-YEAR SURVIVAL WITH UPFRONT RESECTION AND ADJUVANT THERAPY FOR PANCREATIC DUCTAL ADENOCARCINOMA IN A LARGE CONTEMPORARY SERIES. O. Strobel<sup>1</sup>, P. Lorenz<sup>1</sup>, U. Hinz<sup>1</sup>, M. Gaida<sup>2</sup>, A.-K. Stadler<sup>1</sup>, F. Bergmann<sup>3</sup>, T. Hank<sup>1</sup>, H. Gros<sup>1</sup>, W. Niesen<sup>1</sup>, T. Hackert<sup>1</sup>, M.W. Büchler<sup>1</sup>; <sup>1</sup>Department of General Surgery, University Hospital Heidelberg/Germany, <sup>2</sup>Institute of Pathology, Heidelberg University Hospital/Germany, <sup>3</sup>Institute of Pathology, University Clinic Heidelberg/Germany

**P2-74**

CHAI-QIN-CHENG-QI DECOCTION IMPROVES INTESTINAL MOTILITY BY REGULATING PROTEIN KINASE C- AND ADENYLATE CYCLASE-MEDIATED CA<sup>2+</sup> RELEASE IN COLONIC SMOOTH MUSCLE CELLS IN RATS WITH ACUTE NECROTISING PANCREATITIS. Z.Q. Lin<sup>1</sup>, J. Guo<sup>1</sup>, W.W. Chen<sup>1</sup>, L.H. Deng<sup>1</sup>, X.Y. Zhang<sup>2</sup>, W. Huang<sup>2</sup>, J.A. Windsor<sup>3</sup>, R. Sutton<sup>2</sup>, P. Xue<sup>1</sup>, Q. Xia<sup>1</sup>; <sup>1</sup>Department of Integrated Traditional Chinese and Western Medicine, Sichuan Provincial Pancreatitis Centre, West China Hospital, Sichuan University, Chengdu/China, <sup>2</sup>NIHR Pancreas Biomedical Research Unit, University of Liverpool/United Kingdom, <sup>3</sup>Department of Surgery, University of Auckland/New Zealand

**P2-75**

REFINEMENT OF NODAL STAGING FOR PANCREATIC CANCER BASED ON THE NUMBER OF POSITIVE LYMPH NODES: A POPULATION-BASED PROPENSITY SCORE-ADJUSTED ANALYSIS. O. Strobel<sup>1</sup>, I. Tarantino<sup>2</sup>, R. Warschkow<sup>3</sup>, T. Hackert<sup>1</sup>, B. Schmied<sup>3</sup>, M.W. Büchler<sup>1</sup>, A. Ulrich<sup>1</sup>; <sup>1</sup>Department of General Surgery, University Hospital Heidelberg/Germany, <sup>2</sup>General Surgery, Heidelberg University Hospital/Germany, <sup>3</sup>Department of Surgery, Kantonsspital St. Gallen/Switzerland

**P2-76**

THE LOSS OF ATRX PROMOTES SUSCEPTIBILITY TO KRAS-MEDIATED PANCREATIC DISEASE. C. Young<sup>1</sup>, C. Howlett<sup>2</sup>, C. Pin<sup>1</sup>; <sup>1</sup>Physiology & Pharmacology, Schulich School of Medicine & Dentistry, University of Western Ontario, Children's Health Research Institute, London, ON/Canada, <sup>2</sup>Pathology and Laboratory Medicine, Schulich School of Medicine & Dentistry, University of Western Ontario, London, ON/Canada

**P2-77**

TREATMENT RESPONSE OF PANCREATIC CANCER CELLS IS SIGNIFICANTLY IMPAIRED BY TUMOR ASSOCIATED STROMAL CELLS. R.B. Schmuck, C. Neumann, A. Schirmeier, F. Klein, J. Pratschke, M. Bahra; Charité Universitätsmedizin Berlin, Campus Virchow Klinikum, Berlin/Germany

**P2-78**

THE LIVERPOOL IN SITU SUBTOTAL PANCREATECTOMY (LIVOCADO PROCEDURE) FOR THE TREATMENT OF SEVERE ADVANCED CHRONIC PANCREATITIS. J.P. Neoptolemos, A.R.G. Sheel, R.D. Baron, J. Kleeff; Pancreatobiliary Surgery, Royal Liverpool and Broadgreen University Hospitals Trust, Liverpool/United Kingdom

**P2-79**

TARGETING THE NOTCH PATHWAY SHOWS NO EFFECT ON TUMOR STEM CELLS IN PANCREATIC ADENOCARCINOMA. R.B. Schmuck, S. Elisabeth, F. Klein, J. Pratschke, M. Bahra; Charité Universitätsmedizin Berlin, Campus Virchow Klinikum, Berlin/Germany



**P2-80**

L-CARNITINE SUPPLEMENTATION IMPROVED HEPATIC STEATOSIS AFTER PANCREATECTOMY. M. Nakamura<sup>1</sup>, K. Nakata<sup>1</sup>, K. Hino<sup>2</sup>, K. Yoshida<sup>2</sup>; <sup>1</sup>Department of Surgery and Oncology, Kyushu University, Fukuoka/Japan, <sup>2</sup>Department of Hepatology and Pancreatology, Kawasaki Medical School, Kurashiki/Japan

**P2-81**

PROTECTIVE EFFECTS OF NECROSTATIN-1 IN EXPERIMENTAL ACUTE PANCREATITIS. Y. Ouyang<sup>1, 2</sup>, L. Wen<sup>1, 2</sup>, D. Latawiec<sup>1</sup>, J. Armstrong<sup>1</sup>, M. Awais<sup>1</sup>, P.J. Gough<sup>3</sup>, J. Bertin<sup>3</sup>, R. Mukherjee<sup>1</sup>, R. Sutton<sup>1</sup>, D. Criddle<sup>2</sup>; <sup>1</sup>NIHR Pancreas Biomedical Research Unit, University of Liverpool, Liverpool/United Kingdom, <sup>2</sup>Cellular and Molecular Physiology, University of Liverpool/United Kingdom, <sup>3</sup>GlaxoSmithKline, Pattern Recognition Receptor Discovery Performance Unit, Immuno-Inflammation Therapeutic Area, PA/United States of America

**P2-82**

TARGETED POLYPLEX NANOPARTICLE TO GASTRIN INHIBITS GROWTH AND DECREASES METASTASES OF PANCREATIC CANCER. C. Mankongpaisarnrun<sup>1</sup>, J. Burks<sup>2</sup>, S. Nadella<sup>1</sup>, J. Wang<sup>1</sup>, J.-I. Hahm<sup>3</sup>, R. Tucker<sup>4</sup>, A. Mahmaud<sup>5</sup>, S. Stern<sup>5</sup>, J. Smith<sup>1</sup>; <sup>1</sup>Medicine, Gastroenterology, Georgetown University, Washington, DC/United States of America, <sup>2</sup>Medicine, Oncology, Georgetown University, Washington/United States of America, <sup>3</sup>Chemistry, Georgetown University, Washington, DC/United States of America, <sup>4</sup>Comparative Medicine, Georgetown University, Washington, DC/United States of America, <sup>5</sup>NIH, Nanotechnology Characterization Lab, Frederick/United States of America

**P2-83**

EXPLORING MACHINE LEARNING METHODS TO DETERMINE PREDICTORS OF PANCREAS FUNCTION. V. Pidlaon<sup>1</sup>, D. Conwell<sup>2</sup>; <sup>1</sup>Gastroenterology, Hepatology and Nutrition, Ohio State University, OH/United States of America, <sup>2</sup>Ohio State University-Wexner Medical Center, Columbus, OH/United States of America

**P2-84**

NOVEL METHODS FOR THE MEASUREMENT OF BLOOD FLOW IN EXPERIMENTAL ACUTE PANCREATITIS. P. Szatmary<sup>1</sup>, A. Taylor<sup>1</sup>, T. Leather<sup>1</sup>, H. Poptani<sup>1</sup>, D. Criddle<sup>1</sup>, A. Tepikin<sup>1</sup>, R. Sutton<sup>2</sup>; <sup>1</sup>Cellular and Molecular Physiology, University of Liverpool/United Kingdom, <sup>2</sup>NIHR Liverpool Pancreas Biomedical Research Unit, Royal Liverpool University Hospital, University of Liverpool/United Kingdom

**P2-85**

ENHANCER OF ZESTE HOMOLOGUE 2 IS A KEY REGULATOR OF ACINAR TO DUCT CELL METAPLASIA. C. Johnson<sup>1</sup>, L. Yu<sup>2</sup>, L. Luyt<sup>3</sup>, R. Urrutia<sup>4</sup>, G. Lomberg<sup>5</sup>, C. Pin<sup>6</sup>; <sup>1</sup>Paediatrics, University of Western Ontario, London, ON/Canada, <sup>2</sup>Oncology, University of Western Ontario, ON/Canada, <sup>3</sup>Chemistry, University of Western Ontario, ON/Canada, <sup>4</sup>Biochemistry and Molecular Biology, Mayo Clinic College of Medicine, MN/United States of America, <sup>5</sup>Medicine, Mayo Clinic College of Medicine, MN/United States of America, <sup>6</sup>Paediatrics, University of Western Ontario, London/Canada

**P2-86**

CAN HEMOSTASIS PRODUCTS PREVENT POSTOPERATIVE PANCREATIC FISTULAS AFTER DISTAL PANCREATECTOMY. C.M. Kühnbrey, S. Kasper, U.T. Hopt, U.A. Wittel; General- and Viszeral Surgery, University Hospital Freiburg, Freiburg/Germany

**P2-87**

LASER CAPTURE MICRODISSECTION AND PROTEOMIC CHARACTERIZATION OF ACINAR CELLS FROM CAERULEIN TREATED MICE REVEALS SIGNIFICANT UP-REGULATION OF CYTOSKELETAL PROTEINS. J.P. Shapiro<sup>1</sup>, H. Komar<sup>2</sup>, B. Hancioglu<sup>3</sup>, L. Yu<sup>4</sup>, P. Hart<sup>1</sup>, Z. Cruz-Monserrate<sup>1</sup>, D. Conwell<sup>1</sup>, G. Lesinski<sup>1, 2</sup>; <sup>1</sup>Gastroenterology, Hepatology and Nutrition, The Ohio State University Wexner Medical Center, Columbus, OH/United States of America, <sup>2</sup>Division of Medical Oncology, The Ohio State University Wexner Medical Center/United States of America, <sup>3</sup>Biomedical Informatics, The Ohio State University/United States of America, <sup>4</sup>Center for Biostatistics, Department of Biomedical Informatics, The Ohio State University/United States of America



**P2-88**

PORTAL VEIN THROMBOSIS (PVT) IN ACUTE PANCREATITIS (AP) IS ASSOCIATED WITH POOR CLINICAL OUTCOMES AND INCREASED RESOURCE UTILIZATION: A POPULATION BASED COHORT STUDY. G. Trikudanathan<sup>1</sup>, S. Munigala<sup>2</sup>, M. Arain<sup>3</sup>, K.C. Kottapalli<sup>4</sup>, R. Attam<sup>3</sup>, S. Amateau<sup>3</sup>, S. Mallery<sup>5</sup>, M.L. Freeman<sup>6</sup>; <sup>1</sup>Medicine, GI, University of Minnesota, Minneapolis/United States of America, <sup>2</sup>Saint Louis University Center for Outcomes Research (SLUCOR)/United States of America, <sup>3</sup>Medicine, University of Minnesota, Minneapolis/United States of America, <sup>4</sup>Internal Medicine, Wheaton Hospital, Milwaukee/United States of America, <sup>5</sup>University of Minnesota/United States of America, <sup>6</sup>Gastroenterology, University of Minnesota, Minneapolis/United States of America

**P2-89**

PANCREATIC ENZYME REPLACEMENT THERAPY IN CHRONIC PANCREATITIS: SYSTEMATIC REVIEW AND META-ANALYSIS. W. Huang<sup>1, 2</sup>, D. Iglesia-Garcia<sup>1, 3</sup>, P. Szatmary<sup>1</sup>, I. Baston-Rey<sup>3</sup>, J. Gonzalez-Lopez<sup>4</sup>, G. Prada-Ramallal<sup>5</sup>, A. Sud<sup>1</sup>, R. Mukherjee<sup>1</sup>, Q.M. Nunes<sup>1</sup>, J.E. Domínguez-Muñoz<sup>3</sup>, R. Sutton<sup>1</sup>; <sup>1</sup>NIHR Liverpool Pancreas Biomedical Research Unit, Royal Liverpool University Hospital NHS Trust, University of Liverpool/United Kingdom, <sup>2</sup>Sichuan Provincial Pancreatitis Centre, Department of Integrated Traditional Chinese and Western Medicine, West China Hospital, Sichuan University/China, <sup>3</sup>Department of Gastroenterology and Hepatology, University Hospital of Santiago de Compostela/Spain, <sup>4</sup>Department of Pharmacy, University Hospital of Santiago de Compostela/Spain, <sup>5</sup>Department of Preventive Medicine and Public Health, University of Santiago de Compostela/Spain

**P2-90**

ALTERED GUT MICROBIOTA IN PATIENTS WITH CHRONIC PANCREATITIS IS ASSOCIATED WITH ENDOCRINE DYSFUNCTION. S.M. Jandhyala, M. Arutla, D. Govardhan, D.N. Reddy, R. Talukdar; Medical Gastroenterology and Basic Sciences, Asian Institute of Gastroenterology, Hyderabad/India

**P2-91**

REGIONAL DIFFERENCES IN TREATMENT STRATEGIES OF PANCREATIC CANCER: A FINNISH REGISTER STUDY COVERING THE ENTIRE NATION. R. Ahola<sup>1</sup>, H. Hölsä<sup>2</sup>, S. Kiskola<sup>2</sup>, P. Ojala<sup>2</sup>, A. Pirttilä<sup>2</sup>, J. Sand<sup>1</sup>, J. Laukkanen<sup>1</sup>; <sup>1</sup>Tampere University Hospital/Finland, <sup>2</sup>Tampere University/Finland

**P2-92**

INCREASED CAVEOLIN-1 AND CHOLESTEROL METABOLISM IN CD133+ TUMOR INITIATING CELLS REGULATE INVASION AND CHEMORESISTANCE IN PANCREATIC CANCER. V.K. Gupta<sup>1</sup>, A. Nomura<sup>2</sup>, P. Dauer<sup>3</sup>, N.S. Sharma<sup>4</sup>, V. Dudeja<sup>3</sup>, A.K. Saluja<sup>5</sup>, S. Banerjee<sup>6</sup>; <sup>1</sup>Sylvester Cancer Center, University of Miami, Miami/United States of America, <sup>2</sup>Surgery, University of Miami, FL/United States of America, <sup>3</sup>University of Miami/United States of America, <sup>4</sup>Department of Surgery, University of Miami, Miami/United States of America, <sup>5</sup>Dept of Surgery, University of Miami, Leonard M. Miller School of Medicine, Miami, FL/United States of America, <sup>6</sup>University of Miami, University of Miami, Miami/United States of America

**P2-93**

TARGETING CANCER STEM CELLS WITH COMBINED INHIBITION OF MEK AND STAT3 IN PANCREATIC CANCER. C. Roberts<sup>1</sup>, M. Vansaun<sup>1</sup>, P. Lamichhane<sup>1</sup>, F. Messaggio<sup>1</sup>, K. Kovacs<sup>2</sup>, N. Nagathihalli<sup>1</sup>, N. Merchant<sup>1</sup>; <sup>1</sup>Surgery, University of Miami, Miami, FL/United States of America, <sup>2</sup>Surgery, University of Miami, Maimi, FL/United States of America

**P2-94**

VALIDATION STUDY OF THE IAP/APA MANAGEMENT GUIDELINE IN ACUTE PANCREATITIS ON PROSPECTIVELY COLLECTED HUNGARIAN DATA. A. Parniczky<sup>1</sup>, B. Kui<sup>2</sup>, A. Szentesi<sup>2</sup>, A. Balazs<sup>3</sup>, A. Szucs<sup>4</sup>, D. Mosztbacher<sup>5</sup>, J. Czimmer<sup>6</sup>, P. Sarlos<sup>6</sup>, J. Bajor<sup>6</sup>, S. Godi<sup>6</sup>, A. Vincze<sup>6</sup>, A. Illes<sup>6</sup>, I. Szabo<sup>6</sup>, G. Par<sup>6</sup>, T. Takacs<sup>2</sup>, L. Czako<sup>2</sup>, Z. Szepes<sup>2</sup>, Z. Rakonczay<sup>2</sup>, F. Izbeki<sup>7</sup>, J. Gervain<sup>7</sup>, A. Halasz<sup>7</sup>, S. Crai<sup>8</sup>, J. Novak<sup>8</sup>, I. Hritz<sup>9</sup>, C. Gog<sup>10</sup>, J. Sumegi<sup>11</sup>, M. Varga<sup>12</sup>, B. Bod<sup>13</sup>, J. Hamvas<sup>14</sup>, M. Varga-Muller<sup>15</sup>, Z. Papp<sup>15</sup>, M. Sahin-Toth<sup>16</sup>, P. Hegyi<sup>17</sup>; <sup>1</sup>Heim Pal Children's Hospital, Budapest/Hungary, <sup>2</sup>First Department of Medicine, University of Szeged/Hungary, <sup>3</sup>First Department of Medicine, University of Szeged/Hungary, <sup>4</sup>First Department of Surgery, Semmelweis University/Hungary, <sup>5</sup>Department of Pediatrics, Balassa János Hospital of County Tolna, Szekszard/Hungary, <sup>6</sup>First Department of Medicine, University of Pécs/Hungary, <sup>7</sup>Szent György University Teaching Hospital of County Fejér, Székesfehérvár/Hungary, <sup>8</sup>Pándy Kálmán Hospital of County Békés, Gyula/Hungary, <sup>9</sup>Bács-Kiskun County University Teaching Hospital, Kecskemét/Hungary, <sup>10</sup>Healthcare Center

of County Csongrád, Makó/Hungary, 11Borsod-Abaúj-Zemplén County Hospital and University Teaching Hospital, Miskolc/Hungary, 12Dr. Réthy Pál Hospital, Békéscsaba/Hungary, 13Dr. Bugyi István Hospital, Szentes/Hungary, 14Bajcsy-Zsilinszky Hospital, Budapest/Hungary, 15Institute for Translational Medicine, University of Pécs/Hungary, 16Department of Molecular and Cell Biology, Boston University Medical Campus, Boston, MA/United States of America, 17Institute for Translational Medicine, University of Pécs, Pécs/Hungary

**P2-95**

MAIN PANCREATIC DUCT SIZE INDEPENDENTLY PREDICTS HISTOLOGICAL MAIN DUCT INVOLVEMENT, INTESTINAL PHENOTYPE, AND MALIGNANCY IN INTRADUCTAL PAPILLARY MUCINOUS NEOPLASM. V. Morales-Oyarvide<sup>1</sup>, I. Pergolini<sup>1</sup>, C.R. Ferrone<sup>1</sup>, M. Mino-Kenudson<sup>2</sup>, A.L. Warshaw<sup>1</sup>, K.D. Lillemoe<sup>1</sup>, C. Fernandez-Del Castillo<sup>1</sup>; <sup>1</sup>Department of Surgery, Massachusetts General Hospital, Boston/United States of America, <sup>2</sup>Department of Pathology, Massachusetts General Hospital, Boston/United States of America

**P2-96**

SHOULD PATIENTS WITH ESTABLISHED CHRONIC PANCREATITIS UNDERGO TESTING FOR CELIAC DISEASE? A.S. Nett, E.-J. Wamsteker, M. Dimagno; Medicine, University of Michigan/United States of America

**P2-97**

ASSESSING THE CLINICAL SIGNIFICANCE OF PRSS1 INTRONIC VARIANTS. E. Hegyi<sup>1</sup>, A.Z. Toth<sup>1</sup>, P. Hegyi<sup>2</sup>, M. Sahin-Toth<sup>1</sup>; <sup>1</sup>Department of Molecular and Cell Biology, Boston University, Boston/United States of America, <sup>2</sup>Department of Translational Medicine, University of Pécs, Pécs/Hungary

**P2-98**

RISK OF DIABETES MELLITUS IN PANCREATIC CANCER: RESULTS FROM A PROPENSITY MATCHED STUDY (2008-2012). S. Munigala<sup>1</sup>, D. Conwell<sup>2</sup>; <sup>1</sup>Saint Louis University Center for Outcomes Research (SLUCOR)/United States of America, <sup>2</sup>Ohio State University-Wexner Medical Center, Columbus, OH/United States of America

**P2-99**

RISK OF DIABETES MELLITUS IN CHRONIC PANCREATITIS: RESULTS FROM A PROPENSITY MATCHED STUDY (2008-2012). S. Munigala<sup>1</sup>, D. Conwell<sup>2</sup>; <sup>1</sup>Saint Louis University Center for Outcomes Research (SLUCOR)/United States of America, <sup>2</sup>Ohio State University-Wexner Medical Center, Columbus, OH/United States of America

**P2-100**

IN CHRONIC PANCREATITIS, A PREDICTIVE MODEL FOR SMALL INTESTINAL BACTERIAL OVERGROWTH INFLUENCES DECISIONS TO TEST OR JUST TREAT. J. Baker<sup>1</sup>, M. Dimagno<sup>2</sup>, E. Wamsteker<sup>3</sup>, A. Lee<sup>3</sup>, R. Saad<sup>3</sup>; <sup>1</sup>University of Michigan, University of Michigan, Ann Arbor/United States of America, <sup>2</sup>GASTROENTEROLOGY, UNIVERSITY OF MICHIGAN, Ann Arbor, MI/United States of America, <sup>3</sup>University of Michigan, University of Michigan, Ann Arbor, MI/United States of America

**P2-101**

SODIUM SULFATE SUPPRESSES MULTIPLE DAMAGE-ASSOCIATED MOLECULAR PATTERNS IN VITRO. Z. Yuan<sup>1</sup>, X. Wang<sup>2</sup>; <sup>1</sup>Shanghai General Hospital, Shanghai/China, <sup>2</sup>Shanghai General Hospital/China

**P2-102**

MUTY-HOMOLOG MODULATES PANCREATIC CANCER CELL SURVIVAL AND CHEMORESISTANCE. G. Sharbeen<sup>1</sup>, J. Youkhana<sup>1</sup>, A. Mawson<sup>1</sup>, J. McCarroll<sup>2</sup>, A. Akerman<sup>1</sup>, D. Goldstein<sup>1</sup>, P. Phillips<sup>1</sup>; <sup>1</sup>Pancreatic Cancer Translational Research Group, Lowy Cancer Research Centre, University of New South Wales, Sydney, NSW/Australia, <sup>2</sup>Children's Cancer Institute, Lowy Cancer Research Centre, University of New South Wales/Australia

**P2-103**

MICRORNA-345 IN PANCREATIC CANCER PATHOGENESIS. S. Rachagani<sup>1</sup>, M. Kalaga<sup>1</sup>, R. Pothuraju<sup>1</sup>, S.K. Batra<sup>1, 2, 3</sup>; <sup>1</sup>Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE/United States of America, <sup>2</sup>Fred and Pamela Buffett Cancer Center/United States of America, <sup>3</sup>Eppley Institute for Research in Cancer and Allied Diseases, NE/United States of America

**P2-104**

COMPARISON OF CLINICAL COURSE AND OUTCOME OF ACUTE PANCREATITIS, RECURRENT ACUTE PANCREATITIS AND ACUTE ON CHRONIC PANCREATITIS. D.J. Sharma<sup>1</sup>, J. Samanta<sup>1</sup>, N. Dhaka<sup>1</sup>, V. Gupta<sup>2</sup>, A. Gulati<sup>3</sup>, S.K. Sinha<sup>1</sup>, R. Kochhar<sup>1</sup>; <sup>1</sup>Gastroenterology, Postgraduate Institute of Medical Education and Research, Chandigarh/India, <sup>2</sup>Surgery, Postgraduate Institute of Medical Education and Research, Chandigarh/India, <sup>3</sup>Radiodiagnosis, Postgraduate Institute of Medical Education and Research, Chandigarh/India

**P2-105**

DA-CHENG-QI EXTRACT IDENTIFICATION AND THERAPEUTIC POTENTIAL IN EXPERIMENTAL ACUTE PANCREATITIS. T. Jin<sup>1</sup>, D. Du<sup>2</sup>, N. Shi<sup>1</sup>, R. Zhang<sup>3</sup>, Q.M. Nunes<sup>4</sup>, M. Chvanov<sup>5</sup>, D.N. Criddle<sup>5</sup>, W. Huang<sup>4</sup>, R. Sutton<sup>4</sup>, Q. Xia<sup>1</sup>; <sup>1</sup>Department of Integrated Traditional Chinese and Western Medicine, Sichuan Provincial Pancreatitis Center, West China Hospital, Sichuan University/China, <sup>2</sup>West China-Washington Mitochondria and Metabolism Center, West China Hospital, Sichuan University/China, <sup>3</sup>Laboratory of Ethnopharmacology, West China Hospital, Sichuan University/China, <sup>4</sup>NIHR Liverpool Pancreas Biomedical Research Unit, Royal Liverpool University Hospital NHS Trust, University of Liverpool/United Kingdom, <sup>5</sup>Department of Cellular and Molecular Physiology, University of Liverpool/United Kingdom

**P2-106**

CHARACTERIZING FAMILIAL CHYLOMICRONEMIA SYNDROME: BASELINE DATA OF THE APPROACH STUDY. D.J. Blom<sup>1</sup>, A. Digenio<sup>2</sup>, V. Alexander<sup>3</sup>, E. Prokopczuk<sup>4</sup>, L. Hemphill<sup>5</sup>, O. Muñiz<sup>6</sup>, R.D. Santos<sup>7</sup>, J.L. Witztum<sup>3</sup>, S. Baum<sup>8</sup>

<sup>1</sup>University of Cape Town/South Africa, <sup>2</sup>Clinical Development, Akcea Therapeutics, Cambridge, MA/United States of America, <sup>3</sup>Ionis Pharmaceuticals/United States of America, <sup>4</sup>Akcea Therapeutics/United States of America, <sup>5</sup>Massachusetts General Hospital/United States of America, <sup>6</sup>Hospital Virgen del Rocio/Spain, <sup>7</sup>University of Sao Paulo Medical Hospital/Brazil, <sup>8</sup>Boca Raton Regional Hospital/United States of America

**P2-107**

PIK3R3 PROMOTES THE PROGRESSION OF PANCREATIC CANCER VIA NKX2-5/DUSP5/ERK1/2 pathway. Yunpeng Peng<sup>1</sup>, Yi Zhu<sup>1</sup>, Zipeng Lu<sup>1</sup>, Lingdi Yin<sup>1</sup>, Jishu Wei<sup>1</sup>, Yi Miao<sup>1</sup>; <sup>1</sup>Pancreas Center, The First Affiliated Hospital of Nanjing Medical University, China

**P2-108**

ARTERIAL DIVESTMENT INSTEAD OF RESECTION FOR LOCALLY ADVANCED PANCREATIC CANCER (LAPC). Yi Miao<sup>1</sup>, Cuncai Dai<sup>1</sup>, Kuirong Jiang<sup>1</sup>, Baobao Cai<sup>1</sup>, Lingdi Yin<sup>1</sup>, Zipeng Lu<sup>1</sup>, Junli Wu<sup>1</sup>, Wentao Gao<sup>1</sup>, Jianmin Chen<sup>1</sup>, Feng Guo<sup>1</sup>, Jishu Wei<sup>1</sup>; <sup>1</sup>Pancreas Center, The First Affiliated Hospital of Nanjing Medical University, China

**P2-109**

COMPARISON OF PATENCY RATES AND CLINICAL IMPACT BETWEEN DIFFERENT RECONSTRUCTION WAYS FOLLOWING PORTAL/SUPERIOR MESENTERIC VEIN RESECTION DURING PANCREATECTOMY. Wentao Gao<sup>1</sup>, Xinglong Dai<sup>1</sup>, Cuncai Dai<sup>1</sup>, Kuirong Jiang<sup>1</sup>, Junli Wu<sup>1</sup>, Qiang Li<sup>1</sup>, Feng Guo<sup>1</sup>, Jianmin Chen<sup>1</sup>, Jishu Wei<sup>1</sup>, Zipeng Lu<sup>1</sup>, Min Tu<sup>1</sup>, Yi Miao<sup>1</sup>; <sup>1</sup>Pancreas Center, The First Affiliated Hospital of Nanjing Medical University, China





**KEITH D. LILLEMOR, MD**  
CHIEF OF SURGERY & SURGEON-IN-CHIEF,  
MASSACHUSETTS GENERAL HOSPITAL  
W. GERALD AUSTEN PROFESSOR OF SURGERY,  
HARVARD MEDICAL SCHOOL

INVITES YOU TO A

## PRESIDENTIAL RECEPTION

OCTOBER 26 2016 • 7PM

GEORGIAN ABC, BOSTON PARK PLAZA

### HONORING

**CARLOS FERNANDEZ-dei CASTILLO, MD**  
*PRESIDENT, AMERICAN PANCREATIC ASSOCIATION*  
*JORGE & DARLENE PEREZ ENDOWED CHAIR IN SURGERY*  
*DIRECTOR, PANCREAS AND BILIARY SURGERY PROGRAM,*  
*MASSACHUSETTS GENERAL HOSPITAL*  
*PROFESSOR OF SURGERY, HARVARD MEDICAL SCHOOL*



HARVARD  
MEDICAL SCHOOL



MASSACHUSETTS  
GENERAL HOSPITAL



AMERICAN PANCREATIC  
ASSOCIATION



## Sylvester Comprehensive Cancer Center is pleased to welcome

**Ashok Saluja, Ph.D.**, as the Inaugural Director of the Sylvester Pancreatic Cancer Research Institute at the Miller School of Medicine. Dr. Saluja also serves as Sylvester's Associate Director for Research Innovation, Senior Associate Dean for Research, and as Professor and Vice Chair of Surgery at the University of Miami Miller School of Medicine.

Sylvester also welcomes **Sulagna Banerjee, Ph.D.**, **Rajinder Dawra, Ph.D.**, **Vikas Dudeja, M.D.**, and **Mahendra Singh, Ph.D.**, to the Sylvester Pancreatic Cancer Research Institute. These investigators will complement the ongoing pancreatic cancer research of **Nipun Merchant, M.D.**, and his team members, **Michael VanSaun, Ph.D.**, and **Nagaraj S. Nagathihalli, Ph.D.**

We expect great things from these outstanding pancreatic cancer researchers and their teams.



[Sylvester.org](http://Sylvester.org)

